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Abstract 
A major aim of the work described in this thesis is to study functional determinants 
in the Murray Valley encephalitis virus envelope proteins. As a first step in developing 
an expression system for Murray Valley encephalitis virus proteins, randomly generated 
MVE cDNA fragments were expressed in E.coli (Chapter 2). By subcloning a partial 
Sau3A-digest of a cDNA clone coding for the MVE proteins C, prM, E, NS 1, NS2A, 
NS2B and NS3 (Dalgarno et al., 1986) into the pEX expression plasmids (Stanley and 
Luzio, 1984 ), recombinant plasmids which expressed B-galactosidase-MVE fusion 
proteins were generated. Fusion proteins were screened with hyperimmune ascitic fluid 
against MVE and identified by sequence analysis of recombinant plasmids. Fusion 
proteins which contained prM-E, E-NS1-NS2A , E and NS2A were characterized. 
With the exception of an unstable clone containing the largest insert (prM-E; 2.8 kb), 
fusion proteins were expressed in yields of 5-40 mg per litre of induced culture. Little 
evidence for degradation of fusion proteins was observed. 
The neutralization epitopes in MVE envelope protein (E) were examined using the 
above expression system by two methods (Chapter 3). Fusion proteins containing 
various fragments of E were generated by deletion mutation and the reactivity of five 
neutralizing mAbs (defining E-lc, E-ld, E-Sb, E-7 and E-8 epitopes; Hawkes et al., 
1988; J. T. Roehrig, personal communication) with these fusion proteins determined. 
These five m.Abs reacted specifically with unreduced MVE E protein in Western blots. 
However they differed in reactivity with reduced E. Only anti-E-8 m.Ab reacted with 
reduced MVE; the reactivity·of other mAbs with MVE was lQst. This approach allowed 
the mapping of epitope E-8 to a region between Tyr 201 and Pro 224 in E fusion 
proteins. The four other mAbs did not react with the E fusion proteins. 
The second method was based on immunization experiments in mice. By injecting 
mice with partially purified fusion proteins containing E fragments Asp 22-Val 272, 
lV 
Tyr 201-Pro 224 and Leu 327-Gly 429, antisera which reacted with fu sion proteins 
and with MVE by ELISA were generated indicating that the MVE polypeptides present 
in these fusion proteins were immunogenic. However, no significant neutralization 
activity was detectable in these antisera indicating that the fusion proteins were unable to 
elicit neutralizing antibodies. We conclude that the E fusion proteins generated using the 
pEX vectors could be used to map particular epitopes only and to generate protein-
specific antisera. However they were unsuitable for studies on functional activities of E 
as they did not assume the native conformation of E. 
In order to define neutralization epitopes E-lc, E-ld, E-5b and E-7, sequence 
analysis of mAb-selected escape variants was used (Chapter 4). Neutralization escape 
variants of MVE (selected by Dr. R. C. Weir with the anti-E-lc mAb) were sequenced 
in the M and E genes. Single amino acid changes at Phe 274, Ser 276 and Ser 277 
were found. Previous studies mapped Ala 126 as part of the E-lc epitope (S. H. 
Hartley and R. C. Weir, personal communication). We conclude that the E-lc epitope is 
composed of residues far apart on the primary sequence of E. The epitopes E- lc and 
E-8 mapped for MVE are in a domain which corresponds to domain A of TBE (Mandl et 
al., 1989b). Variants resistant to anti-E-ld, E-5b and E-7 were selected (by Dr. J. T. 
Roehrig) using a different method to that used in the above study. These each contained 
multiple changes in E including the common changes Asp 134~ Asn and 
Ala 358~Thr as well as additional changes His 263~Tyr (for E-ld variants) and 
Thr 51 ~ Ala or Asn 197 ~ Asp (for E-5b variants). Although one E-7 variant 
contained Thr 310~Ser change, the other variants were only changed at residues 134 
and 358. We could not determine the changes responsible for resistance to 
neutralization by anti-E-ld, E-5b and E-7 mAbs. 
In view of the possible overlap between neutralization epitopes and determinants of 
mouse virulence, seven sequenced antigenic variants (above) were tested for virulence in 
V 
21-day old mice inoculated by the intracerebral (ic) and intraperitoneal (ip) routes. The 
resulting ic/ip LD50 ratios indicated that two of seven variants were probably of reduced 
virulence. The ic/ip LD50 ratios for these two variants, P4al and P5a l which contained 
single amino acid changes Ser 276~Arg and Ser 277~I1e respectively , were 
approximately 10- and 1000-fold less than that for the parent, MVE-1-51. Thus 
residues 27 6 and 277 may define a virulence determinant in MVE E protein. 
The development of a eukaryotic expression system for the MVE structural proteins 
was explored in Chapter 5. A recombinant baculovirus containing the MVE structural 
protein genes downstream from the polyhedrin promoter was generated. Infection of 
Spodoptera frugiperda (Sf9) cells with this recombinant virus produced MVE proteins 
which corresponded to the envelope proteins prM and E seen in MVE-infected cells. 
Pulse-labelling experiments demonstrated efficient cleavage of polyprotein precursors to 
E. Using tunicamycin, it was demonstrated that recombinant E underwent Asn-linked 
glycosylation and that inhibition of glycosylation affected the cleavage of precursors into 
E in Sf9 cells. Recombinant E reacted with all five neutralizing mAbs directed against 
. , 
MVE E-lc, E-ld, E-5b, E-7 and E-8 epitopes. Reactivities were comparable on a molar 
basis to reactivities against E in MVE-infected cells. We conclude that the baculovirus 
expression system generated MVE E protein in a native conf onnation. The yield of E 
was 4-5 µg per 106 Sf9 cells. Recombinant E in Sf9 cells was distributed in the 
perinuclear region and on the cell surf ace. 
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Abbreviations 
mosquito Aedes albopictus cell line 
competitive binding assay 
complementary DNA 
Carboxy-terminal 
diethylaminoethyl 
dideoxynucleoside triphosphate 
deoxynucleoside triphosphate 
dithiothreitol 
ethylenediaminetetra-acetic acid 
enzyme-linked immunosorbant assay 
Eagle's minimal essential medium 
foetal calf serum 
Freund's incomplete adjuvant 
Hank's balanced salt solution 
N-2-hydroxyethyl piperazine-N'-2-ethane 
sulf onic acid 
haemagglutination-inhibition 
intracere bral 
intraperitoneal 
kilodaltons 
kilobases 
lactalbumin hydrolysate 
Luria-Bertani medium 
50% lethal dose 
low melting temperature 
monoclonal antibcx:ly 
B-mercaptoethanol 
minutes 
vu 
MOI multiplicity of infection 
mol. wt. molecular weight 
mRNA messenger RN A 
N-terminal amino-terminal 
ORF open reading frame 
PAGE pol yacry lamide gel electrophoresis 
PBS phosphate buffered saline 
PEG polyethylene glycol 
PFU plaque forming unit/s 
p.1. post infection 
poly-A polyadenylic acid 
PRNT plaque reduction neutralization test 
RE restriction enzyme 
RER rough endoplasmic reticulum 
RIP radio-immunoprecipitation 
rpm revolutions per minute 
SDS sodium dodecyl sulphate 
SW13 human adenocarcinoma cell line 
Tris Tris (hydroxymethyl) aminomethane 
Vero African green monkey kidney 
Abbreviations of flaviviruses are given in Table 1.1. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1 
1.1 Flaviviruses and their medical significance 
The Flaviviridae is a recently established family of small enveloped RNA viruses 
(Westaway et al., 1986). On the basis of structural features, serological reactions and 
replication strategy, at least 68 viruses have been classified as flaviviruses (Westaway et 
al., 1986). Of the presently recognized flaviviruses, 28 cause diseases in humans and 
eight are associated with diseases in domesticated and wild animals of economic 
importance (see review by Monath, 1986). The most prominent examples are dengue 
fever, yellow fever and Japanese encephalitis which are diseases in humans caused by 
mosquito-transmitted flaviviruses (dengue virus, DEN; yellow fever virus, YF; and 
Japanese encephalitis virus, JE). Flavivirus disease symptoms in humans can vary from 
a mild febrile illness to the more severe encephalitis and hemorrhagic fever. 
In Australia, the most prominent flavivirus disease is caused by Murray Valley 
encephalitis virus (MVE), which has been responsible for epidemic outbreaks of 
encephalitis in human with a focus of activity in the Murray Valley region in South-
eastern Australia. Important outbreaks occurred in 1951 and 1974 during which 19 and 
12 fatal human cases were reported, respectively (Marshall, 1988). 
Flaviviruses of veterinary importance include JE, Wesselsbron virus and Louping 
ill virus. In animals, encephalitis in horses, stillbirth and abortion in pigs are caused by 
JE in many parts of Asia, while Wesselsbron virus and louping ill virus are associated 
with disease in lambs and sheep, respectively (Monath, 1986). 
Prevention of flavivirus diseases depends largely on vaccination of susceptible 
human or animal populations, control of arthropod vectors responsible for transmission 
and protection against mosquito bite or tick bite. As flaviviruses are able to replicate and 
cycle in several host species, eradication of flavivirus diseases which pose serious 
public health problems is difficult. Currently, effective vaccines are only available for 
YF, tick-borne encephalitis (TBE) and JE; the YF vaccine is an attenuated strain of YF 
2 
(17D; Theiler and Smith, 1937), TBE and JE vaccines are derived from inactivated 
viruses (Kunz et al., 1980; Okuda et al., 1975). There is also an attenuated live JE 
vaccine in use in China (Yu et al., 1988). 
1.2 Relationships between flaviviruses 
1.2.1 Serology 
Flaviviruses can be grouped by their natural hosts (mosquitoes, ticks, bats and 
rodents), geographical distribution (Africa, Europe, Asia, Australia and North America), 
disease symptoms in human and animals and serological cross-reactions (Calisher et al., 
1989). The commonly accepted scheme for subdivision of flaviviruses is based on 
antigenic differences determined primarily by cross-neutralization tests with polyclonal 
antisera (De Madrid and Porterfield, 1974; Calisher et al., 1989). The current scheme 
comprises eight antigenic complexes. These are the TBE complex (12 viruses), the Rio 
Bravo complex (6), the JE complex (10), the Tyuleniy complex (3), the Ntaya complex 
(5), the Uganda S complex (4), the DEN complex (4) and the Modoc complex (5). 
There are 17 other viruses apparently not closely related to any of the eight complexes 
(see Table 1.1). The YF is one of these. Members of the same antigenic complex 
generally show cross-neutralization with polyclonal antisera; cross-neutralization is not 
observed between different complexes. Relationships between flaviviruses are also 
demonstrated by less specific serological tests such as haemagglutination-inhibition 
(HI), complement-fixation and immunofluorescence assays with polyclonal antisera 
(Casals, 1957). The close relationship between the three viruses in the Tyuleniy 
complex (Table 1.1) is established by complement-fixation assays rather than 
neutralization (Casals, 1957)~ On the other hand, clear distinction between complexes is 
sometimes difficult when a particular member of a complex (e.g. Edge Hill virus of the 
Uganda S complex, Kokobera of the JE complex) shows a close relationship to another 
complex by criteria such as epitope analysis or RNA sequence homology (Calisher et 
al., 1989). 
3 
TABLE 1.1 
(adapted from Chambers et al., 1990) 
Antigenic complexa 
(number of members) 
Tick-borne encephalitis (12) 
Rio Bravo (6) 
Japanese encephalitis (10) 
Tyuleniy (3) 
Ntaya (5) 
UgandaS (4) 
Dengue (4) 
,• 
Modoc (5) 
Ungrouped (17) 
Type member or members 
with available sequenceb 
Central European encephalitis (TBE) 
Far Eastern encephalitis (TEE-FE) 
Rio Bravo 
Japanese encephalitis (JE) 
Kunjin (KUN) 
Murray Valley encephalitis (MVE) 
St Louis encephalitis (SLE) 
West Nile (WN) 
Tyuleniy 
Ntaya 
UgandaS 
Dengue type 1 (DEN-1) 
Dengue type 2 (DEN-2) 
Dengue type 3 (DEN-3) 
Dengue type 4 (DEN-4) 
Mcxloc 
Yellow fever (YF) 
a Antigenic groups are taken from Calisher et al., 1989. 
Arthropod 
vectorC 
T* 
T 
u 
M 
M 
M 
M 
M 
T 
M* 
M 
M 
M 
M 
M 
u 
M* 
b Sequence data are avilable for JE, KUN, MVE, SLE, WN, DEN-1, DEN-2, DEN-3, DEN-4, TEE and 
YF (cited in the text). 
c Arthropod vectors: T, tick; M, mosquito; U, unknown;*, arthropod vectors for some members of 
these groups have not been identified. 
The JE complex (10 viruses) includes five members which are found in Australia. 
These are MVE, Kunjin virus (KUN), Alfuy virus (ALF), Kokobera virus and Stratford 
virus. Edge Hill virus in the Uganda S complex is also found in Australia but is not as 
closely related by serology to the rest of the Australian flaviviruses (Calisher et al., 
1989). 
The two best studied flaviviruses in Australia, MVE and KUN, both utilize Culex 
annulirostris mosquito as the major arthopod vector; birds are the major vertebrate host 
(Kay, 1980; Marshall, 1979). Other viruses in the JE complex include Saint Louis 
encephalitis virus (SLE) and West Nile virus (WN), which also cycle between 
invertebrate (mosquito) ai,d vertebrate hosts (mainly birds) (see review by Chamberlain, 
1980). 
1.2.2 Sequence homology 
With the availability of nucleotide aI1d protein sequence data for YF (Rice et al., 
1985) and ten viruses of the JE, DEN and TBE complexes (see below), it is found that 
homology at amino acid sequence level is always gre_ater between µiembers of the same 
antigenic complex than between viruses of different complexes. Therefore, the 
serological classification is generally in agreement with sequence homologies between 
flaviviruses (Mandl et al., 1988; Mandl et al., 1989a; Osatomi et al., 1988; Pletnev et 
al., 1990; Trent et al., 1987). 
Sequence data are available for the genomes of five viruses in the JE complex. 
These are MVE (Dalgarno et al., 1986; Hahn et al., 1987a; Lee et al., 1990), WN 
(Castle et al., 1985; Castle et al., 1986; Castle and Wengler, 1987; Wengler and 
Wengler, 1981; Wengler et al., 1985; Wengler and Castle, 1986), SLE (Trent et al., 
1987), JE (Hashimoto et al., 1988; McAda et al., 1987; Sumiyoshi et al., 1986; 
Sumiyoshi et al., 1987; Takegami et al., 1986) and KUN (Coia et al., 1988). 
Comparison of these five viruses provides an interesting contrast in protein sequence 
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homology: WN and KUN are the most homologous pair (93% amino acid sequence 
homology; Coia et al., 1988); the next being JE and MVE (82%; Lee et al., 1990). SLE 
is the least related in sequence to the above four viruses. 
There is little variation in genome or protein sequence between different strains of 
the same flavivirus as shown by comparison of established genome sequence of two 
TBE subtypes (Mand.I et al., 1988), three DEN-2 strains (Hahn et al., 1988) and two JE 
strains (McAda et al., 1987; Sumiyoshi et al., 1988): divergence in amino acid sequence 
between flavivirus strains is generally less than 5%. Comparison of genome sequences 
by oligonucleotide fingerprinting and restriction analysis of natural isolates of DEN-1 
(Chu et al., 1989), DEN-2 (Trent et al., 1983), KUN (Lobigs et al., 1986b) and MVE 
(Lobigs et al., 1986a) also show small variation suggesting that flaviviruses are 
genetically stable relative to genomes of other RNA viruses such as influenza virus and 
polio virus which undergo rapid evolution (Holland et al., 1982; Palese and Young, 
1982). Partial sequence analysis of twelve strains of MVE from various parts of 
Australia and Papua New Guinea defined differences of between one and eleven amino 
acids in the envelope glycoprotein of 501 amino acids (Lobigs et al., 1988). In contrast, 
MVE and its closest relative JE differ in 90 amino acids within the same protein. 
1.3 Virion structure and genome organization 
1.3.1 Virion structure 
The virions of MVE, JE, DEN and WN as visualized by electron microscopy are 
small spherical particles of 40-50 nm in diameter (Filshie and Rehacek, 1968; Kitano et 
al., 1974; Smith et al., 1970; Wengler et al., 1987). Three components make up the 
mature virion; they are the nucleocapsid (20-30 nm) and the envelope (:::::40 nm in 
diameter) with surface projections which are 5-10 nm (Fig. 1.1). 
The nucleocapsid is made up of capsid protein (C; 13-16K) and an RNA molecule 
which is the viral genome. The virus envelope is composed of a lipid bilayer generally 
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Figure 1.1 Flavivirus virion structure (adapted from Chambers et al., 1990a). The nucleocapsid and the 
proteins in the envelope of flaviviruses are represented diagrammatically. The oligomeric association 
between envelope proteins (E, M and prM) in extracellular and intracellular WN is based on data from 
Wengler and Wengler (1989a). 
assumed to derive from membranes of infected cells (see below). Virus-specific 
proteins which are associated with the envelope include the envelope protein (E; 51-
60K), the matrix protein (M; 8-8.SK) and the pre-M protein (prM; 19-23K) (Fig. 1.1). 
Eis the major component of the surface projections (Kitano et al., 1974); Mis a much 
smaller protein present on the envelope of extracellular virions; its glycoprotein 
precursor, prM, is present on the envelope of intracellular virions (Shapiro et al., 1972; 
Wengler and Wengler, 1989a). Traces of prM are also detectable on extracellular 
virions (Westaway, 1987; Wengler and Wengler, 1989a). From protease digestion of 
purified TBE and WN virions which yields proteolytic fragments of E, it is deduced that 
Eis the major component of the surface of the virion (Heinz and Kunz, 1979; Wengler 
et al., 1987). Limited protease digestion of extracellular WN virus by trypsin, 
chymotrypsin and thermolysin reveals two regions in E (Gln 131-Gly 156 and 
Ile 380-Ala 416) which are particularly exposed to cleavage (Wengler et al. , 1987). 
The existence of oligomers on virions is reported for TBE and WN. On the basis 
of cross-linking studies, prM-E heterodimers occur in intracellular WN virions while 
extracellular WN contains E monomers and trimers (Wengler et al., 1987; Wengler and 
Wengler, 1989a). Hence, re-organization of the envelope proteins may occur before or 
during the release of virions, probably in close association with the conversion of prM 
to M. In contrast, extracellular TBE contains E monomers and dimers based on cross-
linking studies (Heinz and Kunz, 1980a; 1980b ). It has been suggested on the basis of 
differences between intracellular and extracellular virions that the rearrangement of 
oligomers on the surface of virions during maturation and release may influence 
infectivity of the virus (Wengler and Wengler, 1989a). 
1.3.2 Structure of genome RNA 
The RNA genome of flaviviruses consists of a single, plus-stranded RNA 
molecule (~11 kb) which is infectious. A type 1 cap of the form m7GpppAmp is 
present at the 5' terminus; there are no internal methylated adenine residues 1n 
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association with the cap structure (Cleaves and Dubin, 1979). It is generally accepted 
that mosquito-borne flaviviruses do not contain a 3'-terminal poly-A tract (Rice et al., 
1986). Instead, the 3' terminus (=100 nucleotides) probably forms a conserved 
secondary structure involving complementary nucleotide sequences (Brinton et al., 
1986; Wengler and Castle, 1986; Hahn et al., 1987a). However, certain strains of TBE 
appear to terminate with a 3'-poly-A tract while others have no poly-A at the 3' terminus 
(F. X. Heinz, personal communication). It has been proposed that the 5' terminus of 
the RNA may also form secondary structures and be involved in cyclization of the 
genome during infection (Brinton and Dispoto, 1988; Hahn et al., 1987a). 
1.3.3 Genome organization of flaviviruses 
The establishment of genome sequence of eleven flaviviviruses including YF, 
viruses of the JE complex (see above), the four DEN subtypes (Biedrzycka et al., 1987; 
Deubel et al., 1986; Deubel et al., 1988a; Gruenberg et al., 1988; Hahn et al., 1988; 
Mackow et al., 1987; Mason et al., 1987a; Osatomi et al., 1988; Zhao et al., 1986) and 
TBE (Mandl et al., 1988; Mandl et al., 1989a; Pletnev et al., 1990; Yamshchikov and 
Pletnev, 1988) has revealed a common theme in organization: the occurrence of a single 
open reading frame (ORF; 10,158-10,299 nucleotides) which codes for 3386-3433 
amino acids and spans at least 90% of the genome, and untranslated regions at the 5' 
and 3' termini. Viral proteins have been mapped on the genome by their N- and C-
terminal sequences. The most complete mapping study has been for the KUN proteins 
(Speight et al., 1988; Speight and Westaway, 1989a; 1989b). Terminal sequences of 
other flavivirus proteins have also mapped them on the genome (see review by 
Chambers et al., 1990a). A common cooing order of these viral proteins is established: 
the structural protein genes for C, prM/M and E occupy a quarter of the ORF at the 5' 
end, the rest of the ORF codes for the nonstructural proteins, which are only found in 
flavivirus-infected cells. The nonstructural proteins are named according to their order 
of appearance in the ORF, hence NSl is followed by NS2A, NS2B, NS3, NS4A, 
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NS4B and NS5. Proteins NS 1, NS3 and NS5 are identified and mapped for a number 
of flaviviruses, including MVE, YF and KUN (Lee et al., 1990; Rice et al., 1986b; 
Speight et al., 1988). Idenfication of the other nonstructural proteins has been achieved 
only for KUN and YF (Speight et al., 1988; Speight and Westaway, 1989a; Chambers 
et al., 1989; see below). 
Fig. 1.2 presents the MVE genome organization based on the genome sequence 
(Dalgarno et al., 1986; Hahn et al., 1987a; Lee et al., 1990; A. Nestorowicz, personal 
communication), terminal sequences of NS 1, NS3 and NS5 and homology with the 
genome organization of KUN and YF (see above). The genome (11,013 nucleotides) 
contains an ORF of 10,302 nucleotides flanked by a 5' untranslated region (:==9-5 
nucleotides) and a 3' untranslated region (616 nucleotides). Proteins encoded in the 
ORF are in the same order as those of other flaviviruses. 
1.3.4 Flavivirus-encoded proteins 
Structural proteins 
Structural proteins C, E, Mand its precursor prM occur in virions (see above) and 
virus-infected cells. Protein C and the genome RNA form the nucleocapsid. There is 
little conservation in C protein sequences between flaviviruses of different complexes 
(Trent et al., 1987). However, there is always a high proportion of basic amino acids 
(Arg and Lys) in the protein consistent with a role in capsid formation (see review by 
Rice et al., 1986a). Intracellular and virion forms of C proteins have been shown to 
differ in mobility by SDS-PAGE (Rice et al., 1986a; Chambers et al., 1990a). The 
virion C protein of WN and KUN lacks a hydrophobic peptide which is at the C-
terminus of the predicted protein sequence (Nowak et al., 1989; Speight and Westaway, 
1989b ). It is has been proposed that the intracellular C protein with the hydrophobic 
sequence is membrane-associated and is converted to the virion C protein by removal of 
the hydrophobic C-terminus (see below). 
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Figure 1.2 Genome organization of MVE. The RNA genome of MVE-1-51 (prototype strain) is 
represented by the solid line. The single long open reading frame (ORF) which spans the genome 
begins with an AUG (solid triangle) and terminates in an UAA (solid diamond) . The polyprotein 
encoded by the ORF is represented by the open bar. Viral proteins (structural and nonstructural) produced 
by proteolytic processing of the polyprotein are shown below, the lengths in amino acids are indicated. 
Cleavage specificity is indicated as follows: open triangles indicate signalase-like cleavage sites 
following a hydrophobic sequence and a short side chain amino acid; arrowheads indicate cleavage after 
two basic residues; the open diamond indicates cleavage after a consensus tripeptide Val-X-Ala without a 
preceding hydrophobic sequence; the arrow indicates cleavage after the consensus sequence Arg-X-
Arg/Lys-Arg. This genome organization is deduced from the NfVE genome sequence (Dalgarno et al., 
1986; Hahn et al., 1987a; Lee et al., 1990; A. Nestorowicz, personal communication) on the basis of 
data on genome organization of YF and KUN (Chambers et al., 1990b; Speight et al., 1989). Positions 
of small nonstructural proteins NS2A, NS2B , NS4A and NS4B are t~nta_tive and based on homology 
with KUN proteins (Speight et al., 1988; Speight and Westaway, 1989a) . 
The envelope proteins E,. prM and M may assume important roles during the 
initiation of flavivirus infection and in assembly of infectious virions. As the dominant 
component of spikes on virus surface (Kitano et al., 1974), E may play a major role in 
cell binding and in the proposed fusion process following endocytosis (see below). The 
importance of E is supported by observations that E isolated from TBE, JE and KUN 
elicits antisera in mice which neutralize infectivity of these viruses in vitro and passively 
protect mice against virus challenge (Della-Porta and Westaway, 1977; Heinz et al., 
1981; Kitano et al., 1974). Immunization with E also induces active immunity in mice 
against lethal TBE challenge (Heinz et al., 1981). As the intracellular precursor to M, 
prM is probably involved in virion assembly and is later converted to M (Wengler and 
Wengler, 1989a). Owing to the significance of envelope proteins in flavivirus infection 
and pathogenesis, their structure has been the focus of various studies and is discussed 
in a separate section (see below). 
Large nonstructural proteins 
Three large nonstructural proteins NS1 (41-49K), NS3 (67-76K) and NSS (91-
98K) have been identified in.flavivirus-infected cells. These proteins are hydrophilic by 
comparison with the smaller nonstructural proteins. Comparison of the molecular 
weights (mol. wts.) and protein sequences between flaviviruses has shown that these 
proteins are strongly conserved (Lee et al., 1990; Rice et al., 1986a). 
Various forms of NS 1 protein including NS 1 dimers (Winkler et al., 1988; 1989), 
a larger NSl protein containing part of NS2A (Mason et al., 1987b; Mason, 1989) and a 
soluble complement fixing antigen (Smith and Wright, 1985; Lee et al., 1989; Winkler 
et al., 1989) have been observed. NS 1 is distinguished from other nonstructural 
proteins by the conservation of positions of 11 cysteines (Rice et al., 1986a), 
glycosylation (see below) and its cell surface distribution (Schlesinger et al., 1990). It 
is likely that the conserved cysteines are involved in disulfide bonds, thus maintaining 
NS 1 in a conserved conformation reminiscent of the structural proteins (see below). 
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NS 1 undergoes Asn-linked glycosylation in various types of cells (Lee et al., 1989; 
Mason, 1989). The positions of the tripeptides Asn-X-Thr/Ser which are potential Asn-
linked glycosylation sites (Kornfeld and Kornfeld, 1985) are conserved in the JE 
complex and in the four DEN subtypes (see Chambers et al., 1990a). Complex glycans 
are attached to NS 1 of JE in the Golgi cisternae and are associated with the secreted 
forms of NS 1 which appear simultaneously with extracellular virus (Mason, 1989). 
Based on the above observations on structure, glycosylation and cellular distribution of 
NSl, it has been suggested (Winkler et al., 1989; Mason, 1989; Lee et al., 1989) that 
NS 1 may have roles in virus assembly or release. NS 1 protects animals from YF and 
DEN-2 challenge by active immunization (Schlesinger et al., 1985; 1987) and elicits 
antisera which can be used to passively protect animals against lethal challenge by 
DEN-2 and YF (Brandriss and Schlesinger, 1984; Schlesinger et al., 1985). 
Monoclonal antibodies (mAbs) against DEN-2 NS 1 also passively protect mice 
(Henchal et al., 1988). 
. The NS3 and NS5 proteins do not contain extensive hydrophobic regions and are 
both strongly conserved. I~ has been suggested that these are cytoplasmic proteins 
which are involved in replication of the RNA genome. Conserved sequence motifs in 
the N- and C-terminal portions of NS3 show resemblance to the active domains of the 
serine protease and the helicase enzymes respectively (Bazan and Fletterick, 1989; 
Gorbalenya et al., 1989). Studies of in vitro translation of NS2B-NS3 genes have 
shown that autoproteolytic activity is associated with the N-terminal region of NS3 
(Chambers et al., 1990c). Thus NS3 may have a dual role in proteolytic processing and 
RNA replication. Conserved sequence motifs in NS5 are homologous to the RNA-
dependent RNA polymerase of eukaryotic viruses indicating that NS5 probably acts as 
the viral polymerase (Rice et al., 1986a). 
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Small nonstructural proteins 
Four smaller proteins NS2A (19K), NS2B (10K), NS4A (13K) and NS4B (21K) 
are identified in KUN-infected cells (Speight et al., 1988; Speight and Westaway, 
1989a). NS2A (20K), NS2B (15K) and NS4B (27K) have also been identified for YF 
(Chambers et al., 1989). These proteins present problems in identification owing to 
their small size, quantity and variable mobility by SDS-PAGE (Speight et al., 1988; 
Chambers et al., 1989). The sequences of NS2A, NS2B, NS4A and NS4B are 
hydrophobic by comparison with the large nonstructural proteins and show poor 
homology between flaviviruses. It appears that these proteins do not have enzymic roles 
but may be required for their hydrophobic properties (see below). 
1.4 Replication of flaviviruses in tissue culture 
Flaviviruses are able to infect a wide range of tissue culture cell lines including 
lines of mammalian, avian and insect origin (Brinton, 1986). There may be differences 
in virus growth and yield as well as in the extent of damage to host cells; however, 
marked inhibition of host macromolecular synthesis is generally not observed 
(Westaway, 1987). The mosquito-borne flaviviruses (YF, DEN subtypes and JE 
serocomplex) often generate cytopathic effects and are commonly cytocidal for 
vertebrate cells. Persistent infection occurs more frequently in mosquito cells and little 
cytopathic effect is observed (Brinton, 1986). Persistent infection of mammalian cells 
has been reported for JE and WN (Schmaljohn and Blair, 1977; Brinton et al., 1985). 
Several features are consistent during flavivirus infection. These include the 
growth curve which shows a latent period of 12-16 hours (Mussgay et al., 1975) and 
the proliferation of membranes in cytoplasm including smooth and rough endoplasmic 
reticulum (RER) (Westaway, 1987). 
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1.4.1 Initiation of infection 
Studies by electron microscopy of WN-infection of a macrophage cell line, 
P388D 1, show that single virions or aggregates appear in clathrin-coated pits on the cell 
surface before rapid uptake (Gollins and Porterfield, 1985) consistent with entry by 
receptor-mediated endocytosis (see review by Marsh and Helenius, 1989). Subsequent 
to entry, WN appears in endosomes where fusion between virus envelope and 
endosomal membrane occurs at acidic pH causing the release of nucleocapsids into the 
cytoplasm (Gollins and Porterfield, 1985; 1986). This acid-induced fusion process is 
inhibited by weak bases such as ammonium chloride and chloroquin (Gollins and 
Porterfield, 1985). Anti-WN rabbit IgG inhibits fusion in a concentration-dependent 
manner parallel to its ability to neutralize virus infectivity in vitro, this indicates that 
neutralization may occur by inhibition of the fusion process (Gollins and Porterfield, 
1986). KUN and YF also adsorb to coated pits on Vero cell surface and appear in 
coated vesicles consistent with uptake by receptor-mediated endocytosis (Ng and Lau, 
1988; Ishak et al., 1988). Enhancement by anti-viral antibodies occurs in the P388Dl 
cell line, whereby the uptake of WN viri<?ns shows at least a nine-fold increase in 
efficiency in the presence of subneutralizing amounts of polyclonal or monoclonal 
antibodies (Gollins and Porterfield, 1984; 1985). The Fe receptor on the surface of 
these cells is thought to be responsible for the enhancement; however, the same pathway 
of endocytosis and fusion appears to be utilized as in the absence of antibody (Gollins 
and Porterfield, 1985). 
A conflicting observation has been reported for the entry of DEN-2 into C6/36 
mosquito cells and human monocytes, and the entry of JE into C6/36 cells: electron 
microscopy shows direct penetration of the plasma membrane with no evidence of 
receptor-mediated endocytosis (Hase et al., 1989a; Hase et al., 1989b). It is not clear if 
productive infection follows such a route of entry. 
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1.4.2 Translation of genome RNA 
After uncoating of the nucleocapsid, the genome RNA is released into the 
cytoplasm and translated into viral proteins. The mechanism of uncoating is not 
known. From immunofluorescence studies which show that accumulation of viral 
proteins occurs primarily in the perinuclear region in the cytoplasm, the site of viral 
protein translation is deduced to be cytoplasmic and is probably assocated with the 
perinuclear RER (Ng et al., 1983; Westaway and Goodman, 1987). 
Translation of the genome RN A is thought to produce a high mol. wt. polyprotein 
which gives rise to individual proteins by co- and post-translational processing. Several 
lines of evidence support this including the existence of a single long ORF and the 
detection of high mol. wt. precursors in KUN-infected Vero cells and DEN-2 infected 
hamster kidney cells (Cleaves, 1985; Crawford and Wright, 1987); the former were 
incubated with a leucine analogue to inhibit signalase cleavage and the latter were pulse-
labelled with s35_methionine. Identification of the proteases and other enzymes 
responsible for processing has been achieved for some viral proteins (see below). 
Translation of the flavivirus genome begins at the first AUG initiation codon in the 
ORF as shown from the N-terminal sequence of the C proteins of YF, SLE, WN, 
KUN, JE, TBE and DEN-3 (Bell et al., 1985; Castle et al., 1985; Coia et al., 1988; 
Sumiyoshi et al., 1987; Boege et al., 1983; Osatomi et al., 1988). However, additional 
forms of WN and DEN-3 C proteins derive from initiation at the second ,.A... UG codon in 
the ORF (Castle et al., 1985; Osatomi et al., 1988). Termination of translation is 
assumed to occur at the first stop codon in the ORF; there appears to be no preference 
for a particular termination codon as UAA, UGA and UAG are all used (see review by 
Chambers et al., 1990a). .The sequence of appearance of viral proteins has been 
determined by translation mapping experiments using KUN-infected Vero cells and 
generally follows the order of proteins encoded in the RN A genome (Schrader and 
Westaway, 1988). However, this study has revealed anomalies in the synthesis of 
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KUN NS5 protein prompting suggestions that an alternative mechanism such as internal 
initiation of translation may also occur (Schrader and Westaway, 1988). 
1.4.3 Proteolytic cleavage 
Proteolytic cleavage sites and the identity of proteases involved in processing 
flavivirus polyproteins are predicted from deduced amino acid sequence data and direct 
N-terminal sequence analyses. At least four types of cleavage events occur based on 
cleavage specificities (see Fig. 1.2). Cleavage sites at the N- and C-temrini of prM and 
E and at the N-tenninus of NS4B are preceded by hydrophobic signal peptides and 
occur after small amino acids, consistent with signalase cleavage; the tripeptide V al-X-
Ala quite often precedes the cleavage sites (see Chambers et al., 1990a). Supporting 
evidence comes from cell-free translation of DEN-2, WN and YF genomes which 
demonstrates the requirement for a microsomal membrane fraction for cleavage of 
polyprotein precursors into C, prM and E in the absence of the nonstructural proteins 
(Markoff, 1989; Nowak et _al., 1989; Ruiz-Linares et al., 1989). Expression of the 
structural proteins of DEN-2, DEN-4 and JE using vaccinia virus and baculovirus 
vectors also demonstrates cleavage of polyprotein precursors into prM and E in the 
absence of nonstructural proteins (Deubel et al., 1988b; Matsuura et al., 1989; Zhao et 
al., 1987; Zhang et al., 1988). 
Cleavage at the C-terminus of NSl is preceded by the tripeptide Val-X-Ala without 
a preceding hydrophobic tract. As NS 1 is probably translocated into the lumen of the 
RER by the signal peptide at the C-terminus of E, this cleavage probably occurs in the 
lumen of the RER. Both JE- and YF-infected cells produce an additional form of NS 1 
which contains a portion of the adjoining NS2A protein (Mason et al., 1987b; Chambers 
et al., 1990b) indicating inefficient cleavage at the C-temrinus of NS 1. 
The nonstructural proteins NS2B, NS3 and NS5 are generated by cleavage after 
two basic residues. From the absence of hydrophobic signal peptides, NS2B, NS3 and 
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NS5 are deduced to be cytoplasmic proteins, thus the cleavage probably occurs in the 
cytoplasm (Speight et al., 1988). A virus-encoded protease has been proposed to be 
responsible for this cleavage (Rice et al., 1985). A possible candidate is the NS3 
protein which possesses sequences homologous to serine proteases (Bazan and 
Fletterick, 1989; Gorbalenya et al., 1989). Two basic residues also precede the 
cleavage site which converts the putative anchored C protein into the anchorless form 
found in KUN and WN virions (by removing the hydrophobic C-terminus; Nowak et 
al., 1989; Speight and Westaway, 1989). 
Cleavage at the N-terminus of M follows the sequence Arg/Lys-Arg-X-Arg/Lys-
Arg (Chambers et al., 1990a) and converts the intracellular precursor prM to M in 
extracellular virions. This conversion occurs late in infection, probably during or before 
virus release as intracellular virus has the prM protein (Wengler and Wengler, 1989a). 
This cleavage is inefficient as prM is still detectable in released flaviviruses (Wengler 
and Wengler, 1989a; Westaway, 1987). Cleavage probably occurs in the lumen of the 
Golgi cisternae where an enzyme with the appropriate cleavage specificity exists (see 
. 
, 
review by Strauss and Strauss, 1985). 
1.4.4 RNA synthesis 
A generally accepted scheme for genome RNA replication during flavivirus 
infection is that the genome RNA is the template for synthesis of full length minus 
strands which are then transcribed into genome length plus strands (Westa,vay, 1987). 
It is expected that transcription is regulated to produce more plus strand than minus 
strand RN As for translation of viral proteins and virus assembly. It has been speculated 
that the association between C and plus strand RNA may prevent generation of the 
minus strand and initiate encapsidation (Rice et al., 1986a). 
RNA species in infected cells have been described for KUN, DEN-2 and WN 
(Chu and Westaway, 1985; Cleaves et al., 1981; Wengler and Wengler, 1981). There 
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are two major forms in addition to the full length plus and minus strand RN As; they are 
the replicative intermediates (RI) and replicative forms (RF). RFs are double stranded 
RNAs and Rls are nascent single stranded RNAs in association with template, single 
stranded RNAs (Westaway, 1987). From incorporation of radio-label and RNAse 
resistance, Ris and RFs are intermediates in viral RNA replication which occurs by a 
semi-conservative mechanism (Westaway, 1987). 
The polymerase complex can be isolated from infected cells in the heavy membrane 
fraction (Grun and Brinton, 1988; Westaway, 1987); however, the composition of these 
complexes is still unresolved. NS3 and NS5, the two possible components of the 
polymerase complex, have been localized by immunofluorescence using protein-specific 
antibodies to the perinuclear membranes where virus-specific RNAs accumulate and are 
detected by anti-dsRNA antibodies (Ng et al., 1983; Westaway, 1987). It appears that 
the replication of flavivirus genome RN A occurs near the cellular membranes; the 
association of the polymerase complex with membranes suggests that hydrophobic viral 
proteins (such as the small nonstructural proteins) and/or host factors may also be 
components in the polymerase complex (Grun and Brinton, 1988). 
1.4.5 Assembly and release of virions 
The assembly of virion particles involves the genome RNA, C, and envelope 
proteins prM and E. Morphological studies by electron microscopy show virions 
predominantly in the lumen of the RER (Filshie and Rehacek, 1968; Hase et al., 1987a; 
Ishak et al., 1988; Leary and Blair, 1980). In some studies (Hase et al., 1987a; Ishak et 
al., 1988; Leary and Blair, 1980), virus is also observed in the Golgi cistemae or 
cytoplasmic vacuoles. Based on the above observations and the perinuclear localization 
of prM and E (Westa\vay and Goodman, 1987), it has been proposed (Hase et al., 
1987a; Leary and Blair, 1980) that envelopment occurs at the perinuclear membranes; 
enveloped virions probably enter the lumen of the RER in the process and undergo 
further processing before release from cells. Questions regarding the site of 
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encapsidation remain unresolved. As naked nucleocapsids or incomplete virions have 
not been observed in those morphological studies which show virions in the lumen of 
the RER, it seems likely that encapsidation and envelopment occurs concurrently at the 
same location. The intracellular form of C containing a hydrophobic membrane anchor 
may be involved in the encapsidation process since the newly formed nucleocapsids may 
contain this anchored C and be close to the ER membranes where envelopment occurs 
(Nowak et al., 1989). The conversion of anchored C to the virion-associated anchorless 
form probably occurs during or after envelopment (Nowak et al., 1989). 
A different pathway of assembly and release of virion is suggested in a study by 
electron microscopy of DEN-2-infected C6/36 cells: naked nucleocapsids appear in the 
cytoplasm and bud into vacuoles or through the plasma membrane into the extracellular 
space (Hase et al., 1987b). By comparing this study and a separate study of JE-infected 
C6/36 cells (Hase et al., 1987 a) which shows virion assembly and release by the 
pathway described in the previous paragraph, Hase et al., (1987a) proposed that 
different mechanisms for vinon assembly may exist for flavivirus infection. 
1.5 Structure of the flavivirus envelope proteins 
1.5.1 Structural properties 
The M protein: The M protein is approximately 8K (75 amino acids for all 
flaviviruses) and is only detected on extracellular virus (Shapiro et al., 1972; Russell et 
al., 1980). The intracellular precursor, prM, is 19-23K (166-168 amino acids). The 
Asn-X-Thr/Ser tripeptide occurs only in the 'pr' segment, consistent with the 
glycosylation of prM but not M (Chambers et al., 1990a). The prM proteins of WN, 
KUN, DEN-2 and DEN-4 contain 'mannose-rich' glycans (see Chambers et al., 
1990a), indicating processing of prM in the lumen of the RER. There are six strictly 
conserved cysteines in the 'pr' segment of prM of all flaviviruses; these may be involved 
in disulfide bonds which contribute to the conformation of prM. There is no conserved 
cysteine in M. Other than the conserved cysteines, the prM protein, including the M 
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sequence appears not to be conserved in sequence. The hydropathy pattern for prM 
reveals that the 'pr' segment is hydrophilic. M contains a hydrophilic region in the N-
terminal half; the C-terminal half comprises two hydrophobic tracts which are 
interrupted by a charged residue. The first hydrophobic tract may act as a 'stop transfer' 
sequence while the latter is possibly a signal peptide for E (Markoff, 1989). The role of 
the prM and M proteins is not clearly defined. The heterodimers of prM-E in 
intracellular WN suggests a close association of prM and E during assembly (Wengler 
and Wengler, 1989a). A conserved conformation of prM based on possible 
conservation of disulfide bonds may be important to this association. 
The E protein: The E proteins of flaviviruses is 51-60K (493-501 amino acids). 
Fig. 1.3 shows the sequence for the MVE E protein and a co-listing of E sequences for 
nine other flaviviruses. The most conserved feature in these sequences is the occurrence 
of twelve cysteines at identical positions in E of all flaviviruses. These cysteines are all 
involved in disulfide bonds in the WN E protein at Cys 3-30, Cys 60-121, Cys 74-
105, Cys 92-116, Cys 186-284 and Cys 301-332 (Nowak and Wengler, 1987). 
These disulfide bonds are likely to be strictly conserved and thus be important in 
maintaining the conformation of E. The pattern of disulfide linkages in WN E protein 
provides valuable data on the two-dimensional structure of E (Nowak and Wengler, 
1987) which probably applies to all flaviviruses (see below). Other than the cysteines, 
strongly conserved sequences occur in the first 40 amino acids at the N-terminus, 
residues 100-110 and in the 40 amino acids after residue 420. The sequence from 
Asp 98 to Gly 111 is the most conserved \vith only one difference in ten flaviviruses 
(see below). By contrast, the region between residues 120 and 210 is highly variable 
between flaviviruses. 
The hydropathy pattern for E shows strong conservation between flaviviruses 
(McAda et al., 1987). The C-terminal 39 amino acids of all E proteins comprise two 
uncharged tracts separated by one or three charged residues. Apart from acting as the 
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Figure 1.3 Co-listing of E protein sequences of ten flaviviruses. The E protein sequences of nine 
flav iviruses, JE (Sumiyoshi et al., 1988), KUN (Coia et al., 1988), WN (Wengler et al., 1985), SLE 
(Trent et al., 1987), YF (17D vaccine strain; Rice et al., 1985), DEN-1 (Mason et al., 1987a), DEN-2 
(Jamaica genotype; Deubel et al., 1986), DEN-4 (Zhao et al., 1986) and TBE (Western subtype; Mandl 
et al., 1988), are aligned to that of MVE (Dalgarno et al., 1986) and are listed below the MVE E 
sequence with dots indicating identical amino acids. Hyphens indicate gaps inserted to maximize 
homology. The twelve conserved cysteines are indicated by asterisks, the Asn-X-Thr/Ser glycosylation 
sites are underlined and the hydrophobic tracts at the C-terminus are overlined. 
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membrane anchor, it has been proposed that the first uncharged tract acts as a stop 
transfer sequence and the second as the signal peptide for NS 1 (Ruiz-Linares et al. , 
1989). There is no other extensive hydrophobic region in E. Based on proteolytic 
digestion of TBE and WN (Heinz and Kunz, 1979; Wengler et al., 1987), it appears that 
the ectodomain occupies most of E except for the hydrophobic C-terminus. There are 
regions in WN E protein particularly exposed to proteolytic cleavage (see above). 
The E proteins of flaviviruses are generally glycosylated. The Asn-linked 
glycosylation site (Asn-X-Thr/Ser) occurs in the E sequences of most flaviviruses 
except WN and KUN (see below). The glycosylation site at Asn 154 is in seven of 
eleven flaviviruses including MVE, JE, SLE, TBE and the four dengue subtypes 
(Chambers et al., 1990a). The dengue viruses all contain additional glycosylation sites 
at Asn 67. The absence of glycosylation site in the WN E protein corresponds with the 
lack of glycosylation (Wengler et al., 1985). For the E proteins of the 17D and Asibi 
strains of YF (Hahn et al., 1987b; Rice et al., 1985), the glycosylation sites are an Asn-
Met-Thr in the hydrophobic C-terminus and an Asn-Pro-Thr in the ectodomain. In view 
of the absence of glycans on some strains of YF (Schlesinger et al., 1983), these sites, 
which are probably not good acceptor sites for glycosylation (Kornfeld and Kornfeld, 
1985), may affect the pattern of glycosylation of YF E protein. Glycosylated forms of 
KUN E have been identified in infected cells (Wright et al., 1981), even though the 
KUN strain used for sequencing does not contain Asn-X-Thr/Ser in E and the E in 
KUN virion is apparently not glycosylated (Wright, 1982). Factors such as strain 
variation and utilization of tripeptides such as Asn-X-Cys (Kornfeld and Kornfeld, 
1985) may account for this phenomenon. 
The composition of the glycans in DEN-2, JE and TBE E has been studied using 
radio-labelled sugars and specific endoglycosidases. Glycans of either the high-
mannose or the complex type are attached to E of these viruses (Mason, 1989; Smith 
and Wright, 1985; Winkler et al., 1987). Studies of JE-infected C6/36 and Vero cells 
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(Mason, 1989) have shown that the cell associated E contains a single mannose-rich 
glycan while extracellular virus associated E has a complex glycan. It has been 
suggested that the glycans are converted to complex forms in the Golgi cistemae before 
or during release (Mason, 1989). Tunicamycin treatment which inhibits Asn-linked 
glycosylation impairs the release of virion-associated E but does not abolish it (Mason, 
1989). Deglycosylation of TEE using endoglycosidase F has no effect on its infectivity, 
haemagglutination activity or reactivity with either polyclonal sera or mAbs defining 
eight epitopes on E (Winkler et al., 1987). Therefore, it appears that glycosylation does 
not affect the critical functions of E although subtle effects on maturation and release of 
virus cannot be ruled out. 
1.5.2 Epitopes in the envelope proteins 
MAbs directed against E show different degrees of cross-reaction with other 
flaviviruses and their biological activities include neutralization, HI and complement-
fixation. It is not uncommon for anti-E mAbs to have more than one of these activities 
(see below). Despite reactivity with virus, anti-M mAbs have not been reported to 
possess these biological activities (see review by Heinz, 1986). Characterization of 
mAbs and epitope mapping studies have been used to determine the antigenic structure 
of E and to locate regions of functional significance in the E proteins of MVE, SLE, JE, 
TBE, DEN-2 and YF (Cammack and Gould, 1986a; Cecilia et al., 1989; Guirakhoo et 
al., 1989; Hawkes et al., 1988; Henchal et al., 1985; Roehrig et al., 1983). 
MAbs against MVE have been characterized (Hawkes et al., 1988), these define 
eight epitopes in E and show different properties of ELISA cross-reactivities, 
neutralization and HI activities. Topological studies by competitive binding assays 
(CBAs) using these mAbs showed that they define a continuum of overlapping epitopes 
(J. T. Roehrig, personal communication). MVE and other viruses of the JE complex 
share extensive homology in E sequence. It is therefore likely that these E proteins have 
similar epitope structure. Roehrig et al. (1983) characterized eight SLE epitopes which 
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overlap and form a continuum based on CBAs; these epitopes are defined by type-
specific or flavivirus cross-reactive mAbs showing various biological activities. 
Notably, both MVE and SLE have an epitope (E-lc), defined by mAbs which have 
strong neutralization and HI activities and are effective in protecting mice against lethal 
intraperitoneal (ip) challenge with virus (Hawkes et al., 1988; Mathews and Roehrig, 
1984). The mAbs against the E-lc epitopes of MVE and SLE are also type-specific in 
ELISA reactivity to the respective virus (Roehrig et al. , 1983; Hawkes et al., 1988). 
Several sets of anti-JE mAbs have been characterized by various investigators. 
The unifying theme which emerges is that mutual blocking occurs between mAbs in 
CBAs such that clusters of overlapping epitopes are defined (Cecilia et al., 1989; 
Kimura-Kuroda and Yasui, 1983; Kobayashi et al., 1985). A set of 16 mAbs to JE has 
been studied by CBA and two distinct clusters of overlapping epitopes defined (Cecilia 
et al., 1989). The remaining four mAbs are not involved in mutual blocking with these 
two clusters. One of the antigenic clusters consists of five epitopes which are all 
flavivirus cross-reactive and have HI activities. One-way inhibition, and one-way and 
reciprocal enhancement occur between some pairs of non-overlapping JE epitopes 
(Cecilia et al., 1989) suggesting interaction between antigenic domains. 
Epitopes on TBE are well studied with respect to function, serological specificity 
and spatial relationship. The most recent report for TBE (Guirakhoo et al., 1989) 
extends the previously established epitope map of TBE (Heinz, 1986). A total of 19 
epitopes on the E glycoprotein of TBE are defined by mAbs which show subtype-, 
type-, complex- and group-specificity in ELISA. Most of these mAbs are active in one 
or both the HI and neutralization assays against TBE; mAbs to two epitopes do not 
show either activity. 
Spatial relationships between the TBE epitopes were determined by CBAs using 
112s_labelled mAbs. As indicated by mutual blocking, 16 of the 19 TBE epitopes form 
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three distinct antigenic domains (A, B, C). There are three epitopes (il , i2, i3) which do 
not overlap with A, B, C or each other. However, one-way inhibition occurs between 
non-overlapping epitopes in the same domain, and between i2, i3 and epitopes in 
domains Band C. Enhancement of binding occurs between il and epitopes in domain 
A; some interaction between domains is also indicated by enhancement. The antigenic 
domains in TBE comprise epitopes defined by mAbs of various specificities and 
activities. Type or subtype-specific epitopes occur in all three domains. Flavivirus 
group- or subgroup-reactive epitopes only occur in domain A. Epitopes in domain B are 
mostly complex-reactive and those in domain C are mostly subtype-specific. MAbs to 
domain A are more likely to have stronger HI or neutralization activities than mAbs to 
domains B and C. 
Topological relationships betweeen epitopes of DEN-2 and YF also demonstrate 
more than one non-overlapping antigenic domain (Henchal et al., 1985; Cammack and 
Gould, 1986a). 
The ability of some mAbs to protect mice against lethal challenge with flaviviruses 
by the ip or the intracerebral (ic) route has been demonstrated :for MVE, SLE, YF, 
DEN-2 and TBE (Brandriss et al., 1986; Hawkes et al., 1988; Heinz et al., 1983; 
Henchal et al., 1983; Mathews and Roehrig, 1984) indicating that the corresponding 
epitopes may be exploited in developing vaccination strategies. Although the most 
effective mAb for passive protection against ip challenge with SLE is an E-specific mAb 
with the highest neutralization titre (Mathews and Roehrig, 1984), neutralizing as well 
as non-neutralizing E-specific mAbs passively protect against lethal challenge with 
MVE, YF and DEN-2 (Brandriss et al., 1986; Hawkes et al., 1988; Henchal et al., 
1983). Mixtures of E-specific mAbs which were non-protective when administered 
singly resulted in protection against ip challenge with SLE and against ic challenge with 
DEN-2 (Henchal et al., 1983; Mathews and Roehrig, 1984). The ability to protect 
against flavivirus challenge is not limited to mAbs against E, as a prM-specific mAb and 
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NS 1-specific mAbs are also effective in passive protection against lethal challenge with 
DEN-2 (Henchal et al., 1983; Henchal et al., 1988). 
1.5.3 Physical location of epitopes and a model of the TBE E 
protein 
The physical location of six TBE neutralization epitopes is defined by single amino 
acids (Mandl et al., 1989b): A3 (Asp 67, Ala 71), A4 (Gln 233), AS (Glu 207), B 1 
(Ser 389), B4 (Tyr 384) and i2 (Lys 171). The location of epitopes in domains A, B 
and C is also deduced from reactivity of mAbs with discrete E proteolytic fragments. 
The boundary of the three TBE domains have thus been defined. Domain A consists of 
two separate regions (residues 50-130, 200-250); domain B consists of the region 
residues 301-395 and domain C is deduced to be within the sequence from residue 145 
to 170 (Mandl et al., 1989b). 
Analysis of escape variants of YF selected with two neutralizing mAbs mapped 
neutralization epitopes to Asp 71 and Asn 72 in E (Lobigs et al., 1987) close to epitope 
A3 of TBE. Bacterial expression of viral proteins has been used to map epitopes in JE 
and DEN-1 E protein (Mason et al., 1989; Zuegel et al., 1987): ten JE neutralization 
epitopes and two DEN-1 neutralization epitopes have been mapped to regions 
homologous to domain B of TBE (Met 303-Trp 396 for JE; Thr 293-Met 401 for 
DEN-1). Two non-neutralizing mAbs also bind to a sequence in DEN-1 E protein 
(Thr 76-Lys 93; Zuegel et al., 1987) homologous to part of domain A of TBE. 
A two-dimensional model of the TBE E protein (Fig. 1.4; Mandl et al., 1989b) has 
been proposed, based on data from epitope mapping, topological studies, physical 
analysis and the disulfide linkage map for WN E (Nowak and Wengler, 1987). 
Physical properties of epitopes in each domain as revealed by chemical treatments (SDS, 
reduction and carboxymethylation, performic acid oxidation, deglycosylation, exposure 
to pH 5, cyanogen bromide cleavage and tryptic cleavage) are remarkably consistent 
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Figure 1.4 A model of TEE E protein (adapted from Mancil et al., 1989b; Chambers et al. 1990a) . 
Circles represent amino acids. Solid circles indicate residues absolutely conserved in the 11 flaviviruses 
(see Fig. 1.3) and open circles indicate nonconserved residues. Disulfide bonds are shown and diamonds 
indicate potential Asn-linked glycosylation sites (see text). Neutralization determinants in TEE (Heinz 
et al., 1989b) and YF (Lobigs et al., 1987) are indicated by arrows and arrowheads, respectively. Thin 
lines denote hyper-variable regions and the thick line a highly conserved sequence in E. 
(Guirakhoo et al., 1989) suggesting that domains A, B and C correspond to structurally 
distinct parts of E. The three domains appear to differ structurally: domain A is 
discontinuous and rich in disulfide bonds, domain B consists of one disulfide bond and 
can be isolated as a tryptic peptide of 9K, and domain C is probably in a hypervariable 
'loop' region containing the glycosylation site (Guirakhoo et al., 1989; Mandl et al., 
1989b). 
Domain A is noted for the presence of the most highly conserved sequence 
(between Asp 98 and Gly 111) in flaviviruses which is rich in glycine (6 out of 14 
residues) (Roehrig et al., 1989). Reactivities of mAbs to domain A are reduced at 
pH 5.5-6 correlating well with conformational changes at similar pH revealed by 
protease K digestion (Guirakhoo et al., 1989). These properties of domain A suggest 
that it may be responsible for the acid-induced fusion activity (Chambers et al., 1990a). 
The discovery of TBE and MVE variants with attenuated virulence for mice and 
amino acid sequence changes in domain B suggests that this domain also has an 
important role (see below). 
Domain C is notable for the existence of the glycosylation site. Although 
glycosylation does not affect the infectivity, haemagglutination activity or antigenicity of 
TBE (see above), deglycosylation renders epitopes in domain C sensitive to SDS 
denaturation judging from reactivity in Western blots (Guirakhoo et al., 1989). It is 
therefore likely that the stability of domain C is affected by glycosyaltion. 
With regards to the structure and functions of E, a lot remains unresolved. A 
significant achievement has been the two dimensional model for the WN and TBE E 
proteins (Nowak and Wengler, 1987; Mandl et al., 1989b). However, not enough is 
known about the location of epitopes in other flaviviruses to establish a unifying view of 
the antigenic structure. Based on sequence similarity, conservation of hydropathy 
character and cysteines, it is expected that the tertiary structure of Eis homologo1:1s to a 
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large extent between flaviviruses. Thus new data on the structure of various E proteins 
can be compared with and used to extend the existing structural models of E. 
Information from epitope mapping and analysis of the three-dimensional structure of E 
would be of great value in predicting the regions involved in cell entry (receptor binding 
and fusion), neutralization and the interaction between E, prM and M during assembly 
of infectious virus. 
1.6 Studies of virulence of flaviviruses 
The flavivirus infection which occurs in humans may be visceromorphic or 
neuromorphic; flavivirus infection can also be less severe and involve no tissue 
specificity (reviewed by Monath, 1986). However, these patterns of infection are not 
mutually exclusive. Some flaviviruses are associated with different infections of 
varying severity. Viruses of the JE complex are capable of causing encephalitis in 
human as well as a less severe febrile illness. Similarly, infection of humans by YF can 
be mild, visceromorphic (hepatotropic) or neuromorphic (Monath, 1986). 
Virus-associated and host-associated factors may moderate pathogenesis (see 
review by Brinton, 1986). Age, sex, ethnicity, genetic and immurtological factors are 
all capable of influencing disease outcome in an infected individual. Viral factors which 
influence the replication and spread in the host, the ability to evade the immune response 
(humoral and cell-mediated immunity, interferons) and tissue tropism of virus may also 
determine virulence. 
1.6.1 Virulence of flaviviruses for mice 
The availability of a laboratory host for experimental infection of flaviviruses is 
essential to studies of virulence and pathogenesis . Mice are the most commonly used 
laboratory host for virulence studies of flaviviruses. Susceptibility of mice to flavivirus 
infection depends on genetic factors , age and route of inoculation (El Dadah et al., 
1967). Although ic inoculation of weanling mice with MVE, SLE, JE and KUN usually 
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results in lethal encephalitis, the outcome of ip inoculation varies greatly according to the 
age of the mice and the virus strain (Monath et al., 1980). 
Infection of mice by the ip route appears to provide a reasonable model for the 
pathogenesis of encephalitic flaviviruses such as MVE, JE, SLE and TBE. Viremia and 
neuroinvasion occur on lethal infection of mice after ip inoculation as in human 
encephalitis caused by flaviviruses (Albrecht, 1968). A method for assessing mouse 
virulence has been developed which relies on mortality ratios after ic and ip inoculation 
of 21-day old mice. Virulence is expressed as the ic/ip LD50 ratio (Monath et al., 
1980). Seven strains of MVE isolated from birds, mosquitoes or infected animals and 
humans from various parts of Australia and Papua New Guinea were virulent using this 
assay (Lobigs et al., 1988). SLE isolates from various parts of the United States fall 
into high, intermediate or low virulence groups by similar criteria (Monath, 1980). The 
highly virulent SLE strains induce high viremia in infected mice and replicate in 
extraneural tissues with earlier neuroinvasion. Mouse virulence shows a good 
correlation with clinical signs (fever, encephalitis) and histopathological markers of 
pathogenicity, in ic-inoculated rhesus monkeys (Monath et al., 1980). There is also a 
correlation between mouse virulence and capacity of virus to induce viremia in the 
House Sparrow, a natural vertebrate host for SLE (Bowen et al., 1980). 
JE strains show variation in virulence for three-week old mice on the basis of 
differences between ic and subcutaneous LD50 values; virulence correlates with level 
and duration of viremia in mice and thermostability of the virus (Huang, 1957). JE 
isolates from humans and pigs are invariably virulent while 10% of isolates from 
mosquitoes have low virulence (Huang, 1982). 
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1.6.2 Sequence studies of variants with attenuated virulence 
for mice 
The genetic basis for differences in mouse virulence between geographical isolates 
of JE and SLE (see above) is· not known although differences between these JE and SLE 
isolates are demonstrated by RN Ase Tl oligonucleotide fingerprinting (Burke et al., 
1985; Trent et al., 1980). 
Sequence analysis of laboratory derived mutants with attenuated virulence is 
particularly useful for assessing the contribution to virulence of particular viral proteins. 
Such studies have been used to compare the virulent YF Asibi strain and the avirulent 
17D vaccine derivative as well as the virulent SA-14 strain of JE and its attenuated 
derivative (Hahn et al., 1987b; Nitayaphan et al., 1990). Extensive passaging of the YF 
Asibi strain in embryonic mouse and chick tissues gave rise to the widely used human 
17D vaccine strain with markedly reduced neurotropism and viscerotropism (Theiler, 
1937). Candidate vaccine strains of JE were derived by passaging in primary baby 
hamster kidney cells and infant mice (Huang, 1982; Yu et al., 1988). 
The YF Asibi strain has been sequenced completely for comparison with the 17D 
sequence (Rice et cil., 1985) in an effort to correlate attenuation of virulence with 
changes in the genome and protein sequence (Hahn et al., 1987b). There is a 0.63% 
nucleotide sequence divergence between the two strains corresponding to 32 amino acid 
differences in the polyprotein (3430 amino acids), 12 of which are in E ( 493 amino 
acids). This biased distribution of amino acid differences indicates possible involvement 
of E in virulence attenuation. It has been proposed that virus binding to the cell receptor 
may be affected as a result of changes in the E protein, thus explaining the reduced 
neurotropism and viscerotropism exhibited by the vaccine strain (Hahn et al., 1987b ). 
Comparison between the JE vaccine strain SA-14-14-2 and its parent strain SA-14 gave 
approximately 0.4% nucleotide sequence divergence corresponding to 15 amino acid 
differences in the polyprotein (3432 amino acids), five of which are in E (Nitayaphan et 
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al., 1990). This biased distribution of amino acid differences is again consistent wi th E 
being involved in attenuation. 
Passaging of MVE in SWl 3 cells and of Louping ill virus, Langat virus and three 
strains of WN in HeLa cells also generated variants with attenuated mouse virulence 
(Dunster et al., 1990; Lobigs et al., 1990). Comparison of the E sequences of the MVE 
variants implicated changes at Asp 390 as being important in attenuation, although 
changes in the rest of the genome may also contribute. An antigenic variant of TBE 
selected with neutralizing mAb was attenuated in mice and induced active immunity 
against lethal challenge (Heinz et al., 1989); it is changed at Tyr 384 in E. This is the 
first demonstration for flaviviruses that a neutralization determinant may overlap with 
determinants of mouse virulence. An important role for the region of E close to 
residue 390 is also supported by the two nonconservative differences between 17D and 
Asibi strains of YF at 380 (Thr/Arg) and 390 (Pro/His) which correspond to Arg 388 
and His 398 in MVE. These results suggest that the E proteins of flaviviruses may 
possess critical virulence determinants and that the region around amino acids 384 and 
390 may be involved directly or indirectly in an important functional domain. 
1. 7 Aims and outline of thesis 
The work described in this thesis aims to increase our understanding of Murray 
Valley encephalitis virus through focusing attention on functional domains in the 
envelope protein (E). There are two broad themes. In the first, covered in Chapters 2, 
3 and 5, we explore the use of expression systems to isolate and characterize segments 
of E and to define immunologically reactive determinants in E. 
In Chapter 2, we investigate the possible use of a bacterial expression system in 
expressing, as immunologically reactive fusion proteins, random overlapping fragments 
of cDNA generated by partial restriction enzyme digestion of a cDNA clone representing 
the 5' terminal half of the MVE genome. In chapter 3, we study the reactivity of five 
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neutralizing mAbs with fusion proteins generated by deletion subcloning of different 
segments of the MVE E gene with a view to map the corresponding epitopes in E. To 
further examine the epitopes in these MVE fusion proteins, they were used to generate 
antisera in mice for tests of activities against MVE in ELISA and neutralization assays. 
It became apparent from the results obtained in Chapter 3 that only certain epitopes 
in the MVE E proteins could be generated in a 'native' conformation and that this would 
restrict us in our aims of defining functional domains using an expression system. 
Accordingly, in Chapter 5 we explore the possibility of using a eukaryotic expression 
system. Data on the yield, processing, conformation and subcellular localization of 
. MVE structural and nonstructural proteins expressed in insect cells from cDNA cloned 
into a baculovirus vector are presented in Chapter 5. 
The second theme of this thesis is a study of the structure-function relationships of 
the MVE E protein in its 'natural' environment (virion). In these studies, described in 
Chapter 4, we map a number of neutralization epitopes in the MVE E protein by 
sequencing neutralization escape variants. To determine whether these changes affect 
' 
the biological properties of the virus in vivo, we examine the virulence of a number of 
these escape mutants for mice. 
The thesis concludes with Chapter 6 in which the main threads are drawn together 
and the contribution of the work described in the preceeding chapters to the structure-
function relationships of the MVE E protein is discussed. 
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CHAPTER 2 
EXPRESSION OF MURRAY VALLEY 
ENCEPHALITIS VIRUS ANTIGENS IN 
E.COLI 
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2.1 INTRODUCTION 
One approach to examining functionai domains in the MVE E protein is to express 
the protein in a bacterial expression system, to screen for immunologically reactive 
clones with polyclonal sera against MVE and to sequence the positive clones. Reactive 
clones could then be subjected to a variety of further levels of analysis. Bacterial 
expression systems have a number of advantages in such studies. These include the 
ease of DNA manipulation and the possibility of obtaining large amounts of proteins 
which could be of value as 'reagents' for various purposes. The value of bacterial 
expression systems has been demonstrated for several flaviviruses. The E proteins of 
JE and DEN-1, and the NSl proteins ofDEN-1 and DEN-2 have been expressed in 
E.coli (Mason et al., 1987b; Mason et al., 1989; Zuegel et al., 1987; Putnak et al., 
1988) and epitopes in these proteins mapped using mAbs. Fragments of the small 
nonstructural proteins of YF expressed in E.coli have been used to generate antisera 
which allowed the identification of NS2A, NS2B and NS4B (Chambers et al., 1989). 
NS 1 of YF expressed in E.coli has been used to immunize mice resulting in a reduction 
of neurovirulence on YF challenge (Cane and Gould, 1988). Thus in some instances 
the native conformation for viral proteins may be retained following expression in a 
bacterial system. However in others, the native conformation is not obtained; thus the 
JE E-B-galactosidase fusion protein reacted with neutralizing mAbs but did not elicit 
neutralizing antibodies in mice (Mason et al., 1989). 
In this chapter we explore the application of the pEX vector system (Stanley and 
Luzio, 1984) to the expression of MVE proteins. The pEX expression system has been 
used extensively in epitope mapping for various virus systems (e.g., for Herpesviruses 
and Coronaviruses; see Lenstra et al., 1990), but not as yet for flaviviruses . pEX 
plasmids have the following useful features. They are inducible (at 42°) and have a 
strong A PR promoter. Insertion in the polylinker region generates a fusion protein 
containing, at its N-terminus, a large portion of the lacZ (B-galactosidase) protein. The 
use of a mixture of three pEX plasmids (pEXl, 2, 3) which differ in the polylinker 
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region, allows translation of inserts in all possible reading frames . When induced, 
proteins accumulate as aggregates and are partially protected from degradation (Stanley 
and Luzio, 1984). We aim to express certain MVE structural and nonstructural proteins 
(those encoded in the 5' terminal half of the genome) using this system. The strategy 
adopted is to clone into the pEX vector, fragments of MVE cDN A generated by partial 
digestion with a 4-bp recognition enzyme in order to obtain a random and overlapping 
set of MVE protein fragments as fusion proteins. We screen for immunologically 
reactive clones with hyperimmune ascitic fluid against MVE. The proteins expressed by 
the recombinant plasmids are then characterized with respect to size, identity, yield and 
stability. 
2.2 MATERIALS AND METHODS 
2.2.1 Bacterial strains and plasmids 
The pEX plasmids (1, 2, 3) (Fig. 2.lA; Stanley and Luzio, 1984) and the host 
E.coli MC1061/pCI857 were provided by Dr M.J. Howell (Zoology Department, 
Faculty of Science, Australian National University). The latter carries the plasmid 
.. 
pCI857 (Fig. 2. lB) encoding kanamycin resistance and the li CI repressor gene of 
bacteriophage A. Growth of bacteria was at 30° in Luria-Bertani (LB) medium (Maniatis 
et al., 1982) supplemented with ampicillin (lOOµg/ml; Sigma Chemical Co. St. Louis, 
Missouri, USA) and kanamycin ( 40µg/ml; Sigma). 
Plasmid p2/1/22 (Fig. 2.2), provided by Dr L. Dalgarno (Biochemistry 
Department, Faculty of Science, Australian National University), is from an M\lE 
genomic library (Rice et al., 1988). It comprises the 1.9 kb plasmid vector pMT21 
(from Dr H.V. Huang, Department of Molecular Microbiology, Washington University 
School of Medicine, St. Louis, Missouri, USA) which codes for ampicillin resistance, 
and the 5' terminal 5.4 kb of the MVE genome coding for C, prM, E, NS 1, NS2A, 
NS2B and half of NS3; the complete sequence of p2/1/22 is established (Dalgarno et al., 
1986). 
32 
A. pEX1 G..UTI..U'ITCCCGGG 
pEX2 G ..UTTCCCGGG 
pEX3 G CCCGGG 
Sma! Bam.H! Sa.lI P,tI Hind!!! 
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EcoRY 
termination uquence 
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Hindi II 
B. 
From 
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~ 
pCl857 I.I \ 
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Figure 2.1 (A) pEX plasmids 1, 2 and 3. The three pEX plasmids are represented diagrammatically 
showing the gene for ampicillin resistance (AmpR ), the cro gene, the lacZ* gene (missing ::::60 bp and 
55 bp at the 5' and 3' termini of lacZ, respectively), and the pBR322 origin of replication (Ori). Arrows 
indicate the direction of transcription and length of genes. Each plasmid also contains a polylinker, stop 
codons in three reading frames ('STOP') and a fragment from phage fd containing a transcription 
termination sequence. The three plasmids differ only in the polylinker region; pEXl is eight and four 
base pairs longer than pEX3 and pEX2, respectively. Data are adapted from Stanley and Luzio (1984). 
(B) Plasmid pCI857. pCI857 (4.1 kb) is made up of the pMC931 plasmid, the kanamycin resistance 
gene and the ts CI repressor gene from phage A. 
0 1 2 3 4 5 6 7 kb 
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Figure 2.2 Sau3A restriction map of linearized p2/l/22. Locations of Sau3A restriction sites were 
determined by a computer search of the pMT21 sequence (H. V. Huang, personal communication) and 
the MVE genome sequence (Dalgarno et al., 1986), and are shown as vertical lines. The p2/l/22 is 
linearized at the 5' terminus of the MVE insert. It contains the 5' untranslated region (=90 bp), coding 
regions for C, prM, E, NS1, NS2A, NS2B and NS3 proteins and the pMT21 plasmid (1895 bp). 
2.2.2 Agarose gel electrophoresis 
Separation of DNA fragments was on 1 % agarose. Agarose was prepared by 
dissolving agarose (1 % w/v; Ultra-pure DNA grade, Bio-Rad Laboratories, Richmond, 
California, USA) in TAE buffer (40 mM Tris-HCl, pH 7.8, 5 mM sodium acetate, 
l llli\1 EDTA). A horizontal slab gel c~12 ml; 50 mm x 75 mm) was used. One tenth 
of a volume of loading buffer containing 15% Ficoll type 400 (Pharmacia Fine 
Chemicals, Uppsala, Sweden), 0.1 M EDTA, 20 mM Tris-HCl (pH 7.8), 2.5 mM 
sodium acetate and 0.25% (w/v) Orange G was added to the sample and the mixture 
incubated at 65° for 5 min. Size markers were A DNA (New England Biolabs, Beverly, 
Massachussetts, USA) digested with Hind.III or Hind.III and EcoRI. Electrophoresis 
was at 60 volts for 1.5 hours or until the dye reached the bottom of the gel. Gels were 
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soaked in ethidium bromide (0.5 µg/ml; Sigma) for 30 min; DNA fragments were 
detected under UV illumination. 
2.2.3 DNA manipulations 
Plasmid DNA for cloning, restriction analysis and sequencing was extracted by 
. , 
alkaline lysis (Maniatis et al., 1982). Bacteria in LB medium containing antibiotics were 
incubated overnight at 30°. Cell pellets from 3 ml of culture were collected in 
Eppendorf tubes by centrifugation for 2 min and resuspended in 100 µl of ice-cold 
50 mM glucose (Sigma), 10 mM EDTA, 25 mM Tris-HCl (pH 8.0) and 4 mg/ml 
lysozyme (P-L Biochemicals, Milwaukee, Wisconsin, USA). After 5 min at room 
temperature, 200 µl of ice-cold 0.2 M N aOH, 1 % SDS was added, and the mixture 
incubated on ice for 5 min. Potassium acetate solution (150 µl; Maniatis et al., 1982) 
was then added, mixed and incubated for 5 min. The mixture was centrifuged for 5 min 
(Eppendorl) at 4 °. The supernatant was extracted with redistilled phenol (British Drug 
Houses, Port Fairy, Australia): isoamylalcohol (Ajax Chemicals, Sydney, Australia): 
chloroform (Ajax) (25:1:24) twice. DNA was precipitated with ethanol (2 volumes), 
recovered by centrifugation and resuspended in 5 mM TE buffer (5 mM Tris-HCl, 
pH 8, 0.5 mM EDTA) containing DNAase-free pancreatic RNAase A (20 µg/ml; 
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Boehringer-Mannheim, Mannheim, West Germany). Digestion was at 37° for 30 min . 
., 
For restriction enzyme (RE) digestion, plasmid DNA was incubated with enzymes 
(New England Biolabs; 2 units per µg DNA) at 37° for 1 hour unless stated otherwise. 
RE buffers were 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 0.1 mg/ml bovine serum 
albumin (Bio-Rad) and Na Cl at 150 mM, 100 mM, 50 mM or O mM according the 
manufacturer's recommendation. Smal digestion was in 10 mM KCl, 10 mM Tris-
HCl (pH 7.5), 10 mM MgCl2 and 0.1 mg/ml bovine serum albumin at 25°. 
Incubation with Smal was carried out first when other enzymes were also used. 
Incubation with other enzymes then followed in appropriate buffer conditions without 
removing the KCL Enzyme digestion was stopped by incubation at 70° for 10 min. 
2.2.4 Construction of pEX-MVE recombinant plasmids 
For the partial digestion of p2/1/22, DNA (2 µg) was incubated with Sau3A (0.2 
units) at 37° for 10 min, heated at 70° for 10 min and used directly for cloning without 
size selection. pEX vector DNA was prepared for ligation with Sau3A-digested cDNA 
by digesting (37°, 1 hour) a mixture of pEXl, 2 and 3 (1.5 µg each) with BamHl (10 
units). Calf intestinal alkaline phosphatase (2 units; Boehringer) was added and the 
mixture incubated at 37° for 30 min and heated at 70° for 10 min. DNA was twice 
extracted with phenol/chloroform and precipitated with sodium acetate (0.3 M, pH 5.2) 
and ethanol (2 volumes). 
For ligation, vector DNA (0.4 µg), Sau3A-digested p2/1/22 (~15 ng) and T4 
DNA ligase (100 units, New England Biolabs) were incubated in a final volume of 
10 µl containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 20 mM dithiothreitol 
(DIT; Boehringer), 1 mM ATP and 50 µg/ml bovine serum albumin. The precise 
molar ratio of vector to insert DNA could not be calculated. Incubation was at 14 ° for 
16 hours followed by heat inactivation at 70° for 10 min. Dephosphorylated vector 
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DNA was ligated alone as control to determine levels of uncut and re-ligated vector 
DNA. 
2.2.5 Preparation of competent Ecoli and transformation (C . 
M. Rice, personal communication) 
E.coli MC1061/pCI857 cells were harvested from 50 ml log phase culture (OD 
630nm = 0.6) by centrifugation at 8000 rpm for 10 min, resuspended in 5 ml of ice-
cold 0.1 M CaCl2, held on ice for 20 min and centrifuged again. Cell pellets were 
resuspended in 0.5 ml of 0.1 M CaCl2 plus 15% glycerol (May and Baker, Sydney, 
Australia) and stored in liquid nitrogen in 50 µl aliquots. For transformation, 
competent cells were diluted in 18 volumes of 0.1 M CaCl2 and divided into two equal 
portions. Ligated DNA mixtures (10 µl) were added to each and the cells were held on 
ice for 30 min followed by a heat shock at 43° for 45 seconds. LB broth (30°) was then 
added to dilute the mixtures 10-fold. Cells were incubated for 1.5 hours at 30° and 
recovered by centrifugation at 4000 rpm for 10 min, resuspended, spread and incubated 
at 30° on LB plates containing 1.5% (w/v) Bacto-agar (Difeo Laboratories, Detroit, 
Michigan, USA), ampicillin and kanamycin. 
2.2 .. 6 Hyperimmune ascitic fluid (HIAF) 
Anti-MVE HIAF was provided by Dr R. C. Weir (Biochemistry Department, 
Faculty of Science, Australian National University). UV-inactivated MVE-1-5 1 (the 
prototype strain; French, 1952) was used to inoculate animals, the animals were boosted 
with live virus and ascitic fluids harvested (Tikasingh et al., 1966). A single batch of 
HIAF was used for the work described in this Chapter. Its ELISA titre was 128,000. 
This antibody preparation immunoprecipitated MVE C, prM, M and E as well as NS 1, 
NS3 and NS5 (Lee et al., 1990; Lobigs et al., 1986). 
2.2. 7 Immunological screening 
Colonies expressing MVE antigens were identified by colony blots following 
Stanley (1983) and M. J. Howell (personal communication). For initial screening, 
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colonies ( ;:;:2000) which grew on LB plates containing 100 µg/ml ampicillin and 
40 µg/ml kanamycin were tested. For subsequent confirmation of positive clones and 
for estimation of percentage of immunoreactive colonies, approximately 100 colonies 
were tooth-picked to LB plates. After incubation at 30° for 16 hours, the colonies were 
transferred to sterile, dry nitrocellulose (0.45 µm, Schleicher and Schuell, Dassel , W. 
Germany) by blotting. Membranes were then placed on two sheets of 3MM paper 
(Whatman Ltd.,, Kent, England) soaked in LB medium containing antibiotics. 
Expression of fusion proteins containing a hybrid protein cro -f3-galactosidase, termed 
f3-gal *, was induced by incubation for 2 hours at 42 °. Membranes were then placed, 
colony-side up, on 3 sheets of 3MM paper moistened with 5% sodium dodecyl sulphate 
(SDS; Bio-Rad), and baked at 100° for 15 min. SDS was removed by soaking 
membranes for 5 min (x4) in wash buffer (WB) which contained 0.05% Tween-20 
(Sigma) in phosphate-buffered saline (PBS; 0.15 M NaCl, 2.7 mM KCl, 10 mM 
N a2HP04, 2 mM KH2P04, pH 7 .5). The membranes were then treated as follows: 
(1) 30 min in WB containing 5% (w/v) non-fat milk powder (Diploma, Melbourne, 
Australia); (2) 30 min in WB containing 0.1 mg/ml DNAase (bovine pancreatic; Sigma); 
(3) 3 x 5 min in WB; (4) 60 min in WB containing anti-MVE HIAF (1/400); (5) 3 x 5 
min in WB; (6) 60 min in WB containing horseradish peroxidase coupled to goat anti-
(mouse IgG) (1/1500; Bio-Rad); (7) 3 x 5 min in WB and 5 min in PBS. Colour 
devolpment was for 30-60 min at room temperature in Tris-buffered saline (0.2 M 
NaCl, 0.05 M Tris-HCl, pH 7.4) containing 4-chloro-1-naphthol (0.5 mg/ml; Bio-
Rad) and hydrogen peroxide (0.02% ; v/v; Ajax). 
2.2.8 DNA sequence analysis 
Recombinant plasmid DNA (1 µg) was incubated \Vith HindIII (5 units) at 37° for 
1 hour followed by 10 min at 70°. The 3' recessed ends were labelled by addition of 
Klenow fragment (5 units; New England Biolabs), a-32P-dCTP (20 µCi; Amersham 
International Ltd., Amersham, U.K.), an excess (0.5 mM) of the other three dNTPs 
and f3-mercaptoethanol (B-ME; Sigma) to a final concentration of 1 mM. Incubation 
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was at 37° for 30 min and then 70° for 10 min. EcoRV (see Fig. 2.1 ) was then added (5 
units) and the mixture incubated (37", 1 hour) to produce fragments labelled at the 3' 
ends. These were separated on 8% (w/v) preparative acrylamide gels (Bio-Rad; 40 cm 
long, 0.4 mm thick) cross-linked with N,N'-bisacrylylcystamine (BAC; Bio-Rad) 
( 19: 1 ). Electrophoresis was at 200 V for 16 hours in TBE buffer (0.1 M Tris-HCl, 
pH 8.3, 0.1 M boric acid, 2 mM EDT A). Size standards were A DNA (0.2 µg) 
digested with Hind.III and labelled with a-32P-dCTP as above. The gel was exposed 
for 15 min to Fuji RX-100 film for autoradiography. DNA fragments were localized, 
excised and extracted by incubation of gel slices with B-NIE and then with DE-52 DEAE-
cellulose resin (Whatman) (Garfinkel et al., 1983). Fragments were subjected to 
cleavage reactions (Maxam and Gilbert, 1980) with hydrazin (Eastman Kodak Co., 
Rochester, New York, USA), dimethyl sulphate (Aldrich Chemical Co., Milwaukee, 
Wisconsin, USA), formic acid, sodium hydroxide and piperidine (Fisher Scientific Co., 
Fair Lawn, New Jersey, USA) for sequence analysis as described by Sambrook et al. 
(1989). Cleavage products were separated on sequencing gels (80 cm long and 
0.4 mm thick) containing 5% acrylamide: bisacrylamide (19:1). They were dried under 
vacuum at 80° in a slab-gel dryer (Bio-Rad) and exposed to Fuji RX-100 films for 
autoradiography. Intensifying screens (Kodak) were sometimes used. 
2.2.9 Induction of MVE fusion proteins and analysis of 
bacterial lysates by polyacrylamide gel electrophoresis 
Bacterial colonies selected by immunological screening were grown in LB medium 
containing ampicillin (100 µg/ml) and kanamycin (40 µg/ml). Incubation was in an 
orbital shaker at 30° overnight. The overnight-cultures were diluted to an absorbance 
( 630 nm) of 0.05 with LB medium containing antibiotics and incubated for a further 1 
hour as above. The temperature was raised to 42° for induction of fusion protein 
synthesis. Bacteria (1.5 ml) were collected after 2 hours by centrifugation for 2 min 
(Eppendorf), resuspended to 75 µ1 in SDS-polyacrylamide gel electrophoresis (PAGE) 
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sample buffer (Laemmli, 1970) and heated for 2 min at 100°. Lysates were sonicated 
(20 seconds), centrifuged (2 min) to remove debris and stored at -20°. 
Lysates (1 µl) were diluted in SDS-PAGE sample buffer containing 5% (v/v) 
B-ME, heated (2 min, 100°) and electrophoresed on vertical slab gels (70 mm x 
100 mm x 0.75 mm) (Laemmli, 1970). The stacking and resolving gels contained 3 
and 7.5% acrylamide respectively. Gels were stained for 30-60 min in 0.25% (w/v) 
Coomassie Brilliant Blue R-250 (Serva, Heidelberg) in 10% (v/v) acetic acid-45 % (v/v) 
methanol (Ajax). Destaining was in 23% (v/v) ethanol-IO% (v/v) acetic acid. Mol. wt. 
standards (43-200K; Bio-Rad) were electrophoresed and stained on the same gel. 
2.3 RESULTS 
2.3.1 Construction of MVE-pEX recombinant plasmids 
The initial objective was to prepare a library containing genes for the MVE proteins 
prM, E and NS 1 in the pEX vector. Plasmid p2/1/22, which derives from ligation of 
the pMT21 vector (see Section 2.2.1) with cDNA coding for the 5' terminal half of the 
MVE genome, was the source of MVE sequences. S au3A digestion was used to 
generate a range of fragments for cloning. Sau3A was chosen for three reasons. First, 
as a 4-bp restriction enzyme, it cleaves frequently and hence a partial digest will, in 
principle, generate random overlapping fragments. Second, it generates fragments with 
BamHI compatible ends. Finally, the number of Sau3A sites in the MVE E gene was 
greater than that for other 4-bp restriction enzymes examined. There are 27 predicted 
Sau3A sites in p2/1/22, including 12 in the insert and 15 in the vector (Fig. 2.2). There 
are five Sau3A sites in the E gene and thus a variety of E gene fragments could be 
generated. It was noted that there is no Sau3A site in the C gene and thus Sau3A 
fragments coding for C would contain the 5' untranslated region (Fig. 2.2). The 
expression of C from these fragments was expected to be disrupted by in-frame 
nonsense codons present in this region. 
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To obtain overlapping restriction fragments, a partial digestion of 2 µg of p2/1 /22 
DNA with Sau3A was performed. Fragments in the restriction digest ranged fron1 
below 100 bp to around 2 kb (Fig. 2.3). As the largest completely digested fragment 
was expected to be = 1.3 kb, this indicated that partial digestion had occurred. To 
minimize the loss of small fragments (=100 bp or less) from the E gene (Fig. 2.2), the 
partial digest was ligated, without extraction, to a mixture of BamHI-digested, 
dephosphorylated pEXl, 2 and 3 vectors. The mixture was used to transform E.coli 
MC1061/pCI857. From 0.1 µg of total DNA, approximately 10,000 ampicillin and 
kanamycin resistant colonies were obtained. 
2.3.2 Immunoscreening of bacterial colonies 
Anti-MVE HIAF was used to identify colonies expressing recombinant MVE 
proteins. Colonies were grown on LB plates containing antibiotics overnight and 
transferred to nitrocellulose. Adherent cells were incubated at 42° for 2 hours to induce 
synthesis of the B-gal* fusion protein, and were lysed by SDS treatment at 100°. MVE-
specific proteins were detected using anti-MVE HIAF and anti-(mouse IgG) coupled to 
peroxidase. Approximately 1 % of the colonies reacted with anti-MVE IDAF. The low 
frequency was not surprising because of the presence of pMT21 sequences during 
cloning, the possibility of out-of-frame translation of MVE sequences and of insertion of 
MVE sequences in the reverse orientation. Eleven immunoreactive clones were 
eventually isolated. These were designated 88-I, 2-II, 4-II, 48-II, 63-II, 60-V, 81-V, 
92-V, 103-V, 9-VI and 11-VI. One of the eleven immunoreactive clones ( 48-m was 
unstable on propagation: the recombinant plasmid (p48-II) was replaced by pEX 
plasmids resulting in a loss of irnmunoreactivity. 
2.3.3 Size of inserts encoding immunoreactive peptides 
As a first step in identifying the positions in the MVE genome represented by the 
immunoreactive fusion proteins, the sizes of the inserts in the recombinant pEX 
plasmids were determined. Using alkaline lysis (Materials and Methods), plasmid DNA 
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Figure 2.3 Agarose gel electrophoresis of a Sau3A-partial digest of p2/l/22. p2/l/22 (2 µg) was 
incubated with Sau3A (0.2 units) in RE buffer containing 0.15 M NaCl at 37° for 10 min and 
electrophoresed on 1 % agarose gel. 
was extracted from the 11 positive clones for RE digestion with Sall and Smal~ these 
sites flank the BamHI site in the polylinker (Fig. 2.1). The size of the insert was 
determined after digestion with these enzymes. Plasmids p63-II, p9-VI, p81-V and 
p48-II each released one fragment (0.4, 0.9, 1.5 and 2.8 kb, respectively) 
corresponding to the insert, together with the vector (5.8 kb) and pCI857 (4.1 kb) 
(results not shown). This indicated that there were probably no SmaI or Sall sites in 
these inserts. Plasrn.ids p88-I, p2-II, p4-II, p60-V, p92-V, pl03-V and pl 1-VI released 
fragments smaller than 200 bp which could not be accurately sized. It was not possible 
to identify inserts from their sizes because p2/1/22 contains several small Sau3A 
fragments of similar size and multiple inserts may be present in some recombinant 
plasmids. 
2.3.4 Characterization and mapping inserts encoding 
immunoreactive peptides 
To map the inserts in the 11 clones, two approaches were used: restriction enzyme 
analysis followed by DNA sequence analysis. 
The large inserts in p9-VI, p81-V and p48-II were characterized by digesting with 
Mlul and Pstl enzymes and agarose gel electrophoresis (results not shown); a Sau3A 
fragment from the E gene (corresponding to nucleotides 1403-2149; 0.75 kb) was 
identified as present in p9-VI and a Sau3A fragment from the prM-E gene 
(nucleotides 534-2149; 1.6 kb) as present in p48-II (Fig. 2.4). However, since inserts 
in p9-VI and p48-II, 0.9 and 2.8 kb respectively, were larger than these two Sau3A 
fragments in each instance, it was concluded that p9-VI and p48-II also contained 
additional Sau3A fragments. Plasmid p81-V did not contain the above fragments from 
similar analysis (results not shown). 
Sequence analysis was performed on all clones. The eleven plasmids were 
digested with HindIII and end-labelled using a-32P-dCTP. A second digestion with 
EcoRV allowed isolation of fragments labelled solely at the one of the 3' ends. 
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Figure 2.4 Orientations and sizes of inserts in recombinant plasmids. The locations of Sau3A 
fragments are indicated by alignment with the MVE genome and with the pMT21 sequence. MVE 
frag ments are numbered from the 5' terminal nucleotide of MVE-1-51 RNA (Dalgarno et al., 1986). 
pMT21 fragments are numbered from the 5' terminal nucleotide in the sequence linearized at the EcoRI 
site at the end of the polylinker (H. V. Huang, personal communication). Arrows indicate the 
orientation of these fragments in the recombinant plasmids: (-) ), orientation identical to lacZ* coding 
region; ( ~ ), opposite orientation. Numbers above the fragments indicate their relative positions in the 
insert. 
Sequencing reactions were performed on these fragments (Maxam and Gilbert, 1980). 
Up to 400 bases from the 3' termini of the inserts were sequenced. Inserts in eight of 
the eleven clones listed in Table 2.1 were completely sequenced including the adjoining 
poly linker region in the pEX vectors. Inserts in the three remaining clones ( 48-II, 81-V, 
9-VI) were only partially sequenced, but could be mapped from the sequence data, the 
size of inserts and RE analysis. 
The MVE E gene, which was our major interest, was represented in the three 
largest plasmids, p48-II, p81-V and p9-VI. Plasmid p48-II contained the largest insert 
and comprised three Sau3A fragments. The first Sau3A fragment (1721 bp), from the 
prM and E genes, was correctly oriented with respect to the lacZ coding region; the 
second and third (36 bp, 663 bp) were from the vector (Fig. 2.4). Translation of the 
insert was predicted to produce an MVE polypeptide of 57 4 amino acids containing 87% 
of prM and 86% of E (Ile 23 in prM to Gly 429 in E). The reading fr~me was 
terminated by a nonsense codon five amino acids into the pMT21 vector sequence. 
Plasmid p9-VI contained a single Sau3~ fragment (852 bp) from the E gene; the insert 
was in the correct orientation and encoded 284 amino acids (Ser.146-Gly 429) which 
represent 57% of E. Plasmid p81-V contained two Sau3A fragments, the first spanning 
the E, NSl and NS2A genes (1430 bp) in the correct orientation while the second 
(78 bp) was from the vector. Translation of the insert was predicted to produce an 
MVE polypeptide of 477 amino acids containing the C-terminus of E (72 amino acids), 
all of NS 1 (352 amino acids) and part of NS2A. This protein therefore comprised 
Ser 430 in E to Asp 53 in NS2A. Translation was terminated by a nonsense codon 
seven amino acids into the pMT21 sequence. 
Plasmids p88-I, p2-II, pl03-V, p60-V, p92-V, pll-VI, p4-II and p63-V were 
sequenced completely through the inserts and the 5' adjoining polylinker region. From 
this it was established that p88-I, p2-II and p103-V were recombinants of pEXl 
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Clone 
88-I 
2-II 
103-V 
60-V 
92-V 
11-VI 
4-II 
63-II 
9-VI 
81-V 
48-II 
TABLE 2.1 
Properties of immunoreactive clones 
Immuno-
reactivitya 
++ 
+ 
+ 
+++ 
++ 
+++ 
+++ 
++ 
+++ 
+++ 
+ 
Size of 
insertb 
<200bp 
<200bp 
<200bp 
<200bp 
<200bp 
<200bp 
<200bp 
=400bp 
=900bp 
1.5K 
2.8K 
Size of fusion Yield d Gene 
proteinc positione 
125K(127K) + NS2A 
125K(127K) + NS2A 
125K(127K) + NS2A 
125K(127K) +++ NS2A 
125K(127K) + NS2A 
125K(127K) +++ NS2_t\ 
125K(127K) +++ NS2A. 
134I( (1341() + NS2A 
158K(153K) ++ E 
174K(175K) + E, NSl, 
NS2A 
not (184I() not prM, E 
detected detected 
a Immunoreactivity: +, weak; ++, moderate; +++, strong. 
b Sizes of inserts were estimated by agarose gel electrophoresis (see text). 
c Size of fusion proteins were estimated by SDS-PAGE of lysates prepared from induced 
bacterial cultures (see Fig. 2.6). Size of fusion proteins in brackets was predicted based 
on the size of 13-gal* (122K) and the amino acid composition of the MVE peptides (See 
text). 
d Yields of fusion proteins were estimated by comparison with the yield of 13-gal* 
(50 µg/ml ): +, 5-10 µg/ml; ++, 10-30 µg/ml; +++, 30-40 µg/ml. 
e MVE protein genes in each clone. Gene fragments in the reverse orientation were not 
listed and fragments inserted in an incorrect reading frame were underlin ed. 
plasmid, that p63-II was a recombinant of pEX2 and that p60-V, p92-V, p 11-V and 
p4-II were recombinan ts of pEX3. 
Plasmids p88-I, p2-II and p103-V contained an identical 138 bp NS2A gene insert 
in the correct orientation (Fig. 2.4 ). The inserts were predicted to be translated as 
Asp 7-Asp 53 of NS2A (Fig. 2.5A). 
Plasmid p63-II contained three Sau3A fragments in the insert (Fig. 2.4). The first 
(91 bp) and third (106 bp) were from the E gene. However, the orientation of both 
fragments was reversed. The second fragment (138 bp) was from the NS2A gene. 
The orientation of this fragment was correct. Translation of this insert was predicted to 
produce a peptide of 110 amino acids, including 47 amino acids of NS2A (Asp 7-
Asp 53) (Figure 2.5B). 
Plasmids p60-V, p92-V and pll-VI also contained the 138 bp NS2A insert, but 
the vector was pEX3 in each case (Fig. 2.5C). Because the insertion was out-of-frame, 
translation was expected to produce a peptide of 45 amino acids in a different reading 
frame (Fig. 2.5C). This is inconsistent with the strong immunoreactivity observed for 
these clones ( see below). 
Plasmid p4-II contained two Sau3A fragments (Fig. 2.4). The first was the 
correctly oriented 138 bp fragment from the NS2A gene and the second (36 bp) was 
from pMT21 (Fig. 2.4). As the vector was pEX3 the predicted translation product was 
an identical fusion protein to that in 60-V, 92-V and 11-VI (Fig. 2.5D). 
Each of the immunoreactive clones contained at least one correctly oriented 
fragment from MVE cDNA, consistent with the immunoblotting data. The question of 
whether the expected reading frames were used for translation is addressed in the 
following sections. All 11 recombinant plasmids were derived from Sau3A fragments 
and three of them (48-II, 81-V, 9-VI) contained internal Sau3A sites indicating 
incomplete digestion (Fig. 2.4), consistent with the cloning procedures used to generate 
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Figure 2.5 Nucleotide and deduced amino acid sequences of inserts in recombinant plasmids. The 
nucleotide sequences of p88-I, p2-II, p103-V, p60-V, p92-V, pll-VI, p4-II and p63-II were determined 
(Maxam and Gilbert, 1980) and presented from the 3' end of the lacZ* coding region ( 12 bp from the 
polylinker) to the 3' end of the insert. The amino acid sequence encoded in these inserts was predicted by 
extending the reading frame for 13-galactosidase. Asterisks indicate termination codons, after which 
amino acid sequence was not shown. The Sau3A sites which flank each MVE or pMT21 fragment in 
the insert are indicated. The NS2A peptide Asp7-Asp53 is underlined. Sequences of inserts in p4-II and 
p63-II are abbreviated, the NS2A gene fragment in these inserts is identical to the insert: in (A).~ -
A. 88-1, 2-II, 103-V 
Poly linker 
lacZ* pEXl MVE NS2A 
TCA GTA TCG GCG GAA TTA ATT CCC GGG ~8I CCT TTT CAG TTA GGC CTT C':'G GTG 
ser val ser ala glu l eu ile pro gly as:9 :9ro :9he g i n l eu gly 1 eu 1 eu val 
ATG TTT CTG GCC ACC CAG GAG GTC TTG AGG AAG AAG TGG ACG GCC AGA CTT ACT 
met Dhe leu ala thr gln alu val leu arg lys lys tro thr ala arg leu th r 
CTG CCA GCA GCG GTT GGG GCT CTG CTA GTC CTC CTC CTT GGG GGC ATT ACC TAC 
leu pro a l a ala val gly ala leu l eu val leu leu leu gly aly , 1 e thr t v r 
ACT lGAI c 
thr as:9 
B. 63-11 
Poly linker 
lacZ* pEX2 MVEE 
TCA GTA TCG GCG GAA TTC CCG GCG AIC CAT GAC ATT CCT .... CCT ACT ~81' CC T 
ser val ser ala glu phe pro gly ile his asp ile pro .... pro thr as:9 :9l: 0 
MVE NS2A MVE E 
TTT .... TAC ACT ~8I CCA AAG TCC .... TGG TGA TTI.; ATC 
phe .... tyr thr asp pro lys ser .... trp * 
C. 60-V, 92-V, 11-VI 
Poly linker 
lacZ* pEX3 MVE NS2A 
TCA GTA TCG GCG GCC CGG ~A ICC TTT TCA GTT AGG CCT TCT GGT GAT GTT TCT 
ser val ser ala ala arg gly ser phe ser val arg pro ser gly asp va l se r 
GGC CAC CCA GGA GGT CTT GAG GAA GAA GTG GAC GGC CAG ACT TAC TCT GCC AG C 
gly his pro gly gly leu glu glu glu val asp gly gln thr tyr ser a l a ser 
AGC GGT TGG GGC TCT GCT AGT CCT CCT CCT TGG GGG CAT TAC CTA CAC 'It:i~ 'T' C 
ser gly trp gly ser ala ser pro pro pro trp gly his tyr l eu hi s 
.., 
D. 4-11 
Poly linker 
lacZ* pEX3 MVE NS2A 
TCA GTA TCG GCG GCC CGG Gt8 TCC TTT TCA GTT AGG CCT TCT .... CTA CAC mt. 
ser val ser ala ala arg gly ser phe ser va l arg pro ser .... l e u his * 
pMT21 
.IJ:C AGT TCG ATG TAA CCC ACT CGT GCA CCC AAC 'ItA 'T' C 
the library. The presence of more than one Sau3A fragment in four plasmids indicated 
that the molar ratio of vector to insert during ligation was not high enough to ensure 
incorporation of a single Sau3A fragment in each recombinant plasmicL 
2.3.5 Yields of MVE fusion proteins 
The yields of MVE fusion proteins from E.coli were roughly quantitated. The 
eleven clones were grown in culture and induced for fusion protein synthesis. Extracts 
containing equivalent amounts of bacterial cells were analysed by SDS-PAGE, stained 
with Coomassie Blue and compared with protein standards. The uninduced culture of 
pEX transf ormants contained trace amounts of the truncated B-galactosidase protein, 
denoted B-gal*; induction resulted in a yield of approximately 50 µg of B-gal* per ml of 
culture (results not shown). Yields of fusion proteins were from 5 to 40 µg/ml (Table 
2.1). The lowest was for 81-V and 63-II while the highest was for 4-II, 11-VI and 
60-V; the latter three colonies were also among the most immunoreactive (Table 2.1). 
Colonies containing large inserts gave poor yields in general. No fusion protein was 
detected for the unstable 48-II although B-gal* was detected (see Discussion). Of the 
three clones prodlfcing MVE E fusion proteins, only 9-VI gave a good yield ( :::::30 µg/ 
ml). 
2.3.6 Molecular weights of MVE fusion proteins 
Molecular weights (mol. wts.). of fusion proteins were predicted from sequencing 
and mapping data (see above). Experimental mol. wts. were determined by SDS-
PAGE. The nominal mol. wt. of B-gal* was 122K (Fig. 2.6). The experimental mol. 
wts. of fusion proteins from ten clones was zl25-174K (Table 2.1), corresponding to 
z3-52K added to the C-terminus of B-gal*. 
The mol. wts. of the fusion proteins in clones 81-V and 9-VI (174K and 158K) 
was consistent with the fusion of 477 and 284 amino acids respectively with B-gal*, 
indicating that translation of the MVE coding regions in the appropriate reading frame 
had occurred. Clone 81-V was predicted to encode E-NS1-NS2A which would 
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Figure 2.6 SDS-PAGE profiles of lysates of immunoreactive colonies. Lysates (1 ml) of clones 88-I, 
2-II, 103-V, 60-V, 92-V, 4-Il, 63-II, 9-VI, 81-V and 48-II were prepared from induced cultures (20 ml) 
by SDS lysis and sonication. Samples (1 µl) were incubated with B-NIE (5%; v/v) in SDS-PAGE 
sample buffer (15 µl final volume) at 90° for 2 min. The reduced samples were electrophoresed on 
SDS-7.5% PA gels at 200 volts for 45 min. The gels were then soaked in Coomassie Blue staining 
solution for 1 hour, destained and photographed. Size markers (SM; ==0.5 µg each) were myosin 
(200K), B-galactosidase (116K), rabbit muscle phosphorylase b (97K), bovine serum albumin (66K) and 
hen egg white ovalbumin (43K). The positions of B-gal* and fusion proteins are indicated by dots next 
to the protein bands. The B-gal* band observed in clone 63-II was due to contaminating pEX plasmids. 
normally undergo proteolytic cleavage in MVE-infected cells at the N-tennini of NS 1 
and NS2A. However the observed mol. wt. of the 81-V fusion protein corresponded to 
the full length E-NS 1-NS2A, suggesting that cleavage had not occurred. This is not 
surprising as signalase in the lumen of the RER is responsible for cleavage at the N-
terminus of NS 1 (see Chapter 1). 
The fusion protein from clone 63-II, which contained three Sau3A fragments, was 
predicted to comprise 110 amino acids including part of NS2A. The observed size of 
134K was in agreement with this prediction (Fig. 2.5). 
Fusion proteins from clones 88-I, 2-II, 103-V, 60-V, 92-V, 11-VI and 4-II were 
all approximately 125K. From the predicted amino acid sequences, two types of fusion 
protein were expected (Fig. 2.5). Their sizes were similar: 47 amino acids from NS2A 
for 88-I, 2-II and 103-V and 45 amino acids from NS2A for 60-V, 92-V, 11-VI and 
4-II. The immunoreactivity of clones 60-V, 92-V, 11-VI and 4-II suggested that an 
NS2A fragment was expressed despite the out-of-frame insertion. It is possible that the 
NS2A fusion protein was expressed by ribosome slippage at the j4nction between lacZ* 
coding region and the NS2A gene fragment . This phenomenon has been reported by 
Stanley (1983) using pEX-like vectors; some clones expressed two types of fusion 
protein resulting from translation of inserts in different reading frames. For clones 
60-V, 92-V and 11-VI, the two types of fusion protein from translation in different 
reading frames would be indistinguishable by size. 
In summary, there was a good correspondence between observed and predicted 
mol. wts. of the fusion proteins (see Table 2.1 ). Extensive degradation of the fusion 
proteins had apparently not occurred. 
2.3.7 Summary 
A Sau3A-partial digest of a cDNA clone of the 5' terminal half of the MVE genome 
was cloned into pEX plasmids to generate an MVE expression library. Eleven 
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recombinant plasmids which expressed fusion proteins of !3-gal * and MVE proteins 
were identified by screening with anti-MVE HIAF. These contained inserts ran2ino-b b 
from = 100 bp to 2.8 kb. Sequence analysis of these plasmids identified the inserts, 
from which it was deduced that fusion proteins containing MVE protein fragments pdvl-
E, E, E-NS 1-NS2A and NS2A were expressed. Three plasmids out of eleven 
expressed portions of the E gene while eight expressed an NS2A sequence. For all of 
these plasmids except one (p48-II, which contained the largest insert), fusion proteins 
were expressed in yields of 5-40 mg per litre of induced culture and appeared to be free 
from proteolytic degradation. 
2.4 DISCUSSION . 
We have investigated the possibility of expressing MVE proteins in E.coli with the 
aim of obtaining a collection of MVE peptides which react with anti-MVE HIAF for 
antigenic analysis and for studies of functionally important regions. By incorporating 
Sau3A-digested MVE cDNA fragments coding for prM, E, NS 1, NS2A, NS2B and 
NS3 in pEX vectors, it was hoped that recombinant pEX plasmids which expressed 
MVE protein fragments, particularly of the E protein, would be generated. 
The construction of an MVE expression library using the pEX vectors 
Colonies producing fusion proteins were identified by immunoscreening with anti-
MVE HIAF. The screening procedure was reliable and identified positive clones with 
ease even when the frequency of immunoreactive colonies was low. The identity of 
fusion proteins was deduced by DNA sequence determination and from the mol. wts. of 
fusion proteins. The eleven positive clones characterized in this study contained 
fragments of the prM, E, NS 1 and NS2A genes. Clones 9-VI, 81-V and 48-II 
expressed parts of E. Colonies expressing NS2B and NS3 epitopes were not isolated. 
Whether or not this was due to the cloning or to the screening reagent (HIAF), is not 
known. 
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It is notable that nine out of the eleven clones analysed expressed the NS2A peptide 
Asp 7-Asp 53, either alone or in conjunction with other peptides. Fragments derived 
from cleavage at certain Sau3A sites (MVE nucleotides 2255, 3547, 3685 and pMT 
nucleotides 1490 and 1529; Fig. 2.4) occurred more than once in recombinant 
plasmids. Thus preferential cleavage of p2/1/22 at some SauA sites occurred and was 
responsible for the occurrence of the NS2A gene fragment in most of the 
immunoreactive colonies. The existence of such preferred cleavage sites imposes a 
restriction on the 'partial digest' approach to obtaining a random set of overlapping 
protein fragments expressed from the pEX plasmids. This limitation is likely to apply 
no matter what restriction enzyme is used to generate the partial digest. Certainly in our 
hands we have not obtained a series of E protein fragments for systematic epitope 
mapping. In Chapter 3, we adopt a directed approach to expressing the unrepresented 
parts of the E gene in the pEX vector, and use constructs generated in this manner to 
define functional determinants in E. 
Yields and stability of MVE fusion proteins 
Degradation of fusion proteins was not extensive as judged by a comparison of 
predicted and actual sizes of proteins in SDS-PAGE profiles. However degradation by 
end-trimming could not be ruled out as we could not detect small differences in mol. 
wts. or small degradation products (less than 40K). Stanley (1983) and Stanley and 
Luzio (1984) also reported that the insoluble B-gal* fusion proteins from expression of 
recombinant pEX constructs were relatively stable. 
A range of yields was observed. Generally, larger MVE fragments were expressed 
poorly. The fusion protein in 81-V comprising E-NS 1-NS2A (476 amino acids) was 
poorly expressed. For 48-II, an even larger fusion protein comprising prM-E (573 
amino acids) was not detectable by staining, and the B-gal * protein was observed 
instead. As the colony was immunoreactive, the MVE fragment was expressed. Two 
explanations may account for this. The intact fusion protein may have been expressed in 
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trace quantities or been degraded into small fragments, some of which reacted with anti-
MVE HIAF. 
Certain 'foreign' sequences in viral proteins affect the yield of fusion proteins or 
the extent of degradation. It has been suggested that hydrophobic sequences in foreign 
proteins are toxic to bacteria, affecting the yield and stability of recombinant proteins 
(Yelverton et al., 1983). This was observed in the expression of JE proteins as 
B-galactosidase fusion proteins in E.coli : fusion proteins with the hydrophobic C-
terminal domains of prM and E were not expressed in abundance (Mason et al., 1987b). 
Although the two large, poorly expressed proteins from MVE clones 81-V and 48-II 
contained the hydrophobic C-termini of E and prM respectively, either the presence of 
hydrophobic sequences or the size of the protein could have accounted for the poor 
yield. The NS2A peptide expressed in several clones contained C-terminal hydrophobic 
sequences (see below); however the effect on yield was probably not significant as some 
of these clones expressed fusion proteins in abundance. 
Reactivity of anti-MVE HIAF with fusion proteins 
The differences in immunoreactivity between clones may result from the following 
factors. First, clones producing moderate to large amounts of fusion protein always 
showed strong immunoreactivity and thus quantity of protein may be a factor. The 
second factor is size: larger MVE peptides are likely, in a general sense, to contain more 
epitopes which react with anti-MVE HIAF than smaller peptides. This could explain the 
strong immunoreactivity of clone 81-V which expressed trace amounts of the second 
largest fusion protein. Similarly, clone 48-II did not express detectable amount of 
fusion protein but was still reactive with anti-MVE HIAF. The third factor is the 
inherent antigenicity and conformation of MVE components of the fusion proteins which 
could also affect immunoreactivity. It is likely that certain parts of MVE proteins are 
immunodominant and would react strongly with anti-MVE mouse HIAF. Although no 
information is available for MVE proteins, DEN-2 NS 1 protein, expressed as 
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f3-galactosidase fusion proteins has been studied with polyclonal rabbit and mouse 
antisera. The N-and C-termini react strongly with mouse and rabbit sera respectively 
(Putnak et al., 1988). The conformation of epitopes in MVE proteins prM, E and NS 1 
will also be influenced by formation of disulfide bonds, folding of discontinuous 
epitopes and glycosylation. These factors are important for the reactivity of some 
epitopes in TBE E (Guirakhoo et al., 1989; Mandl et al., 1989b). As the N1VE fu sion 
proteins are not Asn-glycosylated and only contain fragments of the MVE proteins, 
some epitopes may not be generated. Protein fragments of JE, DEN-1 and DEN-2 
which are expressed in E.coli as fusion proteins react with some, but not all anti-E and 
anti-NS 1 mAbs tested (Mason et al., 1987b; Zuegel et al., 1987; Putnak et al., 1988) 
indicating that some viral epitopes are not present in the fusion proteins. Fusion 
proteins generated in our study were a non-random set, and did not allow analysis of 
immunodominant regions or of the conformation of MVE epitopes. 
Application of fusion proteins to studies of MVE proteins 
In addition to their value in mapping epitopes on E and NS 1, fusion proteins have 
been used in the generation . of specific antisera. Such antisera have been used in the 
isolation of YF proteins by immunoprecipitation and in the identification of NS2A, 
NS2B and NS4B (Chambers et al., 1989). Specific antisera have also been employed 
in studies of the pathway of processing of YF polyproteins (Chambers et al., 1990b). 
Such antisera may also be used to localize viral proteins during infection. 
Some of the MVE fusion proteins generated in this study may be useful in the 
generation of antisera. The fusion protein carrying the NS2A peptide Asp 7-Asp 53 
was most abundantly obtained in this study and may be useful in generating specific 
antisera for studying the expression and roles of the MVE NS2A and of a putative NS 1-
NS 2A protein. NS1-NS2A in IE-infected cells was identified using a bacterial 
B-galactosidase fusion protein containing an NS2A peptide (Mason et al., 1987b). As 
there is identity between MVE and JE in the hydrophilic region between NS2A Asp 7 
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and Arg 31 (McAda et al., 1987; Dalgarno et al., 1986), and strong homology with 
WN, KUN in the same region (Castle et al., 1986; Coia et al., 1988), antisera generated 
against the MVE fusion protein may cross-react and allow comparative studies. 
However, this application of fusion proteins in studying protein processing was not 
pursued further in this thesis. 
We have obtained fusion proteins from clones 9-VI, 81-V and 48-II which contain 
parts of E and could be considered for epitope mapping and for studies of functions of E 
such as interaction with cell receptors and fusion with membranes. However clone 
81-V only expressed the C-terminus of E and 48-II appeared to be unstable. Clone 
9-VI, which expressed fusion protein E 146-429, is employed in epitope mapping 
studies in the fallowing chapter. 
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CHAPTER 3 
EPITOPE MAPPING ON MVE FUSION 
PROTEINS BY DELETION ANALYSIS AND 
IMMUNIZATION STUDIES IN MICE 
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3.1 INTRODUCTION 
In this chapter we explore the possibility of mapping the epitopes of five 
neutralizing mAbs on MVE E protein fragments expressed in E.coli. To do this, we 
use deletion mapping, a method which has been valuable for a number of virus types 
(Picornaviruses, Herpesviruses, Coronaviruses; see Lenstra et al., 1990) including JE 
and DEN-1 (Mason et al., 1989; Zuegel et al., 1987). , In Chapter 2 we have 
demonstrated the expression of the fusion protein E146-429 in an immunologically 
reactive form using the pEX vector system. For the studies described in this chapter, an 
essential further step was to express the N-terminal portion of the E gene in the same 
system. Following this, the two construct could be subjected to deletion analysis to 
localize neutralization epitopes using mAbs. 
Five neutralizing mAbs against MVE were available to us. Three of these mAbs, 
generated against NlVE, had been characterized by Hawkes et al. (1988). The other 
two, which had in fact been generated against the closely related virus JE, were 
characterized by J. T. Roehrig (personal communication). The properties of these mAbs 
including subclass, titres in plaque reduction neutralization tests (PRNT) and HI assays, 
and cross-reactivity with flaviviruses in ELISA have been described (see Table 3.1). 
Each mAb shows a set of different activities and cross-reactivity patterns from the above 
tests. Analysis by competitive binding assays (CBAs) indicated that of the five epitopes 
defined by these mAbs, E- lc, E- ld, E-5b and E-8 are arranged in a continuum of four 
overlapping sites while E-7 appears to be spatially separate (J. T. Roehrig, personal 
communication). With one exception, there were no data available on the location, within 
the E protein sequence, of the epitopes defined by these mAbs. The exception was the 
description by S. H. Hartley and R. C. Weir (personal communication) that Ala 126 in E 
was part of the E-lc epitope. In this and the following chapter, studies which map the 
epitopes defined by these mAbs are reported. 
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TABLE 3.1 
Physical and biological properties of neutralizing mAbs 
against MVEa 
Biological activin,c 
Epitope mAb Subclass 
Cross-reactivity 
in ELISAb HI titred N titree Protectionf 
E-lc 4B6C-2 IgG2a MVE 1024 5120 MVE 
E-ld 4B5A-2 IgG2a MVE <10 320 none 
E-5b 4B3B-6 IgG2b MVE, JE <10 5120 MVE 
E-7 6A4D-1 IgGl MVE, JE, <10 2048 MVE,JE 
WN 
E-8 6B4A-10 IgGl MVE, JE <10 2048 MVE, JE, 
SLE,WN SLE 
a Information on physical and biological properties of anti-E-lc, E-ld and E-5b mAbs are from Hawkes 
et al. (1988). Physical and biological properties of anti-E7 and E-8 mAbs were provided by Dr J. T. 
Roehrig (personal communication). 
b Cross-reactivity was determined by antigen capture ELISA (Hawkes et al., 1988). A large battery of 
antigens including those from MVE, JE, WN, SLE, Alfuy (ALF), YF and DEN-1 were tested; those 
showing positive reactivity are listed. 
c For biological assays antibodies were purified from ascitic fluids by ammonium sulphate precipitation 
and Protein A-Sepharose column chromatography and standardized to 100 µg/ml (Hawkes et al., 1988). 
d Determined against MVE. 
e Neutralization (N) titres of mAbs are reported as reciprocals of 70% end-points in plaque reduction 
neutralization tests using 50-100 PFU per test. 
f Protection of 21-day old Swiss outbred mice by the mAbs was assessed by injecting a range of doses 
of antibodies (0.01 µg-100 µg) into the tail vein of animals 24 hours before ip challenge with 500 
ipLD50 of virus. Anti-E-lc was the most protective antibody tested, requiring 0.1 µg to protect 50% 
of MVE-challenged mice. Other mAbs which protected mice were anti-E-5b, E-7 and E-8 (requiring 5-
100 µg mAbs to protect> 10% of challenged mice). Viruses which could be protected against in the 
assays are listed (J. T. Roehrig, personal communication). 
Another approach to defining functional domains in the E protein is to determine 
the capacity of various E fusion proteins to induce reactive antibodies in mice and to 
assay the properties of such antibodies. Accordingly, in this chapter we explore the 
capacity of fusion proteins containing large MVE E protein fragments to generate 
antisera in mice which react with MVE in ELISA and which neutralize virus infectivity. 
3.2 MATERIALS AND METHODS 
3.2.1 Plasmids and bacterial strains 
See Materials and Methods, Chapter 2. M13 mp8 was used as RF DNA (New 
England Biolabs); sequence data are from the manufacturer's catalogue. 
3.2.2 Cells and virus 
African green monkey kidney (Vero) cells were grown at 37° in medium 
M199/lactalbumin hydrolysate (M199/LAH) supplemented with 10% bovine serum. 
Working stocks of MVE-1-51 were prepared by passing MVE-infected suckling 
mouse brain homogenates once in Vero cells (MOI=l) and harvesting culture 
supematants. The titres on Vero cell monolayers were generally 106 to 107 PFU/ml. 
Purified MVE, provided by Dr R.C. Weir (Biochemistry Department, Faculty of 
Science, Australian National University), was prepared from infected SW13 cell 
supematants by precipitation with polyethylene glycol and was banded in a glycerol-
tartrate gradient (Lobigs et al., 1986). 
3.2.3 Subcloning MVE cDNA into the pEX plasmids 
Procedures for extraction of plasmid DNA, RE and sequence analysis of plasmid 
DNA, transformation of E.coli and preparation of vector DNA for ligation were as 
described in Chapter 2. 
To generate blunt-ends, DNA fragments (1 µg) were incubated (37°, 30 min) with 
T4 DNA polymerase (0.2 units; Boehringer) in the presence of dGTP, dATP, dTIP and 
dCTP (0.5 mM each), 30 mM Tris-HCl (pH 8), 60 mM potassium acetate, 10 mM 
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magnesium acetate, 0.5 mM dithiothreitol (DIT; Boehringer) and 0.1 mg/ml bovine 
serum albumin. The enzyme reaction was stopped by incubation at 70° for 1 O min. 
For ligation, vector DNA (=0.1 µg), digested with restriction enzymes and blunt-
ended, was mixed with MVE cDNA fragments in a molar ratio of 4: 1 in a final volume 
of 10 µl containing 50 mM Tris-HCl (pH 7.8), 10 mM MgCl2, 20 rnM DTT, 1 mM 
ATP, 50 µg/ml bovine serum albumin and T4 DNA ligase (100 units; New England 
Biolabs). Incubation was at 16° for 16 hours. 
M13 mp8 was used to 'adapt' the ends of a TaqI MVE cDNA fragment (see 
Results) for subcloning into the polylinker region of pEX. M13 mp8 plasmid (0.3 µg), 
which contains a unique AccI site in the polylinker was incubated with AccI (5 units) for 
1 hour at 37° and 10 min at 70°. The digested M13 DNA (0.15 µg) and the TaqI 
restriction fragment (==70 ng) were ligated using T4 DNA ligase (100 units) overnight at 
16°. The ligation mixture was then incubated at 70° for 10 min, BamHI and PstI (5 
units each) were added and incubation continued at 37° for 1 hour. The TaqI fragment 
with BamHI and Pstl cohesive ends was isolated on 1 %· low melting temperature (LMT) 
agarose (Bio-Rad). 
Restriction fragments were stained with ethidium bromide (0.5 µg/ml ). Gel slices 
containing DNA fragments were excised under UV illumination (wavelength= 380 nm) 
and melted in two volumes of 5 mM TE buffer containing 5 mM Tris-HCl (pH 8) and 
0.5 mM EDT A at 65° for 5 min. The gel mixture was extracted with phenol (x2), 
phenol/chloroform and chloroform (Maniatis et al. , 1982). DNA was precipitated with 
sodium acetate (0.3 M, final concentration, pH 5.2) and ethanol (2 volumes) and 
dissolved in 5 mM TE buffer at pH 7 .4. 
3.2.4 Anti-MVE HIAF and anti-E mAbs 
Polyclonal antibody against MVE was anti-MVE-1-51 HIAF (Chapter 2). Five 
mAbs against MVE were provided by Dr J.T. Roehrig (Division of Vector-Borne Viral 
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Diseases, Fort Collins, Colorado, USA). Table 3.1 lists their physical and biological 
characteristics. Three features of these mAbs are of interest to our work. First, all of 
the rnAbs neutralize MVE . infectivity. Second, the rnAbs differ in ELIS A cross-
reactivity with other flaviviruses; mAbs to E-lc and E-ld are specific for MVE while 
rnAbs to E-5b, E-7 and E-8 cross-react with other members of the JE complex. Third, 
m.Ab to E-lc is the only one showing both neutralization and HI activities; it is also the 
most effective in protecting mice from ip challenge with MVE. The ELISA titres were 
determined for anti-E-lc (lxl06), anti-E-ld (5xl05), anti-E-5b (3xl 05), anti-E-7 
(6xlo4) and anti-E-8 (5xl05). 
3.2.5 Immunological screening and induction of fusion 
proteins 
See Materials and Methods, Chapter 2. 
3.2.6 SDS-P AGE and immunoblotting of fusion proteins 
Fusion proteins were tested for reactivity with antibodies by either immunoblotting 
after SDS-PAGE or they were dot-blotted on nitrocellulose directly as lysates. To 
transfer proteins to nitrocellulose, SDS-PA gels containing separated proteins (Materials 
and Methods, Chapter 2) were soaked in blotting buffer (200 mM glycine, 10 mM 
Tris-HCl, pH 8.3, 20% methanol) for 15-30 min. Proteins were transferred 
electrophoretically to nitrocellulose (Tow bin et al., 1979) in blotting buffer at 4 ° for 1 
hour. A Transblot apparatus (Bio-Rad) and a Bio-Rad Power Supply (Model 250/2.5) 
with settings at 0.15 Amp (65-75 volts) were used. For dot-blotting, bacterial lysates 
(1 µl) containing ::::1 µg fusion protein (in SDS-PAGE sample buffer without the 
bromophenol blue dye) were dotted on nitrocellulose. Membranes were rinsed with 
wash buffer (WB; 0.05% Tween-20 in PBS), soaked for 30 min in WB containing 5% 
non-fat milk powder, rinsed (x3) in WB, incubated whh anti-MVE HIAF (1/800 
dilution) for 1 hour or mAbs (1/400 dilution) for 16 hours, rinsed (x3) in WB and 
incubated for 1 hour with peroxidase coupled goat anti-(mouse IgG) (1/1500 dilution; 
54 
Bio-Rad). Detection was with 4-chloro-1-naphthol and hydrogen peroxide as described 
for immunoscreening (Chapter 2). 
3.2. 7 Purification of fusion proteins (M. J. Howell, personal 
communication) 
E.coli cells containing- pEX or recombinant plasmids were grown at 30° in LB 
medium containing ampicillin ( 100 µglml) and kanamycin ( 40 µg/ml ) with constant 
agitation until stationary phase was reached. Cells were diluted in fresh medium to an 
O.D. of 0.05 at 630 nm. Incubation was continued at 30° for 1 hour and at 42° for 2 
hours. Cells were collected by centrifugation at 8000 rpm (Sorvall SS-34 rotor) for 10 
min, resuspended in 0.9% NaCl to 1/20th the original volume and lysed by three cycles 
of freezing in liquid nitrogen and thawing at 30°. Lysozyme was added to 125 µglml 
and the extract held on ice for 20 min followed by another cycle of freezing and 
thawing. The lysates were then sonicated for 30 seconds and centrifuged for 15 min in 
an Eppendorf centrifuge at 4 °. The resulting pellets, which were enriched in fusion 
proteins, were resuspended in 8 M urea (Ultrapure; Sigma) in 10 mM Tris-HCl 
(pH 7.4). After clarification by centrifugation, fusion protein solutions were dialysed 
against PBS at 4 ° overnight and stored at -70°. Quantitation was by colorimetric 
analysis using the Bio-Rad protein assay kit. The protein standard used was bovine 
y-gobulin (Bio-Rad). 
3.2.8 Injection of mice with fusion proteins 
Six to eight-week old outbred Swiss mice were injected in groups of five. Fusion 
proteins (10 µg each in 50 µl of PBS) were mixed with equal volumes of Freund's 
incomplete adjuvant (FIA; Difeo), emulsified by passing though a syringe several times 
and injected ip. Booster injections were given four weeks and nine weeks after the 
initial injection. In some experiments, RIBI adjuvant containing monophosphoryl lipid 
A and trehalose dimycolate emulsion (RIBI Immunochem Research, Inc., Hamilton, 
Montana, USA) was used. A single dose for injection contained RIBI adjuvant (1 µg) 
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and fusion protein (10 µg) in 0.2 ml of PBS. A single booster infection was given five 
weeks after the initial injection. Animals were bled two weeks after the first injection 
and a week after boost. Serum samples were prepared by centrifugation (2 min) of 
coagulated blood in Eppendorf tubes and stored at -20°. 
3.2.9 Partial purification of MVE for use as ELISA antigens 
Virus from tissue culture supernatants was concentrated using polyethylene glycol 
(PEG 8000; Koch-Light Laboratories, Suffolk, England) for use as ELISA antigen 
(Cammack and Gould, 1986b). Monolayer cultures of Vero cells in 850 cm2 roller 
bottles (Corning, New York, USA) were infected with MVE-1-51 (M0I=10). At 24 
hours p.i., M199/LAH medium was replaced with 50 ml of Eagle's minimal essential 
medium (EMEM) containing 2 % foetal calf serum (FCS; Commonwealth Serum 
Laboratories, Melbourne, Australia), and incubation continued. At 48 hours p.i., 
culture supernatant was harvested and clarified by centrifugation for 10 min at 10,000 
rpm (Sorvall GSA rotor). PEG ( 40% stock solution in NTE buffer: 0.12 M Na Cl, 
12 mM Tris-HCl, pH 8, 1 mM EDTA) was slowly added to a final concentration of 
8% (w/v) with- constant stirring at 4° for 2 hours. Virus was collected by centrifugation 
for 30 min at 10,000 rpm (Sorvall GSA rotor) and pellets drained and resuspended in 
2 ml (per roller bottle of supernatant) sodium borate-saline (0.05 M borate, pH 9, 
0.12 M NaCl). The concentrated virus solution was clarified by centrifugation and 
stored at -20°. 
3.2.10 MVE plaque assays 
Vero cell monolayers in 6-well plastic trays (TC grade, Linbro Scientific Inc., 
USA) were infected with virus (0.1 ml per well in duplicates) diluted in HESS 
containing 20 mM HEPES (Sigma; pH 8). Adsorption was for 1 hour at 37° in an 
atmosphere of 5% CO2/ 95% air with occasional shaking. Monolayers were overlaid 
with M199/LAH containing 1 o/o agar (Difeo), 0.02% (w/v) diethyl amino ethyl dextran 
(Sigma), 2% FCS and 4% bovine serum. Incubation was for 3 days at 37° as above; 
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plaques were counted after staining for 1 day with 0.015% (w/v) neutral red (Ajax) in 
0.6% agar. 
3.2.11 Enzyme-linked immunosorbent assay (ELISA) 
Reactivity of immune sera with MVE or fusion proteins was examined by ELISA. 
Wells of microtitre plates (Titertek, Netherlands) or 96 well round bottom plates 
(Linbro) were coated for two hours at 37° with MVE (PEG-concentrated preparation) 
diluted to 106 PFU/ml in sodium borate-saline or with fusion proteins diluted to 
10 µg/ml in sodium borate-saline. Plates were rinsed (x 3) with PBS containing 5 % 
non-fat milk powder and incubated for 2 hours at 37° with sera diluted in PBS-5 % milk 
powder. After rinsing (x 6) with PBS containing 0.05% Tween-20, bound antibodies 
were detected with goat anti-(mouse IgG) horseradish peroxidase diluted 1 in 600 in 
PBS-5% milk powder. Colour development was in citrate-phosphate buffer (61 mM 
citric acid, 77 mM Na2HP04, pH4), 0.003% H202 and 1 mg/ml of 2,2'-Azinobis 
(3-ethylbenzthiazoline-sulfonic acid) (ABTS; Sigma). Plates were read at 410 nm 
using an automated plate reader (Dynatech). End-points were taken as the highest 
dilution which gave OD readings of >0.1. Controls were performed using sera collec·ted 
from mice before injection. 
3.2.12 Plaque reduction neutralization tests (PRNT) 
Neutralization titres of anti-MVE mouse sera were determined by PRNT. Serial 2-
fold dilutions of sera in 100 µl HBSS (pH 8) were incubated for 1 hour at 37° with 
100-200 PFU of MVE-1-51 in 100 µl HBSS and the mixtures (200 µl) then assayed 
in duplicate by plaque formation. Control assays were performed using mouse sera 
collected prior to injection. 
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3.3 RESULTS 
3.3.1 Subcloning and expression of the S' half of the MVE E 
gene 
Construction of recombinant plasmid 
As described in the Introduction, our first aim was to subclone and express a 
section of the MVE E gene encoding the N-terminal portion of E. To do this the 
nucleotide sequence of E was scanned for suitable RE sites. It was noted that TaqI sites 
flanked a region encoding MVE peptide Asp 22-Val 272 CE22-272; MVE peptides are 
denoted by numbers in subscript) which represents approximately the N-terminal half of 
E (251 amno acids; Fig. 3.1). The method used for cloning and expressing this region 
is described below (see also Fig. 3.2). 
Plasmid p2/1/22 was digested with TaqI and the appropriate fragment (0.75 kb) 
isolated from LMT agarose and ligated into AccI-digested, dephosphorylated M13 mp8 
(TaqI sites are compatible with the AccI site in M13 mp8). This was done in order to 
modify the 0.75 kb fragment for insertion into the pEX vector. The ligated products 
were digested with PstI and BamHI which cleave on either site of the AccI site and 
allowed insertion into PstI/BamHI-digested pEX vectors. The TaqI fragment with PstI 
and BamHI cohesive ends was isolated after electrophoresis on LMT agarose and ligated 
to BamHl- and Pstl-digested pEX vectors (Fig. 3.2). The ligation mL""<ture was used to 
transform E.coli MC1061/pCI857. Ampicillin resistant colonies were screened with 
anti-NIVE HIAF. pEX plasmid from one such clone was examined by digestion with 
BamHI and Pstl and analysed by agarose gel electrophoresis. The size of the insert \Vas 
-::=770 bp as expected (results not shown). 
Size and yield of the MVE E fusion protein 
The fusion protein expressed from the recombinant plasmid was examined by 
SDS-PAGE to determine its size and yield. The lysate was reduced with 13-11E, 
electrophoresed on an SDS-7.5% PA gel with size markers and stained with Coomassie 
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1.5 2 2.5 kb 
Neal Taql Sa u3 A 
Taql Seu3A Sau3A Stu I Teql Pstl Sau3A Sau 3 A 
E gene 
I I I II I I I 
E protein 22 87 1 46 201 224 272 327 392 429 459 
274 
Figure 3 .1 Restriction sites in the MVE E gene. Restriction sites which are relevant to the 
construction of recombinant plasmids are shown. There are three Taql sites, five Sau3A sites and one 
each of Ncol, StuI and Pstl sites in the coding region for E protein. Number below each site represent 
the corresponding amino acid positions in the MVE E protein (501 amino acids long). The scale 
indicates the location with respect to the 5' terminal nucleotide in the genome of MVE-1-51 (Dalgamo 
et al., 1986). 
Figure 3.2 Construction of plasmid pE22-272. p2/1/22 (1 µg; 7.3 kb) which contains nine TaqI sites 
was incubated with TaqI (5 units) at 60° for 1 hour. The digest was electrophoresed on 1 % LMT agarose 
and a TaqI fragment (753 bp; 70 ng) from the E gene was identified, extracted and ligated to AccI-
digested M13 mp8 followed by digestion with BamHI and PstI to create BamHI and PstI cohesive ends. 
pEXl, 2 and 3 plasmids (0.1 µg each) were incubated with PstI (5 units) and BamHI (5 units) in RE 
buffer (Materials and Methods, Chapter 2) containing 0.15 NI NaCl at 37° for 1 ·hour. Calf intestinal 
alkaline phosphatase (1 unit) was added and incubation continued for 30 min. The mixture was 
electrophoresed on 1 % LMT agarose to isolate the digested pEX vectors (5.8 kb). The pEX plasmids 
(0.2 µg) and TaqI fragment (15 ng), both possessing BamHI and PstI adhesive ends were incubated with 
T4 DNA ligase (100 units) at 16° overnight. The ligation mixture was used to transform competent 
MC1061/pCI857 cells. Screening was on ampicillin plates. 
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Blue. The observed mol. wt. of the fusion protein (156K; Fig. 3.3) was close to the 
predicted mol. wt. of E22-272 (149K). Thus appropriate translation of the E peptide 
probably occurred; there was no significant degradation. 
The yield of E22-272 was compared with that of El46-429 (Chapter 2) by SDS-
PAGE and Coomassie Blue staining. There was no significant difference in the molar 
yields of E22-272 and E146-429 from induced bacterial cultures as judged by staining 
intensity (Fig. 3.3). 
3.3.2 Reactivity of anti-MVE HIAF and mAbs with E fusion 
proteins 
Reactivity of HIAF with E fusion proteins 
To examine the relative antigenicity of the two fusion proteins, approximately 
equimolar quantities of reduced E22-272 and E146-429 were analysed with anti-MVE 
HIAF in immunoblots . E22-272 was less reactive than E146-429 under these 
conditions (Fig. 3.4). Attempts to separate fusion proteins by SDS-PAGE in non-
reducing condition were unsuccessful as the fusion proteins aggregated and did not 
. 
migrate into the gels. Accordingly, HIAF was tested for reactivity with SDS-treated 
bacterial lysates dot-blotted on nitrocellulose without reduction. Again E22-272 was 
less reactive than E146-429 (Fig. 3.5). This may indicate that the MVE component in 
E22-272 contained fewer antigenic sites than that in E146-429 or that E22-272 epitopes 
were sensitive to denaturation by SDS. 
Reactivity of neutralizing mAbs with E fusion proteins 
To examine the feasib~lity of using immunoblotting to assess the reactivity and 
specificity of the five mAbs, purified MVE was electrophoresed, with and without prior 
reduction with B-ME, on SDS-20% PA gels, transferred to nitrocellulose and analysed 
with anti-E- lc, E- ld, E-5b, E-7 and E-8 mAbs. All five mAbs reacted with E in 
immunoblots of unreduced MVE (Fig. 3.6), indicating that the corresponding 
neutralization epitopes are located in E and remain reactive during the procedure used. 
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Figure 3.3 Coomassie blue stained SDS-PAGE profiles of colonies expressing MVE E fusion proteins. 
Immunoreactive colonies which were expected to express B-gal* and the fusion proteins E22-272, 
E146-429, E146-328, E327-429, E201-328, E146-224, E225-328, E225-272 and E201-224 (see Table 
3.2 for abbreviations) were induced for fusion protein synthesis in culture. Bacterial lysates (0.25 ml) 
were prepared from induced cultures (5 ml). Samples (1 µl) were incubated with B-ME and SDS-PAGE 
sample buffer in 90° water bath for 2 min and electrophoresed on an SDS-7.5% PA gel. Proteins were 
detected by Coomassie Blue staining. The mol. wt. standards are myosin (200K), B-galactosidase 
(116K), rabbit muscle phosphorylase b (97K), hen egg white ovalbumin (67K) and bovine serum 
albumin (43K). 
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Figure 3.4 Immunoblot analysis of MVE E fusion proteins using anti-MVE HIAF. Bacterial lysates 
containing f3-gal* and fusion proteins E22-272, E146-429, E146-328, E327-429, E201-328, E146-224, 
E225-328, E225-272 and E201-224 (:==0.5 µg each) were electrophoresed on an SDS-7.5% PA gel after 
incubation with f3-ME for immunoblot analysis. Protein blots were detected with anti-MVE HIAF at 
dilution of 1 in 800 (1 hour incubation). Positions of size markers (in kilodaltons) are indicated. 
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Figure 3.5 Reactivity of anti-MVE HIAF and anti-MVE mAbs with fusion proteins E22-272 and 
E146-429. Bacterial lysates containing B-gal* , E22-272 and E146-429 (1 µg each) in PBS (final 
volume of 0.1 ml) were dot-blotted on nitrocellulose. The nitrocellulose membranes were soaked in 5% 
milk powder for 30 min and reacted with anti-MVE HIAF (diluted 1 in 800; 1 hour incubation) or anti-
E-lc, E-ld, E-5b, E-7 and E-8 mAbs (diluted 1 in 500; overnight incubation). Controls were purified 
MVE containing ""0.3 µg of E protein. 
A. 
E-1c E-1d E-5b E-7 E-8 
-
- -
- E (56K ) 
B. 
E-lc E-1d E-Sb E-7 E-8 
- E (56K) 
Figure 3.6 Immunoblot analysis of reduced and unreduced NfVE proteins using anti-E mAbs. (A) 
Purified MVE containing =0.2 µg E was diluted in SDS-PAGE sample buffer at 4 ° and electrophoresed 
on an SDS-20% PA gel at 200 volts for 45 min. Proteins in the gel were transferred to nitrocellulose 
and detected with anti-E-lc, E-ld, E-Sb, E-7 and E-8 mAbs at dilutions of 1 in 500 (overnight 
incubation at room temperature). 
(B) Purified MVE containing =0.2 µg E was incubated with B-ME at 90° for 2 min and electrophoresed 
on an SDS-20% PA gel as above. Proteins were transferred to nitrocellulose and detected by mAbs as 
abo e. The MVE E protein (56K) is indicated by arrow. 
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However, only anti-E-8 showed reactivity with reduced MVE E protein (Fig. 3.6), 
indicating that epitopes E-lc, E-ld, E-Sb and E-7 are lost on reduction. These results 
indicated that the analysis of the reactivities of mAbs against the E- lc, E- ld, E-5b and 
E-7 epitopes would require unreduced fusion proteins while anti-E-8 mAb would react 
with both unreduced and reduced fusion proteins. 
The reactivity of the two B-gal*-E fusion proteins with mAbs was analysed by dot-
blotting bacterial lysates on nitrocellulose without reduction. Anti-E-8 reacted with 
E22-272 and E146-429 but anti-E-lc, E-ld, E-5b and E-7 mAbs showed no reactivity 
with either of the unreduced fusion proteins (Fig. 3.5). 
Reduced E22-272 and E146-429 were electrophoresed on SDS-PA gels for 
immunoblotting using anti-E-8 mAb. Both fusion proteins were reactive to similar 
extents after reduction (Fig. 3.7). When equimolar amounts of NlVE E protein and 
fusion proteins (E22-272, E146-429) were compared, the reactivity of fusion proteins 
was only slightly less than E (Fig. 3.5). For this experiment, 1 µg of MVE E protein 
(?6K) was taken as equivalent to approximately 3 µg of E22-272 or E146-429. Hence 
both fusion proteins appeared to carry the E-8 epitope. 
3.3.3 Mapping epitope E-8 on the MVE fusion proteins 
Construction of plasmids for deletion mapping 
The above results indicated that fusion proteins E22-272 and E146-429 could be 
used to map the E-8 epitope. Since they both showed reactivity, the simplest 
explanation was that the binding site was located in the overlapping region between 
Ser 146 and Val 272, i.e., in a stretch of 127 amino acids encoded in =380 bp. To 
more closely define this region, recombinant pEX plasmids containing various segments 
of the MVE E gene were derived by subcloning from pE22-272 or pE146-429, and used 
to express fusion proteins for analysis of reactivity with anti-E-8 mAb. In total, seven 
different recombinant plasmids were constructed. Fig. 3.8 shows the inserts and 
corresponding MVE E peptides encoded by these plasmids. 
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Figure 3.7 Immunoblot analysis of reduced fusion proteins (see Table 3.2) using anti-E-8 mAb. 
Bacterial lysates containing B-gal* and fusion proteins (==0.5 µg each) were electrophoresed on an SDS-
7.5% PA gel after incubation with B-ME for immunoblot analysis. Protein blots were detected with 
anti-E-8 mAb at dilution of 1 in 500 (overnight incubation). Positions of size markers (in kilodaltons) 
are indicated. 
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Figure 3.8 Identity of E gene inserts in recombinant plasmids. The solid bar represents the MVE E 
gene. The scale indicates the distance (in amino acids) from the N-terminal amino acid of the MVE E 
protein (501 amino acids) . The three unique restriction sites used in construction of recombinant 
plasmids and the corresponding amino acid positions in the E protein are shown. The open bars 
represent the E gene inserts in recombinant plasmids. The sizes of these inserts are shown in brackets. 
The amino acid positions in E corresponding to the ends of these inserts are shown on either side. 
The strategy for construction of these plasmids, except for pE327-429, relied on 
the presence of unique restriction sites in recombinant plasmids for deleting restriction 
fragments from the 5' or 3' end of MVE inserts. The resulting plasmids were expected 
to express fusion proteins containing the C- or N- terminal portion, respectively, of the 
original E peptides, which could then be tested for reactivity with anti-E-8. Restriction 
sites used were the SmaI and PstI sites which flank the 5' and 3' termini of MVE inserts 
respectively in the pEX plasmids, and StuI, NcoI and PstI sites in the E gene (see Fig. 
3.9). Using pE22-272 or pE146-429 as starting material, restriction digests were 
performed with a restriction enzyme which cleaved once in the MVE insert and with 
either SmaI or PstI to delete a fragment from the 5' or 3' end of the insert respectively. 
The digestion resulted in two fragments, the larger (>5.8 kb) being the desired deleted 
plasmid. The fragments were blunt-ended with T4 DNA polymerase and the larger 
fragment isolated by LMT agarose gel electrophoresis. It was then self-ligated and 
transformed into E.coli MC1061/pCI857. Some of the deleted recombinant plasmids 
were used as starting material for further deletion subcloning. The details of 
construction for pE146-328, pE146-224, pE201-328, pE225-328, pE225-272 and 
pE201-224 are shown in Fig. 3. 9. 
Plasmid pE327-429 was constructed differently. A fragment coding for peptide 
E327-429 (::::350 bp; Fig. 3.1) was isolated from pE146-429 after PstI digestion and 
LMT agarose gel electrophoresis (Fig. 3.10), and ligated to Pstl-digested, 
dephosphorylated pEX 1, 2 and 3 plasmids. The ligation mixture was used to transform 
MC1061/pCI857 cells. Ampicillin resistant colonies were screened using anti-MVE 
HIAF. Plasmids were extracted from immunoreactive colonies and examined by RE 
analysis to estimate size of inserts. A unique EcoRV site located 1.9 kb upstream from 
the 3' terminus of lacZ* (Fig. 2.1) and the PstI or NcoI sites which flank inserts at the 
3' end (Fig. 3.9) were used to cut out the inserts in -full. Fragment sizes were 
determined by agarose gel electrophoresis. The recombinant plasmids each contained an 
insert from the E gene of the expected size (results not shown). 
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Figure 3.9 Construction of recombinant plasmids for deletion mapping. 
pE146-328: pE146-429 (1 µg) was incubated with Pstl (5 units) at 37° for 1 hour. The digest was 
electrophoresed on 1 % LMT agarose, two fragments were observed (6.3 kb and ==300 bp). The larger 
fragment (==0.5 µg) was extracted and self-ligated by T4 DNA ligase (100 units) at 16° overnight. The 
ligation mixture was then used to transform MC1061/pCI857. Colonies carrying the recombinant 
plasmid were selected by immunoscreening using anti-MVE HIAF. 
pE201-328: pE146-328 (1 µg) was incubated with SmaI (2 units) at 25° for 1 hour and then StuI (2 
units) at 37° for 1 hour. The fragments (already blunt-ended) were separated on 1 % LMT agarose; two 
fragments were observed (6.2 kb and <200 bp). The larger fragment was self-ligated and transformed 
into E.coli as above. 
pE225-328: pE146-328 (1 µg) was incubated with Smal (2 units) at 25° for 1 hour and then Ncol 
(2 units) at 37° for 1 hour and incubated with T4 DNA polymerase (0.2 units) in the presence of dNTPs 
(0.5 mM each at 37° for 30 min). The blunt-ended fragments were separated on 1 % LMT agarose; two 
fragments were observed (6.1 kb and ==200 bp). The larger fragment was self-ligated and transformed 
into E.coli as above. 
pE146-224: pE146-328 (1 µg) was incubated with NcoI and Pstl (5 units each) at 37° for 1 hour and 
incubated with T4 DNA polymerase (as above). The blunt-ended fragments were separated on 1 % LMT 
agarose; two fragments were observed (6.0 kb and ==300 bp). The larger fragment was self-ligated and 
transformed into E.coli as above. 
pE225-272: pE22-272 (1 µg) was incubated with Smar and Ncol (5 units each) and incubated with T4 
DNA polymerase (as above). The blunt-ended fragments were separated on 1 % LMT agarose; two 
fragments were observed (6.0 kb and ==600 bp). The larger fragment was self-ligated and transformed 
into E.coli as above. 
pE201-224: pE201-328 (1 µg) was incubated with NcoI and Pstl (5 units each) at 37° for 1 hour and 
incubated with T4 DNA polymerase (as above). The blunt-ended fragments were separated on 1 % LMT 
agarose; two fragments were observed (5.9 kb and ==300 bp). The larger fragment was self-ligated and 
transformed into E.coli as above. 
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Figure 3.10 PstI-cligestion of pE146-429. Plasmid pE146-429 (::::3 µg) was incubated with PstI (5 
units) at 37° for 1 hour and then 70° for 10 min. Restriction fragments were electrophoresed on 1.5% 
LMT agarose at 60 volts for 1 hour. The agaros gel was stained in ethiclium bromide (0.5 µg/ml) for 
30 min and viewed on a UV-transilluminator. A band corresponding to ::::350 bp was excised from the 
gel for cloning into pEX vectors. 
The MVE insert in pE327-429 was labelled at the 3' end with 32P-dCTP and 
sequenced by the chemical method (Materials and Methods; Chapter 2). The sequence 
data obtained confirmed the identity of pE327-429. Plasmids pE201-328, pE225-328 
and pE225-272 were partially sequenced between the polylinker and E insert to ensure 
that translation of the E insert was in frame with .B-gal*. 
Molecular weight and yield of MVE E fusion proteins encoded by 
recombinant plasmids 
The mol. wts. of the fusion proteins were predicted from the lengths of the lacZ*-E 
fused gene (Table 3.2). Fusion proteins from lysates were analysed by SDS-PAGE for 
comparison with these predicted sizes to determine whether the expected translation had 
occurred. The results for the seven deleted recombinant pEX plasmids (Fig. 3.8) are 
shown in Table 3.2. The observed mol. wts. corresponded with the predicted mol. wts. 
and the coding capacity of inserts in recombinant plasmids. This indicated correct 
translation and absence of degradation of fusion proteins. There was no significant 
difference in yields between different fusion proteins and approximately 40 mg of each 
fusion protein per litre of induced culture was obtained (Fig. 3.3). 
Reactivity of anti-E-8 mAb with MVE E fusion proteins 
The seven fusion proteins were used to map the E-8 epitope. To test for reactivity 
with anti-E-8, approximately equimolar quantities of fusion proteins were used. 
Bacterial lysates were reduced, electrophoresed on SDS-PA gels and nitrocellulose blots 
analysed using anti-E-8 mAb. Anti-E-8 reacted with E146-328 but not with E327-429 
(Fig. 3.7) eliminating the latter sequence as a significant part of the epitope. There was 
no reduction in reactivity of E146-328 relative to E22-272 and £146-429. Thus it 
appeared that the binding site remained intact in £146-328. Three fusion proteins, 
E201-328, E146-224 and E201-224 from within this region also reacted with anti-E-8 
(Fig. 3.7). E201-328 showed reactivity similar to E146-328. E146-224 and E201-224 
showed weaker reactivity than E146-328 (by approximately 50%). 
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TABLE 3.2 
Predicted and observed mol. wts. of MVE fusion proteins 
Fusion protein 
E22-272 (Asp 22-Val 272) 
E146-429 (Ser 146-Gly 429) 
E146-328 (Ser 146-Gln 328) 
E327-429 (Leu 327-Gly 429) 
E146-224 (Ser 146-Pro 224) 
E201-328 (Tyr 201-Gln 328) 
E201-224 (Tyr 201-Pro 224) 
E225-328 (Trp 225-Gln 328) 
E225-272 (Trp 225-Val 272) 
Predicted mol. wt. a 
(K) 
149(251) 
153 (285) 
142 (184) 
133 (103) 
131 (80) 
136 (128) 
125 (24) 
133 (104) 
127 (48) 
Observed mol. wt.b 
(K) 
156 
158 
145 
139 
135 
142 
124 
139 
131 
a Calculated from the observed mol. wt. of B-gal* (122K; see Chapter 2) and additional amino acids 
from the E protein of MVE (Dalgarno et al., 1986). The predicted numbers of amino acids are shown in 
brackets. 
b Determined by SDS-PAGE (Fig. 3.3). 
These observations suggested that the major binding site of anti-E-8 was located 
within a stretch of 24 amino acids between Tyr 201 and Pro 224 in the MVE E protein. 
Since fusion proteins lacking E225-328 showed decreased reactivity, this region may also 
influence the binding of anti-E-8. Since this mAb did not react with fusion proteins 
E225-272 or E225-328 in immunoblots, this influence is presumably indirect. 
A search was made of restriction sites located within the region coding for peptide 
E201-224 for further deletion mapping. No appropriate sites were available. Thus 
alternative methods would have to be employed to identify the critical residues within 
E201-224 which were essential for binding of anti-E-8. 
3.3.4 Reactivity of anti-MVE HIAF with deleted fusion 
proteins 
To assess the suitability of the fusion proteins for use in immunization experiments 
(see below), they were examined for the presence of MVE epitopes using polyclonal 
HIAF. Lysates of bacterial cells expressing the nine available fusion proteins were 
electrophoresed, after reduction, on an SDS-7 .5% PA gel and immunoblotted using 
anti-MVE HIAF. Approximately equimolar amounts of fusion proteins were analysed. 
In each bacterial lysate, a single antibody-reactive band was observed (see Fig. 3.4), 
corresponding in size with the fusion protein band observed in Coomassie Blue stained 
profiles (Fig. 3.3). Consistent differences in the reactivities of these reduced fusion 
proteins were observed in several experiments. E201-224 was only detected using more 
concentrated HIAF and large quantities of protein (results not shown). The weak 
reactivity of E201-224 may be due to the small size of the E peptide (24 amino acids). 
Differences in immunoreactivities of other proteins may have been influenced by the 
number of epitopes in these .proteins or the resistance of the epitopes to reduction and 
denaturation. The strong immunoreactivity of E225-272 relative to E225-328 was 
unexpected because MVE peptide E225-272 is also present in fusion protein E225-328. 
This may indicate that in the latter fusion protein, the reactivity of epitopes between 
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Trp 225 and Val 272 was adversely affected by the presence of sequences between 
Glu 273 and Gln 328. 
These results suggested that each of the E fusion proteins contained reactive MVE 
antigenic sites. There were however differences in the overall reactivities with :HIAF. 
Thus it was of interest to determine whether these fusion proteins elicited antibodies 
against MVE in mice. 
3.3.S Isolation of fusion proteins for mouse injection 
Fusion proteins for injection of mice were partially purified as follows. E.coli 
cultures were induced for fusion protein synthesis and cells harvested after two hours. 
Lysates containing B-gal*, E22-272, E146-429 or E201-224 were prepared by freeze-
thawing and lysozyme treatment in the absence of detergent to avoid irreversible 
denaturation, solubilization of fusion proteins and problems of detergent removal. The 
fusion proteins were insoluble under these conditions and were pelleted by 
centrifugation; they were extracted and solubilized with 8 M urea which was then 
removed by exhaustive dialysis against PBS. The yield ranged from 40-50 mg/litre of 
induced culture. As the fusion protein content of total bacterial lysates was 
approximately 40 mg/litre (see above), very little loss had occurred during the 
procedure. Approximately 95% of the stained protein in the preparations was fusion 
protein (Fig. 3.1 lA), by comparison with approximately 80% in induced bacterial 
lysates. Fusion proteins appeared as doublets after partial purification. This may 
indicate partial degradation or incomplete renaturation after urea treatment. 
The possibility that the conformation of fusion proteins was altered during 
purification was examined by assessing their immunoreactivities with HIAF and anti-
E-8 mAb. Purified fusion proteins were dot-blotted on nitrocellulose or electrophoresed 
in the reduced state and transferred to nitrocellulose for immunodetection. After 
purification, E22-272, E146-429 and E201-224 remained reactive to both HIAF and 
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Figure 3.11 SDS-PAGE profiles and immunoreactivity of purified fusion proteins. (A) SDS-PAGE 
profiles of purified fusion proteins. B-gal* and fusion proteins E22-272, E146-429 and E201-224 were 
purified from bacterial lysates by extracting the insoluble fractions. The purified proteins (0.5-1 µg 
each) were incubated with B-NlE at 90° for 2 min and electrophoresed on an SDS-7.5 % PA gel at 200 
volts for 45 min. Proteins were stained with Coomassie Brilliant Blue. The size markers were as 
described in Fig. 3.3. 
(B) Immunoblot analysis of purified fusion proteins. B-gal* and fusion proteins E22-272, E146-429 
and E201-224 were separated by SDS-PAGE as above and transferred to nitrocellulose for detection 
using anti-MVE HIAF as in Fig. 3.4. 
* anti-E-8 (Fig. 3.1 lB; results for anti-E-8 not shown). Doublets were detected on 
immunoblots indicating that both 'species' were antigenic. 
3.3.6 Injection of mice with fusion proteins in Freund' s 
incomplete adjuvant 
ELISA titres against fusion proteins 
Outbred Swiss mice at 6-8 weeks of age were injected with three fusion protein 
preparations (E22-272, E146-429 and E201-224; 10 µg per mouse) emulsified in 
Freund's incomplete adjuvant (FIA). Booster injections with identical preparations were 
given four and nine weeks after the initial injection. Groups of five mice were injected 
with each fusion protein. B-gal *, prepared identically to fusion proteins, was injected 
into a control group of mice. Antibody titres against immunizing proteins were 
determined by ELISA (Table 3.3). Reactivity was detected in most mice 14 days after 
injection but titres were low. Titres generally increased after each boost; after two 
boosts, they ranged from 200 to 12,800. Differences were observed between animals 
injected with identical fusion proteins (Table 3.3). ELISA titres against fusion proteins 
were generally highest for E201-224, intermediate for E146-:429 and lowest for 
E22-272. When ELISA titres against B-gal* were tested after a single boost, it was 
found that there was little difference between anti-B-gal * and anti-fusion protein 
reactivities (Table 3.3). Thus most of the immune response was directed at the B-gal* 
sequence which made up 78-97% of the immunizing fusion proteins. 
ELISA titres against MVE 
To detennine whether any of the above antisera were reactive against virus, ELISA 
was performed with partially purified MVE as antigen. The results (Table 3.3) showed 
that anti-MVE reactivities were detected for two out of 14 mice. One mouse injected 
with E22-272 (no. 3) developed consistent anti-MVE ELISA titres (320, 800) after two 
boosts; the second mouse, also injected with E22-272 (no. 4), was positive at 11 weeks 
* In Fig. 3.llB, the detection of E201-224 by anti-MVE HIAF was not effective owing to 
insufficient quantity of fusion protein (see Section 3.3.4). 
65 
I 
i 
TABLE 3.3 
Anti-fusion protein and anti-MVE ELISA titres of sera from 
mice injected with fusion proteins emulsified in Freund' s 
incomplete adjuvant 
Fusion Mouse ELISA titresa N titres 
protein Weeks post injection 
0 2 5 6 10 11 
E22-272 1 _b(-) 25(-) NDC(-) 100(-)d 200(-) 400(-) _b 
2 -(-) 25(-) ND(-) 100(-) 400(-) 800(-) 
3 -(-) 25(-) 25(-) 100(-)e 400(320) 800(800) 
4 -(-) -(-) ND(-) -(-) 200(-) 800(25) 
5 -(-) 10(-) ND(-) 100(-) 400(-) 400(-) 
E146-429 1 -(-) 10(-) 1600(-) 1600(-) 3200(-) 3200(-) 
2 -(-) 10(-) 400(-) 400(-) 3200(-) 3200(-) 
3 -(-) 25(-) 800(-) 3200(-)f 800(-) 1600(-) 
4 -(-) 25(-) 200(-) 800(-) 3200(-) 3200(-) 
E201-224 1 -(-) 10(-) 400(-) ND(-) 1600(-) ND(-) 
2 -(-) -(-) 6400(-) 6400(-) 12800(-) ND(-) 
3 -(-) 50(-) 3200(-) 6400(-)g 6400(-) 6400(-) 
4 -(-) 25(-) 3200(-) 6400(-) 12800(-) ND(-) 
5 -(-) 10(-) 3200(-) 12800(-) 12800(-) ND(-) 
a Anti-fusion protein ELISA titres are given first; figures in brackets represent anti-MVE ELISA titres. 
b Titres lower than 10 are represented as-. 
c Not done. 
d Anti-f3-gal* titre was 200. 
e Anti-f3-gal* titre was 100. 
f Anti-B-gal* titre was 3200. 
g Anti-B-gal* titre was 6400. 
I 
after injection but gave a much lower titre. E201-224 and E146-429 failed to elicit 
detectable anti-MVE responses in mice. 
3.3. 7 Immunization with fusion proteins in RIBI adjuvant 
Two factors may have conuibuted to the failure of cenain E fusion proteins to elicit 
anti-MVE antibodies: the E components may not have been strongly immunogenic or the 
conformation may not have been native. An attempt was made to improve the 
immunogenicity of E peptides in fusion proteins. First, FIA was replaced with RIBI 
adjuvant (see Materials and Methods) which is reported by the manufacturer to elicit 
high antibody titres and require fewer booster injections by comparison with FIA and 
Freund's complete adjuvant. RIBI has been used successfully to elicit anti-MVE 
antibodies with synthetic peptides (Roehrig et al., 1989). Second, the fusion proteins 
were altered by removing a large portion of the B-galactosidase sequence to increase the 
proportion of MVE in fusion proteins. 
Generation of fusion proteins containing truncated B-galactosidase 
Truncation of the B-galactosidase sequence was achieved by removing a portion of 
the coding region at the 3' terminus. The aim was to express fusion proteins containing 
a smaller B-galactosidase fragment without altering the polylinker sequence. The 
existence of a sequence (1.9 kb) which encompassed 63% of the lacZ* coding region 
and is flanked by the unique EcoRV and EcoRI sites in pEX2 (Fig. 2.1) allowed the 
following strategy to be adopted. Incubation of pEX2 with EcoRV and EcoRI generated 
two fragments (3.9 kb, 1.9 kb). The larger one was the linearized pEX2 plasmid 
containing the truncated lacZ coding region. The polylinker region and the essential 
features of the pEX plasmid for expression of foreign genes were intact. The 3.9 kb 
fragment was isolated (Fig. 3.12), blunt-ended with T4 DNA polymerase and self-
ligated. After transformation, ampicillin resistant clones were selected, plasmids 
extracted and analysed by Pstl digestion and gel electrophoresis. Plasmids were 3.9 kb 
in size and contained the Pstl site in the polylinker region consistent with the desired 
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Figure 3.12 Construction of pEX2D. pEX2 plasmid (1 µg) was incubated with EcoRV and EcoRI (5 
units each) at 37° for 1 hour and then with T4 DNA polymerase (0.2 units) in the presence of d.NTPs 
(0.5 mM each). The digest was electrophoresed on 1 % LMT agarose, soaked in ethidium bromide 
(0.5 mg/ml) for 30 min and viewed on a UV-transilluminator. The larger fragment (3.9 kb) was excised 
from the gel for self-ligation to generate pEX2D. 
plasmid which was designated pEX2D (Fig. 3.13A). The 13-galactosidase sequence 
encoded in this plasmid was predicted to be 37 5 amino acids long and is referred to 
below as I3-galD. 
pEX2D was ligated with a cDNA fragment encoding E327-429 to generate a plasmid 
designated pE327-429D. The cDNA (=350 bp) was derived from pE146-429 by PstI 
digestion as for the construction of pE327-429 (Fig. 3.10). It was ligated to PstI-
digested, dephosphorylated pEX2D. Transformed ampicillin resistant colonies were 
screened with HIAF. A strongly positive clone was picked and the plasmid extracted 
and analysed by gel electrophoresis after PstI digestion. It contained the two expected 
PstI fragments of 3.9 kb and =350 bp (results not shown), consistent with the 
restriction sites in pE327-429D and with its size (Fig. 3.13B). 
Fusion proteins were prepared from expression of pEX2D and pE327-429D. 
Approximately 50 mg B-galD (52K) and E327-429D (63K) were obtained per litre of 
culture. The sizes of I3-ga1D and E327-429D (see Fig. 3.14A) were consistent with the 
presence of 103 amino acids from the MVE E protein in E327-429D. We conclude that 
E327-429D was extracted without degradation in a yield similar to that for I3-gal* fusion 
proteins. 
The reactivity of E327-429D to HIAF was examined after dot-blotting on 
nitrocellulose (results not shown) or after SDS-PAGE and immunoblotting (Fig. 
3.14B). E327-429D reacted strongly in both assays and was therefore a suitable 
replacement for E327-429 in immunization experiments. 
ELISA titres against fusion proteins 
Preparations of I3-ga1D, E327-429D and E201-224 were injected into mice with 
RIBI adjuvant. The dose of each was 10 µg/mouse. Because of the cost of the 
adjuvant, the number of mice injected was reduced to two per fusion protein. Serum 
samples were collected before and 14 days after injection. A booster injection with an 
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Figure 3.13 pEX2D and pE327-429D plasmids. (A) Plasmid pEX2D (3.9 kb) was created by 
truncating the lacZ* gene (3 kb) in pEX2 (Fig_ 2.1) to lacZD (1.1 kb) leaving the 5' portion intact. (B) 
Plasmid pE327-429D (4.2 kb) comprises pEX2D and the E gene fragment coding for the MVE peptide 
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Figure 3.14 SDS-PAGE profiles and immunoreactivity of purified E327-429D and B-galD. (A) SDS-
PAGE profiles of purified E327-429D and B-galD. B-galD and fusion protein E327-429D were purified 
from bacterial lysates by extracting the insoluble fractions. The purified proteins (1 µg each) were 
incubated with B-1v1E at 90° for 2 min and electrophoresed on an SDS-7.5% PA gel. Proteins were then 
stained with Coomassie Brilliant Blue. The size markers were as described in Fig. 3.3. 
(B) Immunoreactivity of fusion protein E327-429D. Purified preparations of E327-429D and B-galD 
(1 µg each) were electrophoresed on an SDS-7.5 % PA gel and transferred to nitrocellulose. Detection 
was with anti-MVE HIAF (1 in 800 dilution; 1 hour incubation). 
identical preparation was given five weeks after the initial injection; serum samples were 
collected seven and 14 days after boost. 
The response was determined by ELISA in microtitre trays coated with E201-224 
or E327-429D (Table 3.4). · ELISA titres of 50-800 were observed two weeks after 
injection with the two fusion proteins in RIBI. The ELISA titres after the boost at five 
weeks were 25,600-51,200. In the earlier experiment (Table 3.3), ELISA titres no 
greater than 12,800 were obtained for mice injected with E201-224 in FIA. This 
represented a large (2 to 16-fold) increase in ELISA titres which may be related to the 
adjuvant used. However, this cannot be stated with certainty due to the small sample 
number. 
The reactivity of sera to sequences in B-galD was assessed by ELISA in microtitre 
trays coated with B-galD. ELISA titres against B-galD were approximately 4-fold lower 
than against E327-429D (Table 3.4; legend). This indicated that the sera contained 
antibodies directed at the MVE component. 
ELISA titres against MVE 
The reactivity of these sera with MVE was examined by ELISA. Both E327-429D 
and E201-224 elicited anti-MVE antibodies, detectable two weeks after injection. The 
titres after one boost rose to 200-400 for both E201-224 and E327-429D (Table 3.4). 
We conclude that the E peptides in these fusion proteins are immunogenic and elicit 
antibodies which react with epitopes in MVE. 
3.3.8 Neutralization activity of anti-fusion protein sera 
It was of interest to determine whether the sera which reacted with MVE in an 
ELISA neutralized virus infectivity. The question of whether E201-224 elicited 
neutralizing antibodies was of particular interest because this region of E appeared to 
define the E-8 neutralization epitope. Neutralization assays (PRl~T) were carried out 
with sera from mice injected with E22-272, E201-224 and E327-429D and \vith control 
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TABLE 3.4 
Anti-fusion protein and anti-lVIVE ELISA titres of sera from 
mice injected with fusion proteins in RIBI adjuvant 
Protein 
E201-224 
E327-429D 
Mouse 
1 
2 
1 
2 
0 
_b (-) 
- (-) 
- (-) 
- (-) 
ELISA titrea 
Weeks post injection 
2 
800 (-) 
50 (-) 
800 (-) 
400 (10) 
6 
25,600 (200) 
51,200 ( 400) 
7 
NDC (200) 
ND (400) 
51,200 (200)d ND (100) 
204,800 (400f ND (200) 
N titres 
_b 
10 
10 
10 
a Determined against immunizing fusion proteins. Figures in brackets represent anti-MVE titres. 
b Titres lower than 10 are represented-as-. 
c Not done. 
d Anti-13-galD titre was 12,800. 
e Anti-3-galD titre was 51,200. 
I 
sera (Table 3.4). The anti-MVE ELISA titres of these sera ranged from 100-800. Sera 
from mice injected with E22-272 in FIA did not neutralize MVE infectivity. Similarly, 
sera from mice injected with fusion proteins E327-429D and E201-224 in RIBI adjuvant 
did not neutralize to a significant degree. 
3.3.9 Summary 
For epitope mapping on E fusion proteins, a recombinant pEX plasmid which 
expressed the N-terminal half of the MVE E protein (fusion protein E22-272) was first 
generated. The reactivity of five neutralizing mAbs with E22-272 and E146-429 
(Chapter 2) was examined to assess the possibility of mapping the corresponding 
epitopes by deletion analysis: All five mAbs reacted specifically with unreduced MVE E 
protein in immunoblots. They differed in reactivity with the reduced protein. Anti-E-8 
reacted with reduced E, though to a decreased level than with unreduced E. The 
reactivities of anti-E-lc, E-ld, E-5b and E-7 mAbs with MVE E protein were abolished 
by reduction of disulfide bonds. Anti-E-8 mAb reacted with both E22-272 and 
E146-429 fusion proteins. Epitope mapping by deletion analysis showed that residues 
201-224 were essential for the interaction of the anti-E-8 mAb with a number of fusion 
proteins. The mAbs against E- lc, E-ld, E-5b and E-7 did not react with either 
unreduced or reduced E fusion proteins. 
Mice were injected with partially purified fusion proteins to generate antisera for 
tests of reactivities against MVE in ELISA and neutralization assays. Four fusion 
proteins, E22-272, E146-429, E201-224 and E327-429D (the latter contained 40% of 
the B-galactosidase component of other fusion proteins) in either FIA or RIBI adjuvant, 
were used. All four fusion proteins elicited antibodies against themselves. E22-272 in 
FIA, and E201-224 and E327-429D in RIBI elicited antibodies against MVE. None of 
the mouse sera neutralized MVE infectivity to a significant degree. 
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3.4 DISCUSSION 
The aim of the work described in this chapter has been to define neutralization 
epitopes in the MVE E protein using I3-gal*-E fusion proteins generated in E.coli. In 
one approach we have subjected the E gene to a series of deletions, characterized the 
resulting fusion proteins and examined their reactivities with neutralizing mAbs to map 
neutralization epitopes. In the second approach, the capacity of mouse sera generated 
against fusion proteins to recognize MVE in ELISA and to neutralize MVE infectivity in 
plaque assays was assessed. 
Reactivities of fusion proteins with neutralizing mAbs 
From immunoblotting experiments using MVE electrophoresed on SDS-PA.GE, it 
was clear that all five neutralizing mAbs reacted with epitopes in the authentic viral 
envelope protein and that these epitopes were either resistant to SDS denaturation or 
renatured after SDS denaturation. On the other hand, four mAbs (all except anti-E-8) 
failed to react with reduced E. We concluded that these four epitopes are likely to reside 
in domains of E which are created by or stabilized by disulfide bonds. By analogy with 
the WN and TBE E proteins (Nowak and Wengler, 1987; Mandl et al., 1989b) they 
could reside in any region of the E protein, with the exception of domain C 
(residues 150-170) and the hydrophobic C-tenninus (residues 460-501). We could not 
obtain further information on E-lc, E-ld, E-5b and E-7 epitopes as the corresponding 
mAbs did not react with either the unreduced or reduced E fusion proteins, indicating 
that these epitopes are absent in the E fusion proteins. Possible explanations are that 
these epitopes were not generated in the E fusion proteins owing to a distorted 
conformation, or to the need for the association of discontinuous stretches of the E 
components, or that the epitopes were located in parts of E not represented in the fusion 
proteins (residues 1-21 and residues 429-501). The epitope mapping studies on JEE-
fusion proteins (Mason et al., 1987b; Mason et al., 1989) are of interest as they provide 
a direct comparison using a similar strategy. Of the eleven mAbs examined (these differ 
in degrees of cross-reaction with different flaviviruses and in activities in passive 
70 
·1 
I 
protection), ten which neutralized JE infectivity reacted with JE fusion proteins 
containing the region in E between Met 303 and Trp 396. This indicated that the 
domain in JE E containing these epitopes, which corresponds to TEE domain B (see 
Fig. 1.4) can retain reactivity when expressed as fusion proteins (with trpE or 
B-galactosidase) in E.coli. The reactivity of these mAbs appeared to require disulfide 
bonds as there was no reaction with reduced and carboxymethylated E or with fusion 
proteins lacking the cysteine in E at 304 (which forms disulfide with Cys 335). The 
MVE mAbs against E-lc, E-ld, E-5b and E-7 were not reactive with unreduced 
E146-429. As E146-429 contains a similar domain B, it seems likely that these epitopes 
are located in parts of MVE E protein outside the region Met 304-Trp 397. In 
summary, our data suggest that these epitopes are stabilized by disulfide bond formation 
and the overall conformation of E, and that they are not in a domain corresponding to 
TBE domain B. 
Anti-E-8 reacted with the two largest fusion proteins E22-272 and E146-429 , 
showing approximately equivalent reactivities on a molar basis with MVE E protein. 
. ' 
Approximately half of this reactivity was associated with a small section of E (Tyr 201-
Pro 224) which corresponds to part of domain A. Four TBE neutralization epitopes 
have been demonstrated in domain A; two of them, the AS determinant (Glu 207) and 
the A4 determinant (Gln 233) map close to the E-8 region defined here (Mancil et al., 
1989b). A point of interest was the degree to which the reactivity of the E-8 antigenic 
site was determined by its 'environment' in E. E22-272, El46-429 and E146-328, 
which all carried the peptide E201-224, had approximately equivalent reactivities on a 
molar basis. On the other hand, E146-224 and E201-224 showed a fall (of ~50%) in 
reactivity compared with fusion proteins also containing E225-328· From this we 
conclude that sequences between Trp 225 and Gln 328 are required for full reactivity 
with anti-E-8, but are not reactive alone (see below). 
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MAb against the E-8 epitope (Table 3.1) cross-reacts in ELISA with JE, SLE and 
WN and also in protection asssays in mice with JE and SLE. Fig. 3.15 shows the 
sequence of the MVE E protein from Tyr 201 to Pro 224 aligned with that of other 
flaviviruses. Fig. 3.16 (adapted from Dalgarno et al., 1986) shows the hydropathy 
characteristics of the E-8 region and its surrounds. The sequence contains two 
hydrophobic regions (at the N- and C-termini) and a hydrophilic central region 
(underlined in Fig. 3.15). The sequence homology in the region 201-224 between MVE 
and JE, WN or SLE is 75, 75 and 58% respectively. Homology is considerably higher 
at the C-terrninal end than overall. Since cross-reaction occurs with SLE ( which shows 
=70% homology in the C-terminal 13 amino acids comprising the hydrophilic segment, 
and only =45% in the N-terminal section), it seems likely that the epitope recognized by 
anti-E-8 mAb is in fact in the C-terminal half (residues 212-224). 
Finally, it is of interest that although a disulfide bond presumably links MVE 
residues 190 and 288, and the E-8 epitope falls within this loop, reactivity was lowered 
but not abolished by B-mercaptoethanol treatment. This suggests that within a domain 
which is stabilized by disulfide bonds, significant variations exist in sensitivity to 
reduction or that disulfide bond reformation has occurred. MAbs against epitopes in 
domain A of TBE lose reactivity after Eis reduced and carboxymethylated, a treatment 
which disrupts disulfide bonds irreversibly (Guirakhoo et al., 1989). As reduction of 
MVE was achieved by B-ME treatment alone, we cannot rule out the possibility that 
renaturation occurred. 
Conformation of viral proteins expressed in E.coli 
The lack of reactivity of the neutralizing mAbs against E-lc, E-ld, E-5b and E-7 
epitopes with E22-272 and E146-429 and the inability of fusion proteins to elicit 
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Figure 3.15 Amino acid sequence of the MVE E protein from Tyr 201 to Pro 224. The N1VE 
sequence is shown on the top line with an underlined segment representing a strongly hydrophilic 
region. Aligned sequences below are for JE (McAda et al., 1987), WN (Castle et al., 1986), SLE (Trent 
et al., 1987), YF 17D (Rice et al., 1985), DEN-1 (Mason et al., 1987a), DEN-2 (Deubel et al., 1986), 
DEN-4 (Zhao et al., 1986) and TBE (Mandi et al., 1988). The single letter amino acid code is used; 
dots represent amino acid residues identical to MVE at similar positions. The arrow indicates the AS 
neutralization determinant of TBE (Mand! et al., 1989b). 
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Figure 3.16 Hydropathy profile of the MVE E protein (adapted from Da1garno et al., 1986). The MVE 
E protein sequence (Dalgarno et al., 1986) is subjected to hydropathy analysis (Ky te and Doolittle, 
1982) and plotted on the vertical axis with positive values indicating hydrophobicity and negative values 
indicating hydrophilicity. The region from Tyr 201 to Pro 224 is indicated. 
neutralizing antibodies in mice can be attributed to the conformation of the E polypeptide 
component of the fusion proteins. Three factors may be involved in this. First, MVE E 
protein has a conserved Asn-linked glycosylation site (at Asn 154) to which 
carbohydrates are normally attached (Winkler et al., 1987). Residue 154 is present in 
both E22-272 and El46-429. As Asn-linked glycosylation only occurs in eukaryotic 
cells (Hubbard and Ivatt, 1981), the conformation of the E components of the fusion 
proteins generated in bacteria may be affected by the absence of glycans attached to 
Asn 154. For TBE, deglycosylation of the virus does not affect the reaction of eight 
anti-E mAbs or anti-TBE polyclonal antibodies with the virus (Winkler et al., 1987) 
although the removal of glycans at an Asn-linked glycosylation site appears to 
destabilize epitopes in close proximity (Guirakhoo et al., 1989). On the other hand, the 
extent of glycosylation modifies the reactivity mAbs and polyclonal antibodies with the 
influenza virus haemagglutinin and gp70 of Rauscher murine leukemia virus (Alexander 
and Elder, 1984). 
The second factor is that bacterial proteins contain more sulfbydryl groups than 
eukaryotic proteins and this appears to be related to a stronger reducing environment in 
the bacterial cytosol (Fahey et al., 1977). The MVE peptide E22-272 would, as 
generated in eukaryotic cells, be expected to carry three disulfide bonds (Cys 60-121, 
Cys 74-105, Cys 92-116). Cys 30 and Cys 190, also present in E22-272, would 
form bridges with Cys 3 and Cys 288 respectively in the native protein (Nowak and 
Wengler, 1987). E146-429 would be expected to have two disulfide bonds (Cys 190-
288 and Cys 305-336) but no cysteine residues without pairing possibilities. This 
protein would be more likely to form the correct conformation. In studies with JE, the 
presence of cysteines at residues 304 and 335 in the E protein was essential to the 
reactivity of mAbs with the fusion proteins used suggesting that the disulfide bond 
(Cys 304-335) in domain B was generated in the bacterial cytosol. Despite these 
indications, no confident predictions can be made concerning the conformation of 
E22-272 and E146-429 as part of fusion proteins in the E.coli cytosol. 
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A third consideration is that the fusion proteins used in this study carried no more 
than 284 amino acids of the MVE E protein fused with a G-gal * protein of more than 
1000 amino acids. The conformation of the MVE components may be influenced by 
interaction with the G-galactosidase sequence. Thus epitopes which depend on specific 
folding of the E sequence or are assembled from distant regions of E may not acquire a 
conformation similar to that in native E protein. 
The results from immunization experiments using the B-gal-E fusion proteins were 
of relevance to our understanding of neutralization epitopes in MVE. We have shown 
that E201-224 in FIA, and E22-272 and E327-429D in RIBI adjuvant elicited antibodies 
which reacted with MVE. These antibodies did not neutralize MVE infectivity in plaque 
assays although a neutralizing mAb (anti-E-8) reacted with both E201-224 and E22-272. 
This indicated that the neutralization epitope in these fusion proteins did not elicit 
neutralizing antibodies in mice. As reactivity of E201-224 is only half that of E22-272, 
indicating incomplete or distorted presentation of the E-8 epitope, it is perhaps not 
surprising that this fusion protein cannot elicit neutralizing antibodies. Even though 
E22-272 may have the intact E-8 epitope, another factor may account for its inability to 
elicit neutralizing antibodies. Although the MVE component of E22-272 elicits a 
polyclonal reponse in mice, perhaps only a small proportion of antibodies are directed at 
the E-8 epitope. As the ELISA titre against MVE was not high ( ::=800), the magnitude of 
the anti-E-8 response may have been too small to neutralize infectivity. 
In relation to flaviviruses in general, our work reinforces the view that 
conformation-dependent epitopes play a major role in neutralization. For JE, 
neutralization epitopes were mapped using fusion proteins to a region of E 
corresponding to TBE domain B (Mason et al., 1989); however, these fusion proteins 
did not elicit neutralizing antibodies in mice. Thus the native and intact E may be 
required to elicit neutralizing antibodies in mice. For WN, E protein purified by SDS-
PAGE elicits neutralizing antibodies in rabbits, while similar preparations of E reduced 
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by S-ME do not (Wengler and Wengler, 1989b). For TBE, epitopes in both domains A 
and B are destroyed by irreversible reduction, and neutralization epitopes in domain A as 
well as the neutralization epitope i2 are also destroyed by SDS treatment (Guirakhoo et 
al., 1989). 
The application of E fusion proteins to studying the mechanism of virus entry and 
of neutralization of infectivity had been one goal of this work. However, these 
processes are likely to depend on the specific conformation of part or all of the E 
protein. In view of the results presented, it seems unlikely that MVE fusion proteins are 
sufficiently conformationally homologous to the native E protein to be useful in 
approaching these goals. The application of bacterial fusion proteins appears to be 
limited to mapping particular epitopes only and to generating specific antisera for use as 
protein-specific 'reagents'. To pursue our objective of studying the functional 
determinants of E, epitope mapping using mAb selected escape variants and the 
expression of E in a more 'native' conformation are explored in Chapters 4 and 5 
respectively. 
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CHAPTER 4 
SEQUENCE STUDIES AND VIRULENCE 
ASSAYS ON MVE ANTIGENIC VARIANTS 
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4.1 INTRODUCTION 
In the first part of this chapter, we aim to map neutralization epitopes in the ?vlVE E 
protein by sequencing mAb escape variants of MVE. As noted in Chapter 1, few data 
exist which define neutralization epitopes in members of the important JE serogroup of 
flaviviruses. Within this group which includes JE, MVE, SLE, WN and KUN, 
published data exist only for JE (Mason et al., 1989). These investigators have shown 
that the region of E between residues 303 and 396 defines a domain against which ten 
neutralizing mAbs are directed; however, the residues recognized by each of the mAbs 
have not been defined. It has been shown for MVE that residue 126 is part of the 
epitope recognized by anti-E-lc mAb (S. H. Hartley and R. C. \tVeir, personal 
communication). For flaviviruses in general, the most extensive data available are for 
TBE; neutralization epitopes have been mapped to residues 67, 71, 171, 207, 233, 384 
and 389 in the E protein (Mandl et al., 1989b). For YF, neutralization epitopes have 
. 
been mapped to residues 71 and 72 (Lobigs et al., 1987); and for DEN-1 to residues 
293-401 (Zuegel et al., 1987). Due to the likely conservation of the basic architecture of 
the flavivirus E protein (Nowak and Wengler, 1987; Mandl et al., 1989b), any data 
obtained on MVE antigenic sites could be of relevance to other flaviviruses, particularly 
to the medically important JE. 
In the second part of this chapter, we describe virulence assays carried out with the 
sequenced MVE mAb escape variants. These studies were performed because of the 
possibility that in the flavivirus envelope protein, neutralization epitopes 'overlap' the 
region of E which recognizes a cell receptor molecule or a molecule which acts in virus 
cell interaction. Changes in such a region could modify virus-cell interaction, tissue 
tropisms and virulence. Of interest in this regard, a neutralization escape variant of TBE 
altered at a single residue in E (Tyr 384) is attenuated in mice (Heinz et al., 1989). 
Furthermore, Lobigs et al. (1990) have shown that passage of MVE-1-51 in cell culture 
can lead to a specific change at Asp 390 in the E protein; this change from the wild-type 
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sequence is accompanied by attenuation of mouse virulence although a causal 
relationship has not been established. 
4.2 MATERIALS AND METHODS 
4.2.1 Viruses and cells 
MVE-1-51 stocks used by Dr R. C. Weir and Dr J. T. Roehrig and for the work 
described in this study were derived from the same source (Yale Arbovirus Research 
Unit, USA). Working stocks of MVE-1-51 were tissue culture supernatants from 
infected Vero cell monolayers. MVE variant E-lcN5b was provided by Dr R. C. Weir 
(see below). 
Vero cells were grown in M199/LAH medium plus 10% bovine serum. 
4.2.2 Monoclonal antibodies 
Anti-Em.Abs 4B6C-2, 4B5A-2, 4B3B-6, 6A4D-1 and 6B4A-10 which defined 
epitopes E-lc, E-ld, E-5b, E-7 and E-8 respectively (Table 3.1) were from Dr J. T. 
Roehrig. The first four were provided as both ascitic fluids and lyophilized ascitic 
fluids. The latter were reconstituted in sterile water upon arrival. Ascitic fluids were 
transported from USA at ambient temperature and were of low titre, presumably because 
of this; they were subsequently stored in aliquots at -70°. Freshly thawed aliquots of 
both farms of m.Abs were used for neutralization tests. 
4.2.3 Plaque reduction neutralization tests (PRNT) 
Serial two-fold dilutions of antibody were in HBSS (pH 8). Diluted antibody 
(100 µl) was incubated with =200 PFU of virus (in 100 µl HBSS; pH 8) for 1 hour at 
37°. The number of remaining PFU was determined by plaque assay on Vero cell 
monolayers without removing the inoculum (Chapter 3). Parallel control PRNTs with 
MVE-1-51 were carried out. 
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4.2.4 Selection of antigenic variants 
Antigenic variants of MVE-1-51 were selected by Dr R. C. Weir or Dr J. T. 
Roehrig. Different methods of selection were used by each investigator. 
Method 1 (R. C. Weir, personal communication) 
Individual MVE-1-51 plaques were taken up in 5 µl HBSS (pH 8), amplified in 
Vero cells and plaque purified again. Virus (102-106 PFU) was incubated with 
neutralizing mAb, diluted 10-fold in HESS (pH 8), at 37° for 1 hour, and used to infect 
Vero cell monolayers for plaque formation. Individual plaques were picked and 
amplified in Vero cells. A second round of selection \vas performed. Resistant plaques 
were ·amplified and used to infect Vero cell monolayers to produce virus stocks. 
This precedure has been used previously to generate four E-lc variants (Vla, V3a, 
V4e and V5b), using as starting material a single stock of MVE-1-51 (S. H. Hartley and 
R. C. Weir, personal communication): V3a and V5b (used for virulence assay; see 
below) each contained an identical nucleotide substitution which gives a nonconservative 
change Ala 126--tGlu; Vla and V4e contained the above substitution as well as 
additional changes at residues 125 and 355 respectively. 
Method 2 (J. T. Roehrig, personal communication) 
MVE-1-51 virus (104 PFU, grown in S\V13 cells) was incubated with mAb (anti-
E-ld, E-5b or E-7; 10-fold diluted in 5 ml E:rvfEM) at 37° for 1 hour, and used to infect 
Vero cells in 25 cm2 flasks. Culture medium was harvested at 6 days p.i.; aliquots 
(0.5 ml) were mixed with mAb (10-fold diluted, 5 ml) and used to infect Vero cells as 
before. Cytopathic effects in Vero cells were observed at 9-10 days p.i., at which 
time culture media were harvested. Aliquots of 0.5 ml were taken and passaged 
twice in Vero cell monolayers in 6-well plastic trays without antibody. The virus 
stocks were harvested at 6 days p.i. and were used for plaque purification 
in the presence of mAb (10-fold diluted) to produce variants. These were tested for 
resistance to neutralization as follows: virus stocks (50 µl; diluted 10-1 in 
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EMEM) were incubated with selecting mAb (50 µl; diluted 1 o-2 in EMEM) at 37° for 2 
hour and subjected to end-point dilution plaque assays on Vero cell monolayers. Anti-
E-ld, E-Sb and E-7 mAbs neutralized more than 99 o/o of MVE-1-51; variants which 
were most resistant to anti-E-ld (60-100% resistant), anti-E-5b (2 1-60% resistant) and 
to anti-E-7 mAbs (57-94% resistant) were used for sequence analysis. 
4.2.5 RNA extraction from MVE-infected Vero cells (Shine 
and Dalgarno, 1973) 
RNA for sequence analysis was extracted from infected Vero cells (MOI:::::0.1) in 
glass Petri dishes (diameter=15 cm) at 48 hours p.i. Vero cell monolayers were lysed 
in 4 ml each of ice-cold 6% sodium para-aminosalicylate (BDH Chemicals Ltd., Poole, 
England) and a mixture of redistilled phenol: m-cresol (BDH): 8-hydroxyquinoline 
(BDH) (80%: 10%: 0.1 %; w/v/w), and extracted by vortexing thoroughly. 
Centrifugation was at 8000 rpm (Sorval SS34 rotor) for 10 min at 4 °; the aqueous phase 
was extracted again with 0.8 ml of 15 % NaCl and 2 ml of ice-cold phenol/cresol. 
Nucleic acids were precipitated with ethanol (2.5 volumes). Nucleic acid pellets were 
resuspended in NET buffer (0.12 M Na Cl, 1 mM N a2EDT A, ._0.012 M Tris-HCl, 
pH 7.4) and mixed with an equal volume of 4 M LiCl. High mol. wt. RNA was 
pelleted after freeze-thawing and centrifugation for 10 min in an Eppendorf centrifuge. 
The RNA pellet was resuspended in NET buffer and precipitated with 4 M Li Cl again. 
The resulting RNA was resuspended and precipitated twice with ethanol before 
dissolving in 5 mM Tris-HCl (pH 7 .5); storage was at -70°. Nucleic acid content was 
quantitated by spectrophotometry; the yield per Petri dish was :::::0.2 mg of RNA. 
4.2.6 Sequence analysis of M and E genes in MVE RNA 
Dideoxy sequencing (Sanger et al., 1977) was with RNA from MVE-infected Vero cells 
as template and HPLC-purified oligonucleotide primers (Bresatec, South Australia or 
Protein/DNA Facility, Australian National University) complementary to sequences in 
the MVE E and NS 1 protein genes (Dalgarno et al., 1986). Eight primers were used: 
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GTGT ATGAAT A TTCC (2528-2542), AAGAGCTGCCAA TCT (2222-2236), 
ATTGATCTGCTTGTC (2141-2155), CATGGTCCATCACTC (198 0-1994), 
AACTCGACTGGTATG (1780-1794), TCACGATGCACTAGA (1600-1614), 
ACTTCATATTTGATG (_1375-1389) and TCCCAGACAGTTAAA (974-988 ). 
Numbers indicate nucleotide positions in the genome of MVE-1-51 (Dalgarno et al., 
1986). Primer and template were annealed by incubating 2-5 µg of infected-cell RNA 
with 75 pmole of primer for 5 min at 56°. The mixture was quick-chilled and KCl was 
added to 80 mM. The final reaction mixture contained 50 mM Tris-HCl (pH 8.3); 
8 mM MgCl2; 50 mM KCl; 0.4 mM dithiothreitol; 50 µM dATP, dTTP and dGTP; 
2.5 µM dCTP; 5 µCi a-32P-dCTP; 0.2 µM ddCTP, 2.5 µM ddTTP, 5 µM ddATP 
or 2 µM ddGTP; 1.5 µl primer/template mixture; and 6 units of avian myeloblastosis 
virus (AMV) reverse transcriptase (Molecular Genetic Resources, Tempa, Florida, 
USA) in a final volume of 5 µl. Incubation was at 42.5° for 1 hour followed by 
addition of each dNTP to 5 µM and incubating a further 30 min at 42.5° to 'chase' 
polymerization of 32P-labelled chains to completion. 20 µl of loading buffer containing 
96% formamide (deionized), 25 mM Tris-borate (pH 8.3) and 0.5 mM Na2EDTA '.\'as 
added to terminate the reaction. The mixture was incubated in a 90° waterbath for 2 min 
immediately prior to electrophoresis on 40 cm-long, 0.4 mm-thick, 6% polyacrylamide 
gels (acrylamide: bisacrylamide, 19:1). Gels were transferred to Whatman 3 MM paper, 
dried under vacuum at 80° and exposed to Fuji RX Medical X-ray film for 
autoradiography. MVE-1-51 RNA was sequenced in parallel as a control; ambiguous 
nucleotides were resolved in most cases by repeating sequencing reactions using 
alternate primers, different concentrations of dNTPs and primers, or higher annealing 
temperatures. 
4.2. 7 Virulence assays in mice (Monath et al., 1980) 
The basis of the virulence assay is to compare mortality ratios in 21-day old mice 
following ic and ip inoculation of ten-fold serial dilutions of virus. In this assay, 
virulent virus (e.g. MVE-1-51) gives similar mortality ratios after ip as after ic 
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inoculation (Lobigs et al., 1988). However attenuated virus, despite being lethal after ic 
inoculatiion, shows a reduction in lethality after ip inoculation, implying a lack of 
neuroinvasiveness using a peripheral route of inoculation. The age of mice is crucial 
because mortality declines with age. The assay was performed on outbred Swiss mice 
(20-22 day old) randomized in groups of five. Virus to be tested was either undiluted or 
diluted 10-fold serially from 10-1 to 10-8 in PBS containing FCS (5%) and an inoculum 
of 30 µl used. Eighteen groups of mice were inoculated in total for each virus. Mice 
were examined daily for 14 days and deaths were recorded. LD50 values from ic and ip 
inoculations were calculated using the method of Reed and Muench (1934). 
4.3 RESULTS 
4.3.1 Sequence analysis of MVE variants selected by anti-E-lc 
MVE-1-51 (prototype) virus stocks, derived from individually plaque purified 
clones, were incubated with anti-E-lc mAb (Table 3.1). Virus which escaped 
neutralization was isolated by plaque formation. Virus stocks grown from such plaques 
were incubated again with anti-E-lc mAb followed by plaque purification to produce 
variants. Variants Plcl, P4al and P5al were from separate plaque purified MVE-1-51 
stocks (Pl, P4, P5) and had thus arisen from independent mutations. The above steps 
were performed by Dr R. C. Weir. This procedure was also used with the anti-E-ld, 
E-5b, E-7 and E-8 mAbs but no antigenic variants were isolated (S. H. Hartley and R. 
C. Weir, personal communication). 
To determine the resistance of variants Plcl, P4al and P5al to the selecting mAb, 
PRNT was performed. For MVE-1-51, 50% neutralization occurred at a 1/1000 
dilution of anti-E-lc whereas less than 2% of Plcl, P4al and P5al was neutralized at 
the same dilution. Less than 30% of Plcl, P4al and P5al was neutralized at a 1/80 
dilution of anti-E-lc. Thus there was more than a 10-fold difference between the 50% 
neutralization titres for MVE-1-51 and the E-lc variants. 
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For sequence analysis, Plcl, P4al and P5al were used to infect Vero cell 
monolayers. High mol. wt. RNA from infected cells was extracted for sequencing 
(Sanger et al., 1977). Primers complementary to sequences in the NS 1 and E genes and 
located 200-400 nucleotides apart were used. The nucleotide sequence of the entire M 
and E genes of the variants was obtained. RNA from MVE-1-51 infected cells was 
sequenced in parallel. 'Cross-bands' were encountered at particular nucleotides in the M 
and E genes. Sequencing with alternate primers and different concentrations of dNTPs 
or ddNTPs resolved some ambiguities. Approximately 5% of the sequence was cross-
banded (Fig. 4.1) and could not be resolved. Since the cross-bands were at identical 
positions for the MVE variants and for MVE-1-51, it is likely that the variants were not 
different from the wild-type at these positions. 
The sequence of MVE-1-51 E and M genes agreed with that reported by Dalgamo 
et al. (1986) except for a silent difference at position 2032 (G~A). E-lc variants Plcl, 
P4al and PSal each contained a different single nucleotide change in the E gene and no 
change in the M gene. These substitutions led to the following nonconservative amino 
' 
acid substitutions: Phe 274~Val (1793, U~G) in Plcl, Ser 276~Arg (1801, C7 A) 
in P4al and Ser277~Ile (1803, G~U) in P5al (Table 4.1). The amino acids 
Phe 27 4, Ser 27 6 and Ser 277 in the E protein of MVE are therefore probably 
involved in determining resistance to anti-E-lc mAb. 
4.3.2 Sequence analysis of E-ld, E-Sb and E-7 variants 
E-ld, E-5b and E-7 variants were provided by Dr J. T. Roehrig. The method used 
by him to generate variants involved incubating MVE-1-51 with the appropriate 
neutralizing mAbs and amplifying in Vero cells. Aliquots of the culture medium, 
harvested after 6 days, was incubated with m.Ab again and further amplified for 9-10 
days. There were two additional passages in Vero cells without antibodies. Then the 
virus stocks were plaqued on Vero cells with the selecting mAb and the plaques 
amplified in Vero cells. Candidate variants were tested (by J. T. R.) for resistance to the 
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Figure 4.1 Nucleotide sequences of the Mand E genes ofMVE-1-51 and variant E-lc/Plcl. Sequences 
of the antigenic variants of MVE are compared with the prototype strain !vIVE-1-51 (top line; Dalgarno 
et al., 1986). Those nucleotides that differ from the prototype sequence are indicated. Nucleotides which 
could not be unambiguously determined are designated N. Numbering is from the 5' nucleotide of the 
MVE-1-51 genome (Dalgarno et al., 1986). 
~ M 
749 UCCAUCACAGUGCAGACUCAUGGUGA.AAGCACUUUGGUCAACAAAAAGGAUGCCUGGCUGGAUUCCACGAAGGCCACGCGUUAUCUCACCAAAA CAGAGA 
MVE 
Plcl 
849 ACUGGAUUAUAAGAAAUCCUGGUUACGCGCUGGUGGCCGUUGUCCUUGGCUGGAUGCUGGGCAGCAACACUGGACAAAAAGUUAUUUUUACAGUGC UU UU 
MVE N N 
Plcl N N 
~E 
949 GCUCCUCGUUGCUCCUGCCUACAGU UUU AACUGUCUGGGAAUGAGCAGCCGUGAUUUCAUUGAAGGUGCUUCAGGAGCUACAUGGGUCGAUUUGGUGCUG 
MVE N 
Plcl N 
1049 GAGGGCGACAGUUGCAUCAC CAUCAUGGCCGCUGACAAACCCACCCUUGACAUAAGAAUGAUGAACAUUGAAGCCACCAAUCUUGCACUGGUUAGAAAUU 
MVE N 
Plcl N 
1149 ACUGCUAUGCAGCUACUGUGUCAGACGUUUCUACGGUGUCAAACUGUCCUACUACAGGGGAGUCACACAACACGAAGCGGGCAGAUCACAAUUACUUGUG 
MVE 
Plcl 
N 
N 
1249 CAAACGAGGUGUGACCGACAGAGGCUGGGGUAAUGGAUGUGGCUUGUUUGGUAAGGGGAGCAUUGACACAUGCGCAAAGUUCACCUGCUCUAAC UCAGCU 
MVE 
Plcl 
13 49 GCGGGGAGACUUAUCUUACCUGAGGACAUCAAAUAUGAAGUUGGGGUUUUUGUUCACGGAUCAACGGACUCAACCAGUCAUGGAAAUUAUUCUACCCAAA 
MVE 
Plcl 
1449 UUGGAGCUAACCAAGCAGUCAGGUUCACCAUUUCACCAAACGCUCCAGCCAUCACAGCAAAGAUGGGCGACUAUGGAGAAGUCACUGUGGAGUGU GAACC 
MVE N N 
Plcl N N 
1549 GAGGAGUGGACUGAAUACAGAGGCCUACUACGUCAUGACCAUUGGAACGAAACACUUUCUAGUGCAUCGUGAGUGGUUCAAUGAUUUGCUCUUGCCAUGG 
MVE N N 
Plcl N N 
1649 ACAUCACCUGCAAG CACGGAAUGGAGGAAUAGAGAAAUUCUCGUGGAGUUUGAAGAGCCACAUGCCACCAAACAAUCAGUGGUUGCCUUGGGUUCACAGG 
MVE NN N 
Plcl N N N 
1 74 9 AAGGAGCUUUGCACCAAGCUCUGGCUGGAGCCAUACCAGUCGAGUUUUCGAGCAGCACACUUAAACUCACUUCAGGACACCUUAAGUGUCGCGUGAAAAU 
MVE N 
Plcl G N 
1849 GGAGAAAUUGAAACUGAAAGGAACCACUUAUGGGAUGUGCACAGAAAAAUUUACUUUCUCAAAGAAUCCAGCCGACACCGGUCAUGGCACGGUAGUUCUA 
MVE 
Plcl 
1949 GAACUGCAGUACACCGGGAGUGAUGGACCAUGCAAAAUUCCAAUAUCCUCUGUAGCAAGUCUCAAUGACAUGACGCCUGUCGGGAGAAUGGUGACAGCUA 
MVE A N 
Plcl A N 
2049 AUCCAUAUGUAGCUUCAUCAAC UG CCAAUGCUAAAGUUCUGGUGGAGAUUGAACCACCCUUCGGAGACUCAUACAU UGUGGUAGGCAGGGGAGACAAGCA 
MVE 
Plcl 
N 
N 
2149 GAUCAAUCACCACUGGCAUAAGGAGGGUAGUUCAAUUGGCAAAGCCUUCAGCACAACCUUGAAGGGAGCACAGAGAUUGGCAGCUCUUGGAGACACGGCG 
MVE 
Plcl 
N 
N 
2249 UGGGACUUUGGAUC AGUAGG CGGAGUCUUCAAUUCAAUCGGAAAGGCAGUACACCAAG UCUUUGGAGGAGCAUUUAGAACCCUCUUUGGAGGAAUGU CAU 
MVE 
Plcl 
2349 GGAUCAGCCCAGGUCUGCUGGGGGCGUUACUGCUAUGGAUGGGGGUCAAUGCUAGAGAUAAAUCAAUUGCUUUGGC UUUCCUAGCAACAGGAGGCGUUUU 
MVE N N N 
Plcl N 
2449 GUUGUUCCUGGCCACAAAUGUCCAUGCU 
MVE 
Plcl 
N N 
a E-lc variants were selected by Dr R. C. Weir, E-ld, E-5b and E-7 variants were selected by Dr J. T. 
Roehrig (Materials and Methods). 
b Variants were sequenced through the entire E and M genes and substitutions were determined by 
comparison with the MVE-1-51 sequence. Numbering is from the 5' nucleotide of the MVE-1-51 
genome (Dalgarno et al., 1986). 
c Substitutions which occur in variants selected by different mAbs are bracketed. Numbering is from 
the N-terminal amino acid of the MVE E protein (Dalgarno et al., 1986). 
d Conservative amino acid substitution; the following changes are designated as conservative: Arg = 
Lys, Ser= Thr, Asp= Glu, Gln = Asn, Val= Leu= Ile= Met, Ala= Gly, Ala= Val, Tyr = Phe. 
TABLE 4.1 
Sequence analysis of MVE antigenic variants 
Epitope Varianta Nucleotide Amino acid 
substitutionsb substitutionsc 
E-lc Plcl 1793 (UUU--"7GUU) Phe 27 4--"7 Val 
P4al 1801 (AGC--"7AGA) Ser 276--"7Arg 
P5al 1803 (AGC--"7AUC) Ser 277--"7Ile 
E-ld VARl 1373 (GAC--"7AAC) [ Asp 134--"7 Asn] 
1760 (CAC--"7UAC) His 263--"7Tyr 
1903 (ACU--"7ACG) 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VAR3 1373 (GAC--"7AAC) [ Asp 134--"7 Asn] 
1760 (CAC--"7UAC) His 263--"7Tyr 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VARS 1373 (GAC--"7AAC) [Asp 134--"7Asn] 
1760 (CAC--"7UAC) His 263--"7 Tyr 
1903 (ACU--"7ACG) 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
E-5b VARl 1373 (GAC--"7AAC) [ Asp 134--"7 Asn] 
1562 (AAU-fuAU) Asn 197 --"7 Asp 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VAR3 1373 (GAC--"7AAC) [Asp 134--"7Asn] 
1562 (AAU-fuAU) Asn 197--"7Asp 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VARS 1124 (ACC--"7GCC) Tor 51--"7Ala 
1373 (GAC--"7AAC) [Asp 134--"7Asn] 
2045 (GCU--"7ACU) [Ala 358~Thr] 
E-7 VARI 1373 (GAC--"7AAC) [Asp 134--"7Asn] 
1907 (ACU--"7UCU) Thr 310--"7Serd 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VAR2 1373 (GAC--"7AAC) [Asp 134--"7Asn] 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
VAR4 1373 (GAC--"7AAC) [ Asp 134--"7 Asn J 
2045 (GCU--"7ACU) [Ala 358--"7Thr] 
selecting mAbs. E-ld, E-Sb and E-7 variants were selected. No E-lc or E-8 variants 
were obtained using this method (J. T. R., personal communication). The three varian.ts 
out of each group which showed most resistance to the selecting mAbs were chosen for 
sequence analysis (see below). 
Sequence analysis of E-ld variants 
The three E-ld variants chosen for sequence analysis (VARI, VAR3, VARS) were 
85, 100 and 60% resistant to anti-E-ld. Sequence analysis was as described above. 
The seed stock of MVE-1-51, used by J. T. R. to generate the antigenic variants, was 
sequenced in parallel. This stock had the same silent difference from the published 
sequence at position 2032 (G-,A) (Dalgarno et al., 1986). The E-ld variants each 
contained three or four nucleotide substitutions, leading to three nonconservative amino 
acid substitutions (Table 4.1). The same substitions, Asp 134--,Asn, His 263--,Tyr 
and Ala 358--,Thr, were found in all three variants and were derived from identical 
nucleotide changes at 1373 (G-,A), 1760 (C-,U) and 2045 (G-,A). V ARl and V AR5 
contained, in addition, a silent nucleotide substitution at position 1903 (U-,G). 
Sequence analysis of E-Sb variants 
E-5b variants used for sequence analysis (V ARl, V AR3, VARS) were 51 %, 21 % 
and 60% resistant to anti-E-5b. VARl, VAR3 and V AR5 each contained three changes 
leading to nonconservative amino acid substitutions (Table 4.1). The substitutions 
Asp 134--,Asn and Ala 358--,Thr were common to all three variants and derived from 
identical nucleotide changes at 1373 (G-,A) and 2045 (G-,A). V ARl and VAR3 also 
contained an additional change Asn 197--,Asp (A-,G) while V P. ... R5 contained the 
substitution Thr 51--,Ala (A-,G). 
Sequence analysis of E-7 variants 
E-7 variants used for sequence analysis (VARl, VAR2, V AR4) were 62, 57 and 
94% resistant to anti-E-7. VARl, VAR2 and VAR4 each contained two or three 
nucleotide changes (Table 4.1 ). The nonconservative substitutions Asp 134--,Asn and 
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Ala 358~ Thr were found in all three variants and were derived from identical 
nucleotide changes at 1373 (G~A) and 2045 (G~ A). V AR l also contained the 
conservative substitution Thr 310~Ser (A~ U). VAR2 and VAR4 had no change at 
residue 310 or at any additional residues , suggesting Thr 310 was probably not a 
determinant of resistance to anti-E-7 mAb. 
Neutralization tests using anti-E-ld, E-5b and E-7 mAbs 
Each of the E-1 d, E-5b and E-7 variants contained two identical changes in E 
(Asp 134~Asn and Ala 358~Thr) as a result of the same nucleotide changes at 1373 
(G~A) and 2045 (G~A). Neither of these changes occurred in the E-lc variants 
which were selected using a different procedure (see Discussion). The question of 
whether the changes at Asp 134 and Ala 358 were responsible for the resistance of 
E-ld and E-5 vari~11ts may have been resolved by performing PRNT on E-7 VAR2 or 
VAR4, which contained only changes at Asp 134 and Ala 358, using anti-E-ld and 
E-5b mAbs. There is also a natural isolate of MVE (TC 123130) which is identical to 
MVE-1-51 in E sequence except for a single Asp 134~Asn change (Lobigs et al., 
1988). This strain could have been used in examining the importance of Asp 134 to 
epitopes E-ld, E-5b and E-7. However efforts to study this in cross-neutralization tests 
with mAbs specific for epitopes E- ld, E-5b and E-7 were unsuccessful due to the low 
titres of some of the mAbs sent from the USA (see Materials and Methods). As a result 
of the loss in neutralization activity of mAbs in transit, the importance of Asp 134 and 
Ala 358 to epitopes E-ld, E-5b and E-7 could not be determined. 
4.3.3 Virulence assays in mice (Monath et al., 1980) 
The virulence ofE-lc variants Plcl, P4al, P5al and V5b (the latter provided by 
R. C. W.; see Materials and Methods), and of E- ld/V AR3, E-5bN AR5 and E-7 N AR4 
was examined (see Table 4.2). Virus stocks were diluted in serial 10-fold steps (from 
1 o- 1 to 1 Q-8), and aliquots of 30 µl inoculated into five mice by ic or ip routes. 
MVE-1-51 was assayed as the control. Deaths were recorded over 14 days for each 
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TABLE 4.2 
Virulence of MVE variants in 1nice 
Virus Amino acid Titreb ic LD50C ip LD50C ic/ip LD50 
difference in Ea ratio 
MVE-1-51 lx106 10-7.2 10-6.5 0.2 
E-lc/Plcl Phe 274-,Val 7xlo5 10-6.l 10-5.9 0.6 
E-lc/P4al Ser 276-,Arg lx106 10-6.7 10-4.9 0.02 
E-lc/P5al Ser 277-, Ile 7x105 10-6.2 10-3.0 0.0006 
E-lcN5b Ala 126-,Thr 5x106 10-8.2 10-7.9 0.5 
E-ldNAR3 Asp 134-,Asn 3xl06 10-7.3 10-6.3 0.1 
His 263-, Tyr 
Ala 358-,Thr 
E-5bNAR5 Thr 51-,Ala 3x106 10-8.3 1 o-7.4 0.1 
Asp 134-,Asn 
Ala 358-,Thr 
E-7/VAR4 Asp 134-,Asn lx106 10-8.0 10-7.8 0.6 
Ala 358-,Thr 
a From wild-type sequence; see Table 4.1. 
b Titre of each virus was determined by plaque assay on Vero cell monolayers. 
c LD50 values for ip or ic inoculation were calculated for each virus by the method of Reed and Muench (1934). 
d Virulence of each virus was assessed on the basis of ic/ipLD50 ratios (Monath et al., 1980). 
Virulenced 
virulent 
virulent 
intermediate? 
intermediate 
virulent 
virulent 
virulent 
virulent 
group of mice (Fig. 4.2). Virulence was assessed by comparison of ic and ip LDSO 
values for each virus (Monath et al., 1980; Table 4.2). 
MVE-1-51 and variants E-lc/Plcl, E-lcN5b, E-ldNAR3, E-SbNAR5 and 
E-7 N AR4 differed no more than 10-fold in ic and ip LDSO values and were therefore 
considered virulent. By contrast, E-lc variants P5al and P4al showed ic/ip LD50 
ratios of 0.0006 and 0.02 respectively indicating attenuation. P5al, changed from 
Ser 277 to Ile, is of 'intermediate' virulence according to the criteria of :tv1onath et al. 
(1980). P4al, changed at an adjacent position (Ser 276~Arg), was also associated 
with some attenuation: the ic/ip LD50 ratio was approximately 10-fold greater than 
MVE-1-51. This attenuation is also evident from Fig. 4.2 which shows a 'prozone' 
effect on ip inoculation at low dilutions of virus (100, 10-1, 10-2; 3 survivors out of 14 
mice). Monath et al. (1980) have also noted that SLE isolates of intermediate virulence 
show a 'prozone' effect. 
4.3.4 Summary 
Changes in E gene sequence of neutralization escape variants of MVE-1-51 were 
used to map neutralization epitopes on the MVE E protein. Variants selected with the 
anti-E-lc mAb had single nonconservative amino acid changes at Phe 274, Ser 276 and 
Ser 277. Variants resistant to anti-E-ld, E-5b and E-7 mAbs were selected using a 
different method from those resistant to anti-E-lc. These contained several changes in E 
including the common changes Asp 134~Asn and Ala 358~Thr as well as 
His 263~Tyr for E-ld variants and Tor 51~Ala or Asn 197~Asp for E-5b variants. 
One E-7 variant contained a Thr 31 O~Ser change; the other E-7 variants did not. 
Seven variants were tested for virulence in 21-day old mice. The ic/ipLD50 ratios 
indicated that two of the seven showed reduced virulence. The ic/ipLD50 ratios for 
E-lc/P4al and E-lc/P5al were approximately 10 and 1000-fold less than that for 
MVE-1-51. These variants had single nonconservative changes in Eat residues 276 and 
277 respectively. 
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Figure 4.2 Virulence of MVE-1-51 and antigenic variants in mice. !vIVE-1-51 and antigenic variants 
were tested for virulence in three week-old mice (Monath et al., 1980). Virus (30 µl) diluted from 100 
to 10-8 was used to inoculate mice in groups of five by the ip or ic route. Deaths were recorded over 14 
days. Mortality ratio (%) at each dilution of virus is plotted. Inoculation by the ic and ip routes is 
indicated by dots and open circles respectively. Only four mice were inoculated ip with undiluted 
E-lc/P4al; hence the mortality of 75%. One mouse in the group of five inoculated ic with E-7N AR4 
at 10-6 dilution died within two days and was disregarded; hence the mortality of 50%. 
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4.4 DISCUSSION 
Neutralization epitopes in the MVE E protein 
In the first section of this chapter we have described the sequencing of NlVE 
neutralization escape variants selected by two different methods. In the first selection 
procedure, virus was incubated directly with mAbs and resistant plaques isolated for 
amplification in Vero cells. In the second procedure, virus was passaged extensively in 
Vero cells in the presence of mAbs and variants isolated. The data obtained using the 
first procedure will be discussed first. 
Three virus isolates resistant to neutralization with anti-E-lc rnAb were selected. 
They were all altered at a different single nucleotide in the E gene and hence arose 
independently of each other. Each mutation generated a single nonconservative amino 
acid change in the same region of E (residues 274,276 and 277). These data, together 
with the previous isolation of an E-lc neutralization escape variant altered at residue 126 
(S. H. H. and R. C. W., personal communication) strongly suggest that the E-lc 
epitope is formed by the association of these two regions of E and thus is a 
'discontinuous' epitope~ Th~ observation that anti-E-lc mAb did not react with fusion 
proteins carrying E peptides Asp 22-Val 272 or Ser 146-Gly 429 (Chapter 3) can thus 
be explained, as neither fusion protein contained both regions of E. The fact that the 
mapped residues of E-lc are close to disulfide bonds at Cys 190-288 and Cys 60-121 
may be reflected in the loss of reactivity of anti-E-lc mAb with reduced E protein. The 
reason for the selection of E-lc mutants with amino acid changes at different locations in 
E is not known, since the same basic procedure was used in each case. Variants 
characterized in this study were derived from independent clones of MVE-1-51 whereas 
the previous study used a single MVE-1-51 stock as starting material (S. H. H. and R. 
C. W., personal communication). 
Anti-E-lc mAb was raised against MVE-1-51; it is type-specific showing no cross-
reactivity with other members of the JE serogroup (Table 3.1). Thus anti-E-lc would 
* However, we cannot discount the possibility that changes in one region of the E protein can 
influence the folding and hence the mAb binding in a quite distinct region. 
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be expected to recognize an epitope which differed in sequence between MVE and the 
closely related virus JE. The regions of E between residues 270 and 280, and around 
residue 126 show strong variations between flaviviruses in general and bet\veen 
members of the JE serogroup (Fig. 4.3). Both regions differ markedly between MVE 
and JE which are 82 % identical overall in the amino acid sequence of E. The sequences 
of the E- lc epitope therefore show the expected divergence between MVE and other 
flaviviruses. It is of interest that two other closely related members of the JE serogroup, 
WN and KUN, are identical in sequence in the regions defined by anti-E-lc. 
Fig. 4.4 is a hydropathy profile of the MVE E protein. In the primary amino acid 
sequence, residues 274, 276 and 277 are adjacent to a strongly hydrophilic region. A 
similar hydropathy profile is seen for YF in the same region (Dalgarno et al., 1986). 
The amino acids in this hydrophilic stretch are strongly conserved as to sequence 
between members of the JE serogroup (Fig. 4.3) suggesting an important function. 
Residue 126 is within a variable region, as noted above. It is adjacent to the possible 
fusion sequence (Chapter 1; see below). Considered together, the data suggest that the 
epitope defined by anti-E-lc may be important not only as a binding site for neutralizing 
antibody but also in virus entry. Data showing alterations in viral virulence for E-lc 
variants support this view (see below). 
Sequence analysis of E-ld, E-Sb and E-7 variants revealed more than one amino 
acid substitution in each. Two common changes, both nonconservative, occurred in all 
variants; these were Asp 134-,Asn and Ala 358-,Thr. The explanation for these 
unexpected results may lie in the method used for selection of these variants which 
involved a series of passages of virus in Vero cells before plaque purification. It seems 
possible that the changes observed at residues 134 and 358 were 'cell-selected' during 
this process rather than mAb-selected. Lobigs et al. (1990) and A. Nestorowicz 
(unpublished results) have previously noted that specific changes in the MVE E protein 
are selected during passaging of MVE in cell culture. Considering the change at residue 
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Figure 4.3 Co-listing of E protein sequences of ten flaviviruses (adapted from Fig. 1.3). References 
for the E protein sequences of flaviviruses are cited in Fig. 1.3. The Asn-X-Thr/Ser tripeptides are 
underlined and the C-terminal hydrophobic regions are overlined. Strictly conserved cysteines are 
indicated by asterisks. Amino acid substitutions which occurred in the neutralization escape variants of 
MVE are shown together with the epitopes defined by the corresponding selecting mAbs. 
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Figure 4.4 Hydropathy profile of the MVE E protein (adapted from Dalgarno et al., 1986). The method of Kyte and Doolitle (1982) was 
used to dctennine hydropathy profile of the MVE E protein. Positions where amino acid substitutions occurred in the neutralization escape 
variants of MYE arc indicated. 
134, it is noteworthy that Asn 134 is encoded in the E gene of all eleven MVE isolates 
which have been examined except MVE-1-51 (Lobigs et al., 1988) as well as in all other 
members of the JE serogroup. The change from Asp to Asn at this position may 
therefore be to the wild-type sequence rather than away from it. The MVE-1-51 stock 
used in all of these studies had been subjected to an extensive, though incompletely 
characterized, number of passages in suckling mouse brain which may have selected for 
the unusual Asp at residue 134. Given that the changes at residue 134 in the antigenic 
variants arose from identical nucleotide sequence changes (as did those at residue 358), 
it appears that these mutants may have been present in the parental MVE-1-51 stock 
before antibody selection. Attempts to test our hypothesis by repeating the 
passaging/selection procedure in the absence of mAbs (in our laboratory) have so far 
been inconclusive due to the lack of information on the original experimental conditions. 
Irrespective of the origin of t:4e changes in residues 134 and 358, it is possible that 
they were partly responsible for the resistance to mAbs and/or that these changes 
affected the E-1, E-5b and E-7 epitopes indirectly. However, in the absence of 
definitive data we will interpret our results in the simplest way; this interpretation would 
need to be tested in future experiments. We propose that the crucial change in the E-ld 
variants was the nonconservative change at residue 263 (His~Tyr), and in the E-5b 
variants the change at residue 51 (Thr~Ala) or 197 (Asn~Asp). In the case of the E-7 
variants, only one of the three variants had a change (conservative) at residue 310 and 
this mutant was not reported to be more resistant to anti-E-7 mAb than the other two 
variants (J. T. R., personal communication). This could be interpreted as follo'.vs: 
residue 310 is not part of the neutralization epitope and changes at 134 and 35 8 are 
responsible for generating the resistant phenotype. Following from this interpretation, it 
would be predicted that the E-ld and E-5b variants should be resistant to neutralization 
with anti-E-7 mAb as well as to anti-E-ld and E-5b mAbs respectively. Although 
identification of the determinants of these three epitopes has not been achieved, the 
variants focus attention on a limited number of residues that may affect neutralization. 
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The MVE E protein in relation to the TBE model 
From this study and the work described in Chapter 3, we have mapped 
determinants of the E-lc epitope to residues 126, 274, 276 and 277 in the MVE E 
protein and the E-8 epitope to between residues 201 and 224. Since the TBE E protein 
is the most completely mapped flavivirus E protein in terms of neutralization epitopes, it 
is appropriate to examine our data in relation to those of Mandl et al. (1989b). As 
previously noted, the TBE E protein may be subdivided into three domains based on 
data from CBAs, protein fragmentation studies and epitope mapping (Fig. 4.5). 
Domain A contains neutralization, protective and ill epitopes with flavivirus-group, 
complex and subtype specificities; it is sensitive to conformation changes (induced by 
SDS or reduction of disulfides) and is altered in conformation at pH 6 as judged by 
protease cleavage patterns and by the reactivity of domain A-specific mAbs with E 
(Guirakhoo et al., 1989). Domain B also contains neutralization, protective and HI 
epitopes with both complex and type specificities. It can be isolated as a protease-
resistant 'core' of approximately 9K, and loses antigenic reactivity after irreversible 
reduction; reactivities of mAbs against domain B are not affected· at pH 6. Domain C 
contains a neutralization epitope and HI epitopes with complex, type and subtype 
specificities. It is resistant to irreversible reduction and incubation at pH 6 but loses 
reactivity on tryptic digestion. 
The MVE E-lc and E-8 epitopes fall into domain A, which comprises 'left-hand' 
(residues 50-130) and 'right-hand' (the loop between disulfide bond at Cys 190-288) 
components (Fig. 4.5). E-8 is in the right-hand loop; residues defining E- lc are in both 
left and right components, giving support to the 'discontinuous' nature of domain A. 
Epitopes E-lc, E-ld, E-5b and E-8 have been characterized by CBAs as a continuum of 
overlapping epitopes; they are all sensitive to incubation at pH 6 (J. T. R., personal 
communication). Thus it is not surprising that E-lc, E-8 and the changes in E-ld and 
E-Sb variants all fall in domain A, with the exception of Thr 358 which is in domain B 
(Fig. 4.5). All these MVE epitopes, with the exception of E-8, map to positions in 
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Figure 4.5 The TBE E model showing positions of neutralization determinants for TBE, YF and MVE 
(adapted from Fig. 1.4). Solid circles indicate amino acids completely conserved in flaviviruses and 
open circles indicate nonconserved amino acids. The neutralization determinants of TBE are indicated by 
arrows and those of YF by open arrowheads. Amino acids in the TBE E protein corresponding to the 
neutralization determinant E-lc of MVE are indicated by solid arrowheads (see Fig. 4.4). Positions 
corresponding to substitutions in MVE neutralization escape variants selected by anti-E-ld, E-Sb and 
E-7 mAbs are indicated by dashed arrows. The epitope E-8 mapped in Chapter 3 is shown in bracket 
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domain A not previously identified as neutralization determinants . The E-7 epitope, 
which is separate from the other MVE epitopes by CBA, cannot be mapped with 
certainty; however if Ala 358 is a determinant, it is in a domain homologous to domain 
B. 
The MVE E- lc epitope is defined by mAb with high specific activities 1n 
neutralization, HI and passive protection assays (Hawkes et al., 1988). For TBE, this 
reactivity pattern seems to define mAbs against domain A epitopes; mAbs against these 
epitopes have the higher specific activities in neutralization or HI assays than mAbs 
against domains B and C (Guirakhoo et al., 1989). In particular, mAbs against TBE 
epitopes A3 and A4 show strong activities in both neutralization and HI assays; the 
former also protects mice (Heinz et al., 1983) and is therefore similar in properties to 
anti-E- lc mAb. An mAb against the SLE E- lc epitope also shows strong activities in 
neutralization, HI and protection assays but the location of this epitope has not been 
established (Roehrig, 1986). Neutralization determinants in YF (residues 71, 72) are 
also defined by mAbs with both neutralization and HI activities; however, passive 
protection studies with these mAbs have not been reported (see Lobigs et al., 1987). 
For JE, residues 303-396 of E contain ten epitopes which are all associated with 
neutralization; mAbs against six of these epitopes passively protect mice, but none of the 
ten mAbs show HI activities (Mason et al., 1989). 
Considered together our data suggest that the MVE epitope E- lc is in a domain of 
the E protein which corresponds functionally and in terms of primary amino acid 
sequence to domain A. Domain A includes a highly conserved sequence (residues 98-
111; Fig. 4.5) which is hydrophobic, glycine-rich and flanked by hydrophilic regions 
which are not conserved in sequence. This conserved region may be involved in an 
early, acid-induced fusion event during endocytosis. In support of this, epitopes in 
domain A of TBE undergo conformational changes at pH 6 (see above). Epitope E-lc 
of SLE and MVE are also sensitive to incubation at pH 6 as judged by reactivity with 
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the corresponding mAbs (J. T. R., personal communication). It is therefore possible 
that neutralization of flaviviruses by some mAbs specific for domain A occurs by 
inhibition of the acid-induced fusion. Such a mechanism has been proposed for WN 
(Gollins and Porterfield, 1986), herpes simplex virus (Fuller and Spear, 1987; Fuller et 
al., 1989) and rabies virus (Dietzschold et al., 1987). 
Virulence of MVE antigenic variants 
We have examined seven antigenic variants of MVE for evidence of attenuation 
following ip inoculation of 21-day old mice. In these variants there were various 
combinations of changes in E from the prototype sequence at residues 51, 126, 134, 
263, 274, 276, 277 and 358. No variants were completely 'attenuated' according to the 
criteria of Monath et al. (1980). However variant P5al was of intermediate virulence 
(Table 4.2); variant P4al had an ic/ip LD50 ratio 10-fold lower than MVE-1-51 
indicating a significant though small reduction in virulence. Thus two variants altered in 
the E- lc epitope (at residues 277 and 276 respectively) appeared to be attenuated. Other 
E-lc variants altered at residues 274 (Phe~Val) and 126 (Ala~Glu) did not appear to 
be attenuated. Thus attenuation did not correlate completely with resistance to an mAb 
directed against the E- lc epitope. The different effects on virulence of various changes 
in the E-lc epitope could have several interpretations. The first is that any change at 
residue 277 is more influential than any change at residue 27 6 (i.e. that amino acid 
position is of prime importance); the second is that the nature of the amino acid 
substitution is critical; the third possible explanation is that all changes at the E-lc 
epitope did lead to partial attenuation but that reversion to a virulent form occurred in the 
variants for which no attenuation was seen. These possibilities should be amenable to 
study with an infectious MVE cDNA clone, when available. 
In earlier studies (Lobigs et al., 1988), all seven isolates of MVE which were 
assessed for virulence following ip inoculation had a virulent phenotype; however, two 
showed a 'prozone' effect (see below). The seven isolates included MVE-1-51, four 
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others from Australia and two from Papua New Guinea. At the genetic level, the seven 
isolates differed in E protein sequence by up to eleven residues in pairwise comparisons 
(Lobigs et al., 1988). The positions of difference from the prototype sequence were at 
residues 64, 123, 134, 141, 165, 166, 187, 229, 238, 240, 270, 275, 310 and 442. 
Since a 'prozone' effect could be regarded as evidence of attenuation, it is of interest to 
note the changes for isolates in which a 'prozone' effect was seen. The changes in 
MRM15019 were at residues 134 (Asp--,Asn), 238 (Ile--,Val) and 275 (Ser--,Pro); the 
changes in MK6684 were at residues 123 (Asn--, Ser), 134 (Asp-, Asn), 141 
(Val--,Ile), 165 (Val--,Ala), 229 (Ala--,Ser), 240 (Val--,Met) and 275 (Ser--,Ala). It is 
of interest that nonconservative changes at residue 275 were observed in both variants. 
Comparative sequence data exist for the E protein of the SA-14-14-2 vaccine strain 
of JE and the SA-14 parent strain (Nitayaphan et al., 1990). There are five differences 
in E between these strains. These are at residues 107, 138, 17 6, 243 and 279. The 
change at residue 279 (Lys--,Met) is nonconservative and close to residue 277 in MVE 
E protein (Lys 279 in JE corresponds to Lys 280 in MVE). This also supports the 
view that residues in the E- lc region are involved in an important function which may 
affect virulence. 
The above data indicate that the E- lc region of domain A of the MVE E protein 
may have functions which determine the pattern of replication of the virus in vivo and its 
virulence. Data for MVE and other flaviviruses also suggest that epitopes in domain B 
determine virulence in mice. Lobigs et al. (1990) and A. Nestorowicz (unpublished 
results) have demonstrated that MVE passaged in tissue culture and changed in E at 
Asp 390 is completely attenuated in 21-day old mice (see above). Although it has not 
been rigorously demonstrated that the change at residue 390 causes attenuation, data 
showing that a single-step neutralization escape variant of TBE altered in the same 
region (Tyr 384--, His) is also attenuated supports the view that this region of domain 
B is also critical for pathogenesis. Comparative sequence data for the vaccine and the 
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parental strains of YF also suggest an important role for this region of domain B 
( Chapter 1 ). 
In summary, we can define two regions of the MVE E protein which influence 
virulence in 21-day old mice. These are the residues around Ser 277 (in domain A) and 
Asp 390 (in domain B). It is not clear whether residues 277 and 390 are close in the 
tertiary structure of E; an answer to this point will be of importance in furthering our 
understanding of the molecular basis of virulence. 
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CHAPTER 5 
EXPRESSION OF MURRAY VALLEY 
ENCEPHALITIS VIRUS STRUCTURAL 
PROTEINS IN INSECT CELLS USING A 
BACULOVIRUS VECTOR 
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5.1 INTRODUCTION 
In Chapters 2 and 3, we investigated the expression of MVE cDNA in E.coli, with 
a view to generating MVE E protein fragments for analysis of functional determinants. 
Various fragments of E from 24 to 284 amino acids long were fused to B-galactosidase. 
The fusion proteins reacted with anti-MVE HIAF in Western blots indicating that they 
carried MVE epitopes. A neutralizing mAb defining the E-8 epitope also reacted with E 
fusion proteins to allow mapping of this epitope to residues 201-224 in domain A. 
However four other neutralizing mAbs did not react with the E fusion proteins. The 
fusion proteins elicited antibodies against MVE in mice but these antibodies did not 
neutralize the virus. We concluded that the fusion proteins generated in E.coli could be 
useful in mapping certain epitopes, but that they were probably not suitable for a 
comprehensive analysis of the structure and function of E. 
In this chapter, we explore the expression of MVE proteins in a baculovirus 
expression system. The baculovirus system was developed with the aim of generating 
large quantities of 'native' foreign protein (Summers and Smith, 1987) and has been 
shown to process eukaryotic proteins properly with respect to glycosylation, 
phosphorylation and proteolytic cleavage. Correct targeting of the foreign proteins to 
the cell surface, to nuclei or for secretion is observed in the Spodopterafrugiperda (Sf9) 
cell line used for such studies (Luckow and Summers, 1988a). Important features of 
the system include the strong polyhedrin promoter, the ease of propagating Sf9 cells and 
the efficient infection of Sf9 cells with baculoviruses (Summers and Smith, 1987). A 
range of plasmid 'transfer' vectors is available (Luckow and Summers, 1988b; 1989), 
among the most efficient is pVL941 which contains Autographa californica nuclear 
polyhedrosis virus (AcNPV) DNA sequences. These vactors allow homologous 
recombination with baculovirus DNA; the recombinant viruses can express open reading 
frames introduced into the transfer vector as non-fused proteins (Luckow and Summers, 
1989). 
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Previous studies on the expression of flavivirus structural proteins in a baculovirus 
sytem have been with JE and DEN-4 (Maatsura et al., 1989; Zhang et al., 1988). The 
structural proteins of Sindbis virus, an alphavirus, have also been expressed in a 
baculovirus sytem (Oker-Blom and Summers, 1989). The studies with JE demonstrate 
that prM and E can be generated in Sf9 cells by proteolytic processing. These proteins 
were identified by their reactivities with protein specific mAbs and elicited neutralizing 
antibodies in mice. The studies with DEN-4 showed that prM and E were generated and 
on immunization protect mice against ic challenge with lethal doses of DEN-4. 
In this chapter we introduce, via p VL941, genes for the MVE proteins C, prM and 
E into the AcNPV genome. We examine the production, proteolytic cleavage, 
glycosylation, yield and conformation of the expressed proteins. 
5.2 MATERIALS AND METHODS 
5.2.1 Cells and viruses 
Spodoptera frugiperda cells (clone Sf9) \Vere obtained from the American Type 
Culture Collection (ATCC; Rockville, Maryland, USA) and were propagated at 27° in 
TNM-FH medium plus 10% FCS (Summers and Smith, 1987). TNM-FH was Grace 
medium (Grace, 1962) supplemented with 6.6 g/litre lactalbumin hydrolysate (Difeo) 
and 6.6 g/litre yeastolate (Difeo). SW13, a human adenocarcinoma cell line, was 
grown at 37° in EMEM supplemented with 10% FCS. Aedes albopictus cells (C6/36; 
Igarashi, 1978) were grown at 28° in Eagle's basal medium (EBM) containing lOo/o 
FCS. 
Autographa californica nuclear polyhedrosis virus (AcNPV) was a gift from Dr 
M.-C. Fung (Division of Clinical Sciences, John Curtin School of Medical Research, 
Australian National University). MVE-1-51 was used as a 10% suckling mouse brain 
homogenate in HBSS. Purified MVE was provided by Dr R. C. Weir (Materials and 
Methods, Chapter 3). 
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5.2.2 Anti-MVE HIAF and anti-E mAbs 
See Nlaterials and Methods, Chapter 3. 
5.2.3 Plasmids, plasmid preparation, restriction 
digestion, transformation of E.coli 
enzvme 
.. 
Procedures were as described for Chapter 2 or Chapter 3. The baculovirus transfer 
vector pVL941 (9.8 kb; Luckow and Summers, 1989) was a gift from Dr M.-C. Fung. 
It contains 7 .8 kb of AcNPV genome sequence, the pUC8 plasmid and codes for 
ampicillin resistance (see also Fig. 5.1). 
5.2.4 Generation of recombinant MVE-baculovirus tranfer 
vector 
Preparation of vector DNA: pVL941 was used to transform E.coli MC1061.1 
with ampicillin selection (100 µg/ml ampicillin in LB agar). Plasmid DNA was 
extracted by alkaline lysis and quantitated by UV spectrophotometry. DNA (5 µg) was 
incubated with BamHI (5 units) at 37° for 1 hour. Calf intestinal alkaline phosphatase 
(0.2 units) was added and the mixture incubated at 37° for 30 min and at 70° for 10 min. 
DNA was extracted with phenol and quantitated by ethidium bromide staining. 
Ligation of BamHI linkers to MVE cDNA: MVE cDNA (p2/1/22; encoding the 5' 
5.4 kb of the MVE genome) was digested with EcoRI and SacI (5 units each), blunt-
ended with T4 DNA polymerase and purified on LMT agarose. BamHI linkers (5 µg; 
CGGGATCCCG; New England Biolabs) were phosphorylated by incubation with 
0.4 mM ATP, 70 mM Tris-HCl (pH 7.6), 10 mM MgCl2, 5 mM DTT and T4 
polynucleotide kinase (9 units; BRL, Life Technologies Inc., Gaithersburg, USA) at 
37° for 1 hour and the reaction stopped by heating at 90° for 5 min. The 2.5 kb MVE 
cDNA fragment (0.5 µg; see Fig. 5.2) was mixed with the phosphorylated BamHI 
linkers (0.2 µg) and incubated with T4 DNA ligase (100 units, New England Biolabs) 
at room temperature overnight. BamHI (50 units) was added; incubation was at 37° for 
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Figure 5.1 The transfer vector pVL941 (Summers and Smith, 1987; Luckow and Summers, 1989). 
pVL941 (9.8 kb) consists of pUC8 (2.7 kb) and a fragment (7.1 kb) from the genome of AcNPV 
containing the polyhedrin gene (::0.7 kb; solid arrow) and flanking sequences. A unique BamHl site is 
at position + 171 in the polyhedrin coiling region (+ 1 represents the first nucleotide of the polyhedrin 
coding region). A segment of the polyhedrin gene from +36 to +170 is deleted. The ATG initiation 
codon of the coding sequence is mutated to A TI for expression of nonfused recombinant proteins. The 
nucleotide sequence of the polyhedrin gene is shown from position -7 to+ 179. The unique EcoRI and 
EcoRV sites are inclicated. 
A. 
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Figure 5.2 Construction of the pVL941-MVE recombinant plasmid. (A) Plasmid p2/l/22 (7.3 kb) 
contains 5' non-coding regions (::::90 nucleotides) and coding regions for MVE C, prM, E NSl, NS2A, 
NS2B and half of NS3. Incubation of p2/l/22 (5 µg) with EcoRI and Sac! (5 units each) produced three 
fragments (2.9 kb, 2.5 kb, 1.9 kb), which were blunt-ended with T4 DNA polymerase and separated on 
1 % LMT agarose. The 2.5 kb fragment contains the 5' untranslated region, the structural proteins (C, 
prM, E) and part of NS 1 (11 amino acids) . It was isolated and BamHI cohesive ends were attached 
before ligation to BarnHI-digested, dephosphorylated p VL941 (B). The resulting pVL941 -MVE plasmid 
(C) was 12.3 kb in size and contained a new BamHI restriction fragment (2.5 kb) and an EcoRV-Pst.I 
restriction fragment (2 kb). 
4 hours to produce BamHl cohesive ends and to remove concatemers of linkers from 
MVE cDNA. Linkered MVE cDNA was extracted from 1 % LMT agarose and 
quantitated on the basis of ethidium bromide staining. 
Ligation of linkered MVE cDNA to vector: MVE cDNA (5 ng) was incubated 
with vector DNA (80 ng), T4 DNA ligase (100 units), 50 mM Tris-HCl (pH 7. 8), 
10 mM MgCl2, 20 mM dithiothreitol, 1 mM ATP and 50 µg/ml bovine serum 
albumin in a final volume of 10 µl at 16° for 16 hours. A control ligation was 
performed with vector DNA alone (80 ng) to determine the efficiency of 
dephosphorylation; self-ligation was not detected as there were no ampicillin-resistant 
colonies. Ligation mixtures were heated (70°, 10 min) before transformation of 
competent MC1061.l. 
Selection of ampicillin resistant colonies: Transformed MC1061.1 was grown 
overnight at 37° on LB plates containing 100 µg/ml ampicillin. Ampicillin resistant 
colonies were picked for plasmid extraction using the alkaline lysis method. 
5.2.5 Cotransfection of Spodoptera frugiperda cells with 
recombinant transfer vector and baculovirus DNA 
Extraction of plasmid DNA: Recombinant plasmid (pVL941-MVE) was extracted 
by alkaline lysis and further purified by addition of SDS to 0.5% and proteinase K 
(Boehringer) to 20 µg/ml, followed by incubation at 50° for 1 hour. DNA was 
extracted with phenol/chloroform, chloroform and twice with diethyl ether (Ajax). 
Traces of ether were removed by incubation at 70° for 5 min in an open Eppendorf tube. 
Plasmid DNA was precipitated with 7.5 M ammonium acetate (1/2 volume) and ethanol 
(2 volumes), held on dry ice for 30 min and pelleted by centrifugation. DNA pellets 
were washed once with 80% ethanol and resuspended in 10 mM TE (10 mM Tris-HCl, 
1 mM EDTA, pH 7.5). 
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Preparation of baculovirus genome DNA (Summers and Smith, 1987): Sf9 cell 
monolayers (3 x 107 cells in 75 cm2 flasks; Corning) were infected with AcNPV 
(MOI=l). Supernatant was collected at 3 days p.i. and centrifuged at 2500 rpm for 10 
min. The virus was pelleted by centrifugation for 30 min at 24,000 rpm. The pellet was 
resuspended in 0.1 x TE, layered on a linear 25-56% sucrose gradient in 0.1 x TE 
(11 ml in SW41 tubes) and centrifuged at 18,000 rpm for 90 min. The viral band 
(3 ml) was collected, diluted with 0.1 x TE (5 ml) and pelleted in an SW41 tube 
(18,000 rpm, 30 min). The pellet was resuspended in 4.5 ml extraction buffer (0.1 NI 
Tris-HCl, pH7.5, 0.2M KCl, 0.09M Na2EDTA) containing 0.2mg of 
proteinase K and incubated for 1 hour at 50°. Sarkosyl (Sigma; 0.25 ml of 20% 
solution) was added for a further 2 hours at 50°. The mixture was extracted twice with a 
phenol:isoamyl alcohol:chlorofonn mixture (25:1:24; 5 ml) and the phases separated by 
centrifugation at 2000 rpm (Sorvall SS-34 rotor). Ethanol (10 ml) was added and DNA 
precipitated (-80°, 10 min). The pellet was collected by centrifugation at 2500 rpm for 
20 min, washed with ethanol (90%) and resuspended in 0.1 x TE (0.5 ml). Incubation 
at 65° for 15 min and 4° overnight was required to dissolve the DNA which was stored 
at 4°. 
Cotransfection of Sf9 cells (Summers and Smith, 1987): Sf9 cells were incubated 
to form monolayers in 25 cm2 flasks (Coming). The TNM-FH medium was replaced 
with Grace medium (0.75 ml) containing 10% FCS. Cotransfection was with 2 x 106 
Sf9 cells using 1 µg of AcNPV DNA and 4 µg of pVL941-MVE DNA. The DNA 
mixture in transfection buffer (0.75 ml; 0.025 M HEPES, pH 7.1, 0.14 M NaCl, 
0.125 M CaCl2) was added drop-wise. The medium was removed after incubation for 
4 hours at 27° and replaced with TNM-FH containing 10% FCS. Cells were incubated 
for four days at 27°. The supernatant containing a mixture of wild-type and recombinant 
AcNPV was harvested and stored at 4 °. 
100 
5.2.6 Screening procedures and isolation of recombinant 
MVE-baculovirus 
Three methods were tested. These involved an assessment of plaque morphology, 
reactivity with HIAF against MVE or hybridization with MVE cDNA. 
Method 1 (Summers and Smith, 1987): Recombinant AcNPV does not produce 
the polyhedrin protein which is the major component of the virus-containing occlusion 
bodies in the nuclei. Thus, normal AcNPV plaques consist of cells with enlarged nuclei 
containing occlusion bodies, while recombinant plaques shO\\-' enlarged nuclei without 
occlusion bodies. Both wild-type and recombinant plaques are visible by eye in 
unstained plates. However in order to distinguish wild-type from recombinant plaques 
(which do not form occlusion bodies), light microscopy is needed. The titre of the 
mixture of AcNPV and recombinant virus in the cotransfection supernatant was 
determined by plaque formation on Sf9 cell monolayers. Vin1s (1 ml) diluted in TNM-
FH was used to infect semi-confluent monolayers of Sf9 cells (2 x 106) in 60 mm 
Petri dishes (Nunc, Roskilde, Denmark) by incubation at 27° for 1 hour with frequent 
rocking. The inoculum was removed and monolayers : over-laid with TNM-FH 
containing 1.5% (w/v) LMT agarose (Seaplaque, Rockland, USA) and 10% FCS. 
Incubation was for 4 days at 27° followed by light microscopy. 
Method 2: This was based on perfonning limiting dilutions of the cotransfection 
supernatant and the immunodetection of MVE antigens in infected Sf9 cells. The 
cotransfection supernatant was used to infect Sf9 cells (1.5 x 105 per well) in 96-well 
flat-bottom trays (Nunc) in dilutions from 10-2 to 10-6. After incubation for 4 to 6 days, 
the cells were lysed in radio-immunoprecipitation (RIP) buffer, a solution containing 
0.15 M NaCl, 10 mM EDTA, 1 % sodium deoxycholate, 1 % Nonidet P-40 (NP-40; 
Sigma), 0.1 o/o Triton X-100 and 20 mM Tris-HCl (pH 7 .8). The mixture was 
transferred to nitrocellulose and probed with anti-MVE HIAF (Chapter 2). 
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Method 3 (adapted from Fung et al., 1987): The cotransfection supernatant was 
diluted from 10-2 to 10-6 and 40 µl aliquots used to infect Sf9 cells in 96-well trays (as 
above). After 6 to 8 days at 27°, the supernatant in each well was transferred to a 
duplicate 96-well tray for storage at 4 °. The Sf9 cells were lysed in 0.2 M N aOH (0.2 
ml) and incubated (15 min, room temperature). Lysates from each well were transferred 
to nitrocellulose pre-equilibrated with 20 X SSC (1 X SSC: 0.15 M NaCl, 0.015 M 
sodium citrate, pH 7.4) in a Bio-Dot apparatus (Bio Rad). 2 M NaCl (0.4 ml) was 
added to each well before the lysates and suction applied. The filter was washed once in 
2 X SSC and baked (2 hours, 80°) under vacuum in a slab-gel dryer (Bio-Rad). It was 
then incubated (3 hours, 68°) in pre-hybridization fluid: 1.5 X SSPE (0.27 M NaCl, 
0.015 M EDTA, 0~015 M NaH2P04, pH 7.5), 1 % SDS and 0.5% BLOTIO (10% 
non-fat milk powder in 0.2% NaN3). A 32P-labelled DNA probe was generated from 
p2/1/22 by nick-translation. p2/1/22 (0.5 µg) was incubated with DNasel (1 ng; 
bovine pancreatic; Sigma) for 20 min at 14 ° in the presence of 50 mM Tris-HCl 
(pH 7.5), 7.5 mM magnesium acetate, 5.7 mM DTT, 0.1 mg/ml bovine serum 
albumin (BRL), 2.86 µmoles each of dATP, dGTP, dTTP and 6.6 pmoles of a-32p_ 
dCTP (3 Ci/µmole); the final volume was 35 µl. E.coli DNA polymerase 1 (2.5 units; 
New England Biolabs) was added (20 min, 14°). EDTA was added to 30 mM to 
terminate nick-translation. Immediately prior to hybridization, 0.3 ml of 30 rn.1t1 N aOH 
was added to the probe ( 40 µl), the mixture was incubated for 5 min in a boiling water 
bath and quick-chilled. Denatured probe (0.34 ml) was added to 5 ml of freshly 
prepared pre-hybridization fluid and incubated with the nitrocellulose membrane for 15 
hours at 68° (shaking was not necessary). The membrane was washed sequentially in 
(1) 2 X SSC, 0.1 % SDS; (2) 0.5 X SSC, 0.1 % SDS and (3) 0.1 X SSC, 0.1 % SDS 
for 15 min each at room temperature, then in 0.1 X SSC, 1 % SDS for 30 min at 50°. 
The air-dried nitrocellulose was exposed to Fuji X-ray film for autoradiography. 
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5.2.7 Extraction of nuclear DNA from infected Spodoptera 
frugiperda cells (Summers and Smith, 1987) 
Sf9 cell monolayers (2 x 106 cells) in 25 cm2 flasks were infected with wild-type 
or recombinant AcNPV (M(?I=0.1) and incubated for 4 days . The supernatant wa 
removed and the cells resuspended in 5 ml of lysis buffer (10 mM magnesium acetate, 
1 % NP-40, 30 mM Tris-HCl, pH 7.5). Incubation was for 3 min at room temperature 
and 5 min at 4°. Nuclei were collected by centrifugation at 2000 rpm for 3 min, washed 
once with PBS, re-pelleted and resuspended in extraction buffer (4.75 ml) containing 
0.2 mg of proteinase K. Purification of DNA was as in Section 5.2.5. DNA was 
resuspended in 0.5 ml 0.1 x TE and stored at 4 °. 
5.2.8 Semi-quantitative comparison of polyhedrin mRNAs by 
dot-blot hybridization (Luckow and Summers, 1988b) 
Sf9 cells (5 x 106) in 25 cm2 flasks were infected with wild-type or recombinant 
AcNPV (M0I=10) and incubated for 2 days at 27°. The cells were dislodged by 
shaking, collected by centrifugation at 2000 rpm for 5 min and washed once in ice-cold 
Grace medium. The cell pellet was resuspended in 45 µl of ice-cold 1 x TE containing 
5 µl of 5% NP-40 and incubated for 5 min at 4°. Another 5 µl of NP-40 was added 
and nuclei pelleted by centrifugation for 2.5 min in an Eppendorf microfuge at 4". The 
supernatant (50 µl) was incubated with 20 X SSC (30 µl) and formaldehyde (20 µl; 
37% solution; Sigma) for 15 min at 65° and stored at -80°. The crude cytoplasmic 
extract was used for hybridization without further treatment. It was diluted serially with 
15 X SSC. Aliquots (100 µl) equivalent to 2 x 103, 104, 5 x 104 and 2.5 x 10s 
cells were dot-blotted on nitrocellulose, rinsed with 6 X SSC and baked for 2 hours at 
80° under vacuum. Hybridization probes were a-32P-labelled pVL941 and a-32p_ 
labelled p2/1/22 (see above). Levels of polyhedrin mRNAs were estimated from 
hybridization signals with the p VL941 probe. It was expected that the p VL941 probe 
would be of low mol. wt. ( <400 bp) and not affected by the presence of additional 
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sequence in the coding regions of the polyhedrin and polyhedrin-MVE mRNAs. \Ve 
have assumed that it hybridizes to these mRNAs with approximately equal efficiency. 
5.2.9 SDS-PAGE and immunoblot analysis of infected cell 
lysates 
Sf9 cell monolayers in 24-well trays (Nunc) were infected with wild-type or 
recombinant AcNPV (M0I=40), incubated for 48 hours and harvested in 100 µl of ice-
cold RIP buffer. Cells were agitated for 10 min to completely lyse cells. Debris was 
removed by centrifugation for 2 min and clarified lysates stored at -20°. Aliquots 
(10 µl) equivalent to 5 x 104 cells were made up to 16 µl in SDS-PAGE sample 
buffer (Laemmli, 1970) containing 1 % SDS and 5% !3-NIE (reducing condition) or in 
identical sample buffer containing 0.1 % SDS and no !3-NIE (non-reducing condition; 
Cohen et al., 1986). Samples containing !3-NIE were held in boiling water for 2 min. 
Electrophoresis was on SDS-20% PA gels for both reduced and unreduced samples. As 
controls, purified MVE and MVE-infected Vero and C6/36 cell lysates were used. 
Proteins were stained in gels with Coomassie Brilliant Blue or electrophoretically 
-
transferred to nitrocellulose for detection using anti-MVE HIAF and mAbs (Chapter 3.). 
As size standards, low mol. wt. proteins (14.4-94K; Pharmacia) were electrophoresed 
and transferred to nitrocellulose for staining in 0.1 % (v/v) 'India' ink (Rotring, 
Germany) in PBS and 0.3% Tween-20. 
5.2.10 Radiolabelling, immunoprecipitation and fluorography 
of proteins in infected cells 
Sf9 cell monolayers in 24-well trays were infected with wild-type or recombinant 
AcNPV (M0I=40) and incubated at 27°. At 47 hours p.i., the medium was replaced 
with Grace medium (1 ml) lacking methionine; 35S-methionine (80 µCi/ml final 
concentration; 800 Ci/mmole; Amersham) was added for 10 min at 48 hours p.i .. After 
10 min, labelling medium was replaced with Grace medium containing a 20-fold excess 
of 'cold' methionine plus 0.1 mg/ml cycloheximide (Boehringer) and incubated for 1.5 
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or 3 hours (see text). Cells were harvested in RIP buffer (100 µl ) before or after the 
chase. Where indicated, tunicamycin (10 µg/ml; Boehringer) was added 4 hours before 
labelling. C6/36 cells were infected with MVE-1-51 (MOI= 10) and incubated at 28° in 
EMEM containing 10% FCS. At 20 hours p.i., medium was replaced with EMEM 
lacking methionine. 35S-methionine (30 µCi/ml) was added at 21 hours p.i. and lysates 
harvested in RIP buffer after incubation for 2 hours. 
For immunoprecipitation, labelled lysates (10 µl) were diluted in 0.1 ml RIP 
buffer containing 1-2 µl of undiluted anti-MVE HIAF and incubated at 4° overnight. 
Staphylococcus aureus (Cowan I strain) cells (Calbiochem, Behring Diagnostics, La 
Jolla, California, USA) were added (40 µl of a 10% suspension in RIP buffer) to the 
mixture; incubation was at 4 ° for 1 hour. Cells were collected by centrifugation ( 4000 
rpm, 15 min) through 10% sucrose in RIP buffer (1 ml). Cells were washed twice 
with RIP buffer, resuspended in 20 µl of SDS-PAGE sample buffer and incubated for 
30 min at 65°. After centrifugation for 2 min, the supernatant was analysed by SDS-
PAGE (Chapter 2). For fluorography, gels were stained with Coomassie Brilliant Blue, 
destained, soaked for 15 min in Amplify (20 ml; Amersham) and dried at 80° in a slab 
gel dryer (Bio-Rad). Fuji RXlOO X-ray film was used for fluorography. Low mol. wt. 
marker proteins (14.4K-94K) were electrophoresed and stained on each gel. 
5.2.11 Localization of MVE E protein by immuno-fluorescence 
(Harlow and Lane, 1988; Hardham, 1985) 
To determine the intracellular distribution of MVE E protein, fixation of cells was 
in paraformaldehyde (Harlow and Lane, 1988). To demonstrate the existence of Eon 
cell surface, parafonnaldehyde-glutaraldehyde fixation was used (Hardham, 1985). Sf9 
cells on glass coverslips in 35 mm Petri dishes (N unc) were infected in duplicate ,vith 
wild-type or recombinant AcNPV (M0I=10). As controls C6/36 cells were infected 
with MVE (MOI= 10) in duplicate or were mock-infected. At 48 hours p.i., coverslips 
were washed in PBS and either fixed in 4% paraformaldehyde (Sigma) for 10 min for 
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detection of internal antigens, or in 4% paraformaldehyde-0.2% glutaraldehyde 
(Aldrich) for 1 hour for detection of cell surf ace antigens. Paraformaldehyde was 
freshly prepared in PBS (Harlow and Lane, 1988). For detection of intracellular 
antigens, cells on coverslips were permeabilized for 3 min in PBS containing 0.2 % 
Triton X-100; washed twice in PBS and incubated for 10 min in blocking solution 
containing PBS, 5% (w/v) milk powder and 5% FCS. To detect cell surface antigens, 
fixed cells were rinsed twice in a solution of buffered glycine (50 mM in PBS, pH 7.5) 
and incubated in blocking solution as above. The neutralizing mAb against the MVE 
E-5b epitope (see Table 3.1) reacts specifically with the unreduced E protein (Chapter 3) 
and was used for detection of E. Coverslips were incubated (1 hour, 37°) with anti-
E-5b mAb diluted 10-3 with the blocking solution, washed in blocking solution (x 3) 
and incubated (30 min, 37°) with FITC-conjugated anti-(mouse IgG) (Bio-Yeda Ltd., 
Kiryat Weizmann, Rehovot, Israel) diluted 1 o-2 with blocking solution. Coverslips 
were mounted in a solution of glycerol (30%) in PBS and immediately examined by UV 
microscopy. Filter settings were appropriate for FITC fluorescence; oil-immersion 
lenses (40X or lOOX; Olympus) were used. Photographs were taken with the 
assistance of Dr A. Hardham (Research School of Biological Sciences, Australian 
National University) using Kodak films (Tri-X or T-max; SA400) rated at ASA1600. 
5.3 RESULTS 
5.3.1 Construction of recombinant pVL941 transfer vector 
The first step in the expression of the MVE structural proteins was to construct a 
transfer vector (pVL941) with the appropriate MVE cDNA inserted downstream of the 
polyhedrin promoter. pVL941 (9.8 kb) has a unique BamHI site 37 bp downstream 
from a mutated, inactive, polyhedrin initiation codon and a polyhedrin coding region 
with a deletion between nucleotides 36 and 170 (Fig. 5.1). The MVE cDNA clone used 
for the construction is shown in Fig. 5.2A. p2/l/22 is 7 .3 kb and consists of pMT21 
with 5.4 kb of MVE cDNA introduced at the unique EcoRI site. The insert codes for 
106 
almost the complete 5' non-coding region (::::::90 nucleotides), C, prM, E, NS 1, NS2A, 
NS2B and half of NS3 (Dalgarno et al., 1986) . By digesting with EcoRI and SacI, a 
cDNA fragment coding for the 5' untranslated region, C, prM, and E should be 
generated; it would also include 34 bp from the 5'-terminus of the NS 1 gene (Fig. 
5.2A). 
Assuming successful construction, the recombinant baculovirus (see below) would 
generate a hybrid rnRNA transcribed from the polyhedrin promoter 5' to the + 1 
nucleotide (Fig. 5.1). The transcript would terminate near the poly-A addition site of the 
polyhedrin mRNA (Summers and Smith, 1987). Translation would be expected to start 
at the C protein initiation triplet rather than at the mutated polyhedrin triplet (Fig. 5.1 ) 
and should generate a polyprotein containing C, prM, E, NS 1 (1 1 amino acids) and part 
of the polyhedrin protein. The construct is deleted in the polyhedrin ORF from 
nucleotides 36-170 (Fig. 5 .1 ); however readthrough past nucleotide 171 is arrested by a 
termination codon about 60 nucleotides downstream and the polyprotein would be 
expected to contain only 20 amino acids read from the polyhedrin mRNA. 
To construct the recombinant plasmid, p2/1/22 was digested with EcoRI and SacI 
(Fig. 5.2). Fragments of 2.9 kb, 2.5 kb and 1.9 kb were produced as expected (Fig. 
5.2A). They were blunt-ended with T4 DNA polymerase and the 2.5 kb fragment 
isolated. BamHI linkers were ligated to it and the mixture was digested with BarnHI to 
produce a 2.5 kb fragment for ligation to BamHI-digested pVL941 vector (9.8 kb). 
The ligation mixture was used to transform E.coli MC1061.1. Twelve ampicillin 
resistant transformants were picked, plasmids were extracted, incubated with Barn.HI 
and electrophoresed on agarose gels. Two plasmids contained inserts of 2.5 kb at the 
Barn.HI site; the others contained no inserts. The two plasmids (12.3 kb) were 
incubated with PstI and EcoRV to determine the orientation of the MVE cDNA. The 
appropriate plasmid was expected to generate two fragments (10.3 kb, 2 kb) on 
incubation with Pstl and EcoRV (Fig. 5.2C). One plasmid contained the MVE cDNA in 
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the reverse orientation. The other contained the expected BamHI and EcoRV-PstI 
fragments (Fig. 5.3) and is referred to below as pVL941-MVE. 
5.3.2 Generation and isolation of MVE-baculovirus 
recombinant 
Cotransfection of Sf9 cells with AcNPV genomic DNA and recombinant pVL941 
generates wild-type virus and 0.1-10% of the recombinant baculovirus (Summers and 
Smith, 1987). Three methods were tested for the isolation of recombinant AcNPV-
MVE from the cotransfection supernatant (see Materials and Methods for details). These 
relied on (1) the predicted distinct plaque morphology of AcNPV-MVE, (2) the detection 
of MVE proteins using anti-MVE HIAF, and (3) the detection of MVE cDNA 
sequences. 
The first method was unsuccessful as none of the many plaques examined 
microscopically (=100) were devoid of occlusion bodies, indicating that these cells were 
infected with the wild-type AcNPV and that the cotransfection supernatant contained a 
low percentage of recombinant virus. The second method was unsuccessful because 
weak signals were obtained and could not be differentiated from the background. The 
third method was successful. 10-2 to 10-6 dilutions of cotransfection supernatant were 
used to infect Sf9 cells in 96-well trays. After incubation for 6 days, supernatants were 
transferred to a fresh tray for storage. The cells in each well were lysed in sodium 
hydroxide and dot-blotted on nitrocellulose for detection of MVE sequences by 
hybridization with p2/1/22. Cells from nine out of twelve wells infected with a 10-2 
dilution hybridized to MVE cDNA (the faint signal in well J was not reproduced 
adequately by photography in Fig. 5.4); at 10-3 cells from nine out of twelve wells 
hybridized, and at 10-4 cells from two out of twelve wells hybridized (Fig. 5.4). From 
the titre of the undiluted virus (108 PFU/ml) and the volume added, it was estimated 
that at 10-3 and 10-4 dilutions, each well was infected with approximately 4000 and 400 
PFU of AcNPV respectively. Hence the positive wells (C, E) at a 10-4 dilution were 
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Figure 5.3 Restriction enzyme digestion of pVL941-MVE recombinant plasmid DNA. pVL941 DNA 
(Lanes 3, 5; 1 µg) and recombinant DNA (Lanes 2, 4, 6, 7; 1 µg) was incubated with 2 units each of 
Pstl (Lane 2), BamHI (Lanes 3, 4), EcoRI (Lanes 5, 6), or EcoRV+ Pstl (Lane 7) at 37° for 1 hour. 
Electrophoresis was on 1 % agarose at 60 volts for 1.5 hours. The gel was stained in ethidium bromide 
(0.5 µg/ml) for 30 min, destained and photographed under UV. Size standards were A DNA diges ted 
with HindIII and EcoRI (Lane 1) or HindIII alone (Lane 8). 
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Figure 5.4 Hybridization screening for recombinant AcNPV. Sf9 cells in a 96-well tray (1 x 104 
cells/well) were infected with 40 µ1 aliquots of diluted cotransfection supernatant. 12 wells (A to L) 
were infected for each dilution. Incubation was for 6 days at 28°. Lysate from each well was transferred 
to nitrocellulose (70 mm x 105 mm). Detection of MVE-specific sequences was by hybridization 
using the 32P-labelled p2/1(22 and autoradiography. The controls (bottom left corner) were, from left to 
right, 30 ng, 0.1 ng of p2/1(22 plasmid DNA and DNA from AcNPV-infected Sf9 cells. 
expected to be enriched in recombinant AcNPV by comparison with the positive wells at 
the 10-2 and 10-3 dilutions. The AcNPV-MVE recombinant was estimated to be less 
than 0.1 % of the original cotransfection supernatant based on these results. 
Supernatants from the two positive wells (C, E; 10-4 dilution) were diluted 10-S and 10-7 
and used to infect 96-well trays (16 wells for 10-5 dilution, two trays for 10-7 dilution) 
for hybridization screening. Three positive wells were obtained with the 10-7 dilution. 
The supematants were used to infect Sf9 cells in 25 cm2 flasks. At 4 days p.i., 
enlarged nuclei were visible in most of the cells examined (:::::500), but no occlusion 
bodies were detected indicating that the inoculum did not contain contaminating wild-
type AcNPV. Virus was harvested at 4 days; titres were :::::5xl08 PFU/ml (assayed by 
plaque titration). Three recombinant AcNPV stocks (Reel, Rec2, Rec3) were obtained 
from two further rounds of screening. The latter two were derived from the same well 
(E) from the first round while Reel was from a different well (C) and thus was likely to 
be due to a different recombination event. 
5.3.3 .Restriction enzyme analysis of DNA from infected 
Spodoptera frugiperda c~Ils 
Reel and Rec2 were expected to contain 2.5 kb of the MVE cDNA in the 
polyhedrin coding region. This could be confirmed by comparing the restriction enzyme 
(RE) profiles of Reel, Rec2 and wild-type AcNPV genome DNAs using BamHI, BglII 
and PstI. Fig. 5.5 shows that the polyhedrin gene is in the 3rd largest BglII fragment 
(:::::13 kb) and the 4th largest PstI fragment (:::::11 kb); it also contains a BamHI site 
where the MVE cDNA was· inserted. Insertion of the MVE cDNA in the polyhedrin 
coding region was expected to alter these fragments and create a new BamHI fragment 
of 2.5 kb. 
For RE analysis, total nuclear DNA from infected Sf9 cells was used, as 25% is 
AcNPV genomic DNA (Summers and Smith, 1987). Sf9 cells were infected with 
recombinant (Reel or Rec2) or with wild-type virus (MOI:::::l) and nuclear DNA 
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Figure 5.5 Restriction map of the AcNPV genome showing BamID, Pstl and BglII sites (Summers and 
Smith, 1987). The circular genome (:::120 kb) is linearized and is shown as solid lines. The largest 
fragment for each restriction enzyme is designated 'A', the second largest 'B' and so on. The coding 
region for the polyhedrin protein is inclicated. The MVE cDNA fragment at the BamHI site in the 
polyhedrin gene is shown. It contains a Pstl site but no BglII sites. 
extracted at 3 days p.i. DNA from 105 cells was digested with BamHI, BglII or PstI 
and electrophoresed on 1 % agarose (Fig. 5.6). Restriction fragments from recombinant 
and wild-type viral genomes were visible. With Reel and Rec2, a new 2.5 kb BamHI 
fragment was detected. The 13 kb BglII fragment in AcNPV was replaced by a 15-
16 kb fragment in Rec 1 and Rec2; the 11 kb PstI fragment in AcNPV was replaced by 
8 and 5.6 kb fragments in Reel and Rec2 (Fig. 5.6). These observations were 
consistent with the insertion in the polyhedrin coding region of a BamHI fragment 
(2.5 kb) which contains a PstI site. There was no apparent difference between the 
restriction profiles for Rec 1 and Rec2. We conclude that both Rec 1 and Rec2 represent 
the desired recombinants. 
5.3.4 Semi-quantitative comparison of viral mRNA levels in 
Spodoptera frugiperda cells infected with recombinant and 
wild-type baculovirus 
Sf9 cells infected with AcNPV produce an abundance of mRNA for the synthesis 
of polyhedrin protein (1.2 mg/106 cells) late in infection (Luckow and ~ummers, 
1988b). The transfer vector used in this study, pVL941 (Fig. 5.1), is not altered in the 
sequence 5' to the polyhedrin coding region and should generate recombinant AcNPV 
with a normal polyhedrin promoter activity (Luckow and Summers, 1989). The effect 
on the level of polyhedrin-MVE mRNA of the insertion of MVE cDNA in the polyhedrin 
coding region was examined. Levels of polyhedrin mRNA and polyhedrin-MVE 
mRNA in cells infected with wild-type AcNPV and the recombinant respectively were 
compared. Cytoplasmic RNA was extracted at 2 days p.i. from cells infected (M0I=10) 
with AcNPV, Reel or Rec2. 32P-labelled pVL941 was used as a probe for wild-type 
and polyhedrin-MVE mRL~As; 32P-labelled p2/l/22 was used as probe for polyhedrin-
MVE mRNA. 32P-labelled pVL941 hybridized to RNA from cells infected with wild 
type and recombinant AcNPV (Fig. 5.7). 32P-labelled p2/1/22 only hybridized to RNA 
from Reel and Rec2-infected Sf9 cells (results not shown). The levels of polyhedrin 
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Figure 5.6 Restriction digest profiles of nuclear DNA from Sf9 cells infected with AcNPV (1), Reel 
(2) and Rec2 (3). DNA from 105 infected-cells (MOI:==1; 3 days p.i.) was incubated with BamHI, Bg1II 
or PstI for 1 hour and electrophoresed on 1 % agarose. Detection was by ethidium bromide staining 
(0.5 µg/ml) and UV illumination. Fragments expected to contain MVE sequences are indicated by 
arrows. 
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Figure 5.7 Semi-quantitative comparison of mRNA levels in infected Sf9 cells. Cytoplasmic RNA 
was extracted from Sf9 cells infected with AcNPV, Reel or Rec2 (MOI::::10; 48 hours p.i.). Aliquots 
were dot-blotted on nitrocellulose which was then baked at 80° for 2 hours under vacuum. Detection of 
polyhedrin mRNA and polyhedrin-:NIVE mRNA was by hybridization to 32P-labelled p\lL941 probe 
(see text). 
mRNA and polyhedrin-MVE mRNA were compared. For hybridization to p\TL941, the 
signals from 2 x 1 Q3, 1 a4 and 5 x 1 Q4 cells increased with cell number (Fig. 5 .7 ). 
However the signal from 2.5 x 1 os Rec2-infected cells was weaker than the signal 
from fewer cells and this may be due to proteins in the RN A preparation (Luckow and 
Summers, 1988b). Using the three lower amounts of infected cells as the basis for 
comparison, similar polyhedrin-MVE mRNA levels were present in Rec 1 and Rec2-
infected cells (Fig. 5.7). Probing \Vith pVI. .. 941, approximately equal intensities were 
observed for 2 x 1 Q3 AcNPV-infected cells and 2.5 x 1 os Rec-infected cells (Fig. 
5.7). We conclude that there was approximately 125-fold less polyhedrin-MVE mRNA 
in Rec-infected cells than polyhedrin mRNA in AcNPV-infected cells. 
5.3.5 Expression of MVE structural proteins in Spodoptera 
frugiperda cells infected with recombinant baculovirus 
In preliminary studies, the expression of recombinant MVE proteins in Sf9 cells 
was shown to be maximal between 48 and 120 hours p.i. To characterize the proteins, 
Sf9 cells infected with Reel or Rec2 (M0I~40) were harvested at 48 hours p.i., lysed 
and the extract electrophoresed on an SDS-20% PA gel without heat denaturation or 
reduction. Proteins were transferred to nitrocellulose for detection with anti-MVE 
HIAF. Lysates of AcNPV-infected Sf9 cells, MVE-infected Vero cells, MVE-infected 
C6/36 cells and disrupted purified MVE were electrophoresed and blotted as controls. 
Reel and Rec2 gave identical profiles (Fig. 5.8). Four MVE-specific proteins with mol. 
wts. of approximately 90K, 55K, 40K (trace) and 24K were observed. The most 
abundant was the 55K protein which corresponded to E in MVE-infected cells and 
purified virus (Fig. 5.8). The greater mobility of the 55K protein by comparison with E 
in MVE-infected cells and virus was noted (see below). The 24K protein corresponded 
to prM in MVE-infected C6/36 cells. PrM in purified MVE migrated as a doublettai.11d 
the 24K protein corresponded to the faster migrating band. The 40K protein was 
detected on immunoblots but was not adequately reproduced on photography; it showed 
* This presumably reflects the two forms of prM, one with and one without carbohydrates attached 
at the single glycosylation site. 
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Figure 5.8 Immunoblot analysis of MVE-specific proteins in Sf9 cells infected with wild-type AcNPV, 
and with Reel and Rec2. Infected cells (MOI:::::40; 48 hours p.i.) were lysed and aliquots equivalent to 
5 x 1 o4 cells separated on an SDS-20% PA gel in the absence of B-ME and transferred to 
nitrocellulose. MVE proteins from purified virus (V) containing ::::0.2 µg E, and from 1'IVE-infec ted 
Vero and C6/36 cells (MOI::::10) harvested at 48 hours p.i. were controls. Detection was with anti-M'"VE 
I-IlAF. Positions of size markers are are shown. MVE proteins M (8K), C (16K), prM (26K), E (56K), 
NS3 (70K) and NS5 (103K) are indicated. 
variable mobility on SDS-PA gels (results not shown). The 90K protein corresponded 
in mobility to NS5 but since it derives from cDNA without this region of the genome, it 
cannot be NS5. The identities of the 90K and 40K proteins are discussed further 
below. MVE-specific proteins were not detected in culture medium equivalent to 
5 x 1 Q4 cells, indicating that the proteins were mainly cell-associated (results not 
shown). 
To determine the time course of protein synthesis, cells were infected with 
AcNPV, Rec 1 or Rec2 (M0I===40) and incubated for 18, 24, 48, 72, 96 or 120 hours. 
Cell lysates were electrophoresed without prior heating or reduction on an SDS-20% PA 
gel and the proteins transferred to nitrocellulose for detection by HIAF. No proteins 
were detected in AcNPV-infected cells. MVE-specific proteins were detected at 18 
hours p.i. The relative intensities of the four MVE-specific proteins did not vary with 
time after infection. The profiles for Rec 1 and Rec2-infected cells at 18-120 hours p.i. 
were identical. Proteins of 55K, 40K and 24K were observed (results for Rec 1 are 
shown in Fig. 5 .9). 
Differences are seen between Figs. 5.8 and 5.9. The 40K protein is of stronger 
relative intensity in Fig. 5.8; the 24K protein migrated slower as judged by its position 
relative to the prM doublet in purified MVE; and the 90K protein was not detected in 
Fig. 5.9. Both experiments used unreduced proteins denatured in 0.1 % SDS; 
immunoblots were performed under similar conditions. We believe that the different 
mobilities and reactivities with HIAF resulted from differences in the extent of 
denaturation during electrophoresis or of renaturation during immunoblotting. 
5.3.6 Proteolytic • processing and glycosylation of 
recombinant MVE proteins in Spodoptera frugiperda cells 
To define the pathway of proteolytic cleavage in Sf9 cells and to assess its 
efficiency, infected cells were pulse-labelled and lysates examined after various lengths 
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Figure 5.9 Time course of MVE-specific protein synthesis in Reel-infected Sf9 cells. Cells were 
infected with AcNPV or Reel in 35 mm Petri dishes (M0I==40) and incubated for 18, 24, 48, 72, 96 and 
120 hours at 28°. Cells were lysed and aliquots of total lysate corresponding to 5 x 104 cells were 
electrophoresed on an SDS-20% PA gel under non-reducing conditions for immunoblot analysis using 
anti-MVE HIAF (as in Fig. 5.8). C, MVE-infected (M0I==10) Vero cell lysate (48 hours p.i.; 105 
cells); V, purified MVE containing ==0.1 µg E. Arrows to the left of the photograph indicate the 55K, 
40K and 24K proteins in Sf9 cell lysates. 
of chase. Preliminary studies showed that the synthesis of both polyhedrin and MVE 
proteins was most rapid from 24-48 hours p.i. ; synthesis of cellular proteins was 
inhibited at 48 hours p.i. (results not shown). In further studies, Sf9 cells were infected 
with Reel or AcNPV (M0I=40) and labelled with 35S-methionine for 10 min at 48 
hours p.i. followed by a chase of 1.5 or 3 hours with unlabelled methionine and 
cycloheximide. Lysates were irnmunoprecipitated with anti-MVE HIAF and the proteins 
separated by SDS-PAGE (Fig. 5.10). Control lysates were MVE-infected SW13 
(human adenocarcinoma) cells labelled (from 24-36 hours p.i.) with 3H-glucosamine 
and MVE-infected C6/36 cells labelled (21-24 hours p.i.) with 35S-methionine. The 
four MVE glycoproteins labelled in SW13 cells were E (56K), NS 1 (SOK and 46K) and 
prM (26K) (Fig. 5.10A; see also Lee et al., 1990). E generated in C6/36 cells migrated 
faster (54.5K) than E generated in SW13 cells. The only protein immunoprecipitated in 
AcNPV-infected Sf9 cells was a 35K protein (Fig. 5.10B), probably the polyhedrin 
protein. The immunoprecipitation of this protein appeared to be non-specific. 
In cells infected with Rec 1, a complex pattern was observed in pulse-chase 
experiments (Fig. 5.10). After a 10 min labelling period, a number of relatively large 
proteins of nominal mol. wts. 90, 60 and 58K were observed. Other proteins of lower 
mol wts. (36-SOK) were seen. Following a chase, the 90, 60 and 58K proteins 
disappeared as did all the small proteins except the 36K protein. Only two proteins were 
detected after a 1.5 hour chase: a protein of 54.SK and the 36K protein. Only the 54K 
protein was stable after a 3 hour chase. The 54.5K protein is E on the basis of its size, 
absence in tunicamycin-treated cells and reactivity with mAbs (see below). Proteins 
corresponding to prM, M and C were not detected in infected cells after a pulse-chase. 
The identification of the other labelled proteins is less certain. Fig. 5 .11 shows a 
possible processing pathway for the C-prM-E-NS 1-polyhedrin polyprotein. The 90K 
protein may represent the full length polyprotein with or without the NS 1-polyhedrin 
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Figure 5.10 Processing of MVE proteins in Sf9 cells. Cells in 24-well trays (5 x 105 cells/well) were 
infected with Rec 1 or with AcNPV (MOI:::40) and incubated at 28°. At 48 hours p.i., cells were labelled 
with 35s-methionine (80 µCi/ml) for 10 min without or with tunicamycin (10 µg/ml). Medium 
containing an excess of unlabelled methionine and cycloheximide (0.1 mg/ml final concentration) was 
then added and incubation continued for 1.5 or 3 hours. Control lysates were from :MVE-infected SW13 
cells labelled (12 hours) with 3H-glucosamine and :MVE-infected C6/36 cells labelled (2 hours) with 
35s-methionine. Lysates were immunoprecipitated with anti-MVE HIAF for analysis by SDS-PAGE 
and fluorography. Positions of size markers are shown. E and prM proteins in C6/36 cells and in 
S\Vl3 cells are indicated. Ae, Aedes a/bopictus (C6/36) cells; Met, 35S-methionine labelled; Sw, 
SvV13 cells; Glc, 3H-glucosamine labelled. (A) and (B) are autoradiographs of the same gel exposed for 
1 and 14 days respectively. 
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Figure 5.11 MVE coding region in recombinant AcNPV showing possible proteolytic processing 
pathway. The MVE cDNA inserted in the polyhedrin coding region of AcNPV is shown. It contains 
the 5' untranslated region of MVE genome (:==90 nucleotides), and coding regions for C (375 
nucleotides), prM (501 nucleotides), E (1503 nucleotides) and part of NS1 (34 nucleotides). The 
predicted size (in amino acids) and mol. wts. of prM and E glycoproteins and of C are indicated. 
Sequence and protein data are from Dalgarno et al. (1986) and Lee et al. (1990). The ORF begins with 
the initiation codon (triangle) and ends with T AA (diamond). The position of the termination codon was 
deduced on the basis of sequence data for pVL941 and for the polyhedrin coding region (Summers and 
Smith , 1987). 
-
fragment at the C-terminus. The 58-60K proteins may be the E-NS 1-polyhedrin and the 
36K protein C-prM. 
To determine whether the MVE proteins were Asn-glycosylated, tunicamycin, an 
inhibitor of this process in animal and insect cells, was used (Butters et al., 1981; 
Hubbard and Ivatt, 1981). Three stable MVE-specific proteins were observed after 
pulse-chase in tunicamycin treated cells (Fig. 5.10B). These were of nominal mol. wts. 
59, 52.5 and 36K. The 36K protein (C-prM?) was identical in size to a protein in cells 
untreated with tunicamycin suggesting that it was not glycosylated. The 52.SK protein 
had the properties expected of unglycosylated E. The 59I( protein appeared to be the 
unglycosylated E-NSl-P. Its presence after 1.5 and 3 hours chase suggests that 
tunicamycin affects the cleavage at the C-tenninus of E. 
Figs. 5 .1 OA and B permit a comparison to be made benveen the mobilities of the 
MVE E proteins generated in mosquito (C6/36), moth (Sf9) and human (SW13) cells. 
By alignment (results not shown), it can be demonstrated that E generated in Sf9 and 
C6/36 cells have id~ntical mobilities whereas E generated in SW13 cells is of slightly 
lower mobility. 
We have noted differences in the profiles of MVE proteins in Fig. 5.8 and Fig. 
5.10B. The detection of proteins was by the same HIAF in both cases. However in 
Fig. 5.8, unreduced proteins in lysates were electrophoresed, transferred to 
nitrocellulose and reacted with antibodies. In Fig. 5. lOB, labelled native proteins in 
lysates were reacted with antibodies and then reduced and electrophoresed. The 
54.5/55K protein and the 90K protein was observed in both, but the 24K and 40K 
proteins in Fig. 5.8 were not in Fig. 5.10B. The 24K protein may not be detected by 
RIP in Fig. lOB due to less effective labelling by 35S-methionine relative to the larger 
proteins. We do not consider the size estimation of the 40K protein to be accurate as it 
was based on mobilities of unreduced proteins in SDS-P AGE and the 40K protein 
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showed variable mobilities in such analysis (see above). It is likely that this protein 
corresponded to the 36K protein in Fig. 5.10B (see above). 
5.3. 7 Reactivity of E protein with neutralizing mAbs 
The 54.5K protein corresponded in size to the MVE E protein and it was also Asn-
glycosy lated. It was also of interest to examine the reactivity of this protein with 
neutralizing mAbs to confirm that it was E and as an index of conformation. MAbs 
against five different epitopes (E-lc, E-ld, E-5b, E-7 and E-8) were available and these 
reacted strongly with the unreduced authentic MVE E protein (Chapter 3). Lysates of 
Sf9 cells infected with Reel and with AcNPV (MOI:==10; 48 hours p.i.) were 
electrophoresed, unreduced, on an SDS-20% PA gel. Control lysates (unreduced) of 
MVE-infected C6/36 and Vero cells were electrophoresed on the same gel. Proteins 
were transferred to nitrocellulose for detection by mAbs. Unreduced recombinant E 
reacted with all five mAbs: no protein in AcNPV-infected Sf9 cells reacted with any 
mAb (Fig. 5.12). Reactivity was strongest with anti-E-5b and E-8, and moderate to 
weak with anti-E-7, E-ld and E-lc. The same pattern of reactivity was obtained with E 
in MVE-infected C6/36 and Vero cells (Fig. 5 .12). These results suggested that 
recombinant E was similar in conf onnation to authentic E. 
5.3.8 Localization of E protein in Spodoptera frugiperda cells 
The MVE-specific proteins which reacted with anti-MVE HIAF were not secreted 
in quantity from Sf9 cells. To explore the subcellular localization of the MVE proteins, 
nuclei from infected Sf9 cells were first examined. Rec 1-infected cells were lysed with 
1 % NP-40. Lysates were centrifuged and nuclei pelleted and resuspended in RIP 
buffer. Nuclear extracts were dot-blotted on nitrocellulose and reacted with anti-MVE 
HIAF. No MVE-specific proteins were detected in a nuclear extract from 5 x 105 Sf9 
cells even though total lysates from a similar number of cells contained MVE proteins 
(results not shown). 
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Figure 5.12 Immunoblot analysis of E protein synthesized in Sf9 cells using anti-E mAbs. Lysates of 
cells infected with Reel and AcNPV were prepared as in Fig. 5.8, electrophoresed on an SDS-20% PA 
gel in the absence of B-ME and transferred to nitrocellulose which was reacted with anti-E-lc, E-ld, 
E-5b, E-7 and E-8 mAbs (see Table 3.1). Lane 1, MVE-infected Vero cells (2 x 105); lane 2, MVE-
infected C6/36 cells (5 x 104); lane 3, AcNPV-infected Sf9 cells (5 x 104); lane 4, Rec 1-infected Sf9 
cells (5 x 104). 
Immunofluorescence was used to localize the E protein in the extranuclear region. 
Two approaches for fixation were examined. The first (paraformaldehyde fixation) was 
used to localize internal antigens (Harlow and Lane, 1988); the second 
(paraformaldehyde plus glutaraldehyde) was used to detect cell surface antigens 
(Hard.ham, 1985). 
Paraformaldehyde method: Sf9 cells on coverslips were infected with AcNPV or 
with Reel (M0I=l0). Control C6/36 cells were infected with MVE (M0I=10). At 48 
hours p.i., coverslips were fixed in 4% paraformaldehyde, permeabilized with Triton X 
and reacted with anti-E-Sb mAb. FITC-conjugated anti-(mouse IgG) was added and 
immunofluorescence detected by UV microscopy. Fluorescence was observed in the 
cytoplasm of Reel- but not AcNPV-infected Sf9 cells (Fig. 5.13A, B). The intensity 
was strongest in the perinuclear region. The MVE-infected C6/36 cells were more 
weakly stained than the Reel-infected Sf9 cells, but a similar distribution of E was seen 
(Fig. 5.13C). The nuclei in infected C6/36 cells were not enlarged as in infected Sf9 
cells. No fluorescence was seen in mock-infected C6/36 cells (Fig. 5.13D). 
Paraformaldehyde-glutaraldehyde fixation: Coverslips infected as above were 
fixed in paraformaldehyde (4%)-glutaraldehyde (0.2%), and reacted with anti-E-Sb mAb 
and HTC-conjugated anti-(mouse IgG). Approximately half the Reel-infected Sf9 cells 
were stained at the cell membrane (Fig. 5.13E, F), indicating that the recombinant E was 
located on the surface of infected cells. Some infected cells were permeabilized by this 
technique and perinuclear fluorescence was detected in these cells (Fig. 5.13E). MVE-
infected C6/36 cells showed staining predominantly in the cytoplasm due to 
permeabilization (Fig. 5.13G, H). The staining was weak and it could not be 
ascertained whether E was absent from the surface. From both types of fixation 
technique, we conclude that there was less intense staining overall in C6/36 than in Sf9 
cells. This was probably due to lower amounts of E being produced in C6/36 cells. 
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Figure 5.13 Immunofluorescence localization of MVE E protein in infected cells. Sf9 cells on glass 
coverslips were infected with Reel (M0I=10; A, E) or with AcNPV (M0I=10; B, F). C6/36 cells were 
infected with MVE (M0I=10; C, G) or mock infected (D, H). At 48 hours p.i., coverslips were fixed 
in paraformaldehyde (A, B, C, D) for detection of internal antigens or parafonnaldehyde-glutaraldehyde 
(E, F, G, H) for detection of cell surface antigens. The coverslips were reacted with anti-E-5b mAb. 
FITC-anti-(mouse IgG) was used for immunofluorescence detection. The photographs were taken at 
magnifications of lOOOX (E, F) or 400X (A, B, C, D, G, H) under microscopy. 
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5.3.9 Yield of E protein from Spodoptera frugiperda cells 
An attempt was made to quantitate levels of recombinant E generated in Sf9 cells. 
The method was based on a comparison of relative reactivities of HIAF and anti-E-5b 
mAb with standardized amounts of purified MVE and with infected Sf9 cell lysates. 
MVE was purified by gradient centrifugation (Chapter 3). Analysis by SDS-PAGE 
showed that the preparation was approximately 50% viral protein and approximately 
50% bovine serum albumin. Quantitation of the MVE proteins was by Bio-Rad 
colorimetric assay (Chapter 3). The results of a number of immunoblotting experiments 
with anti-MVE HIAF and anti-E-5b mAb indicated that the yield of E was =4 µg/106 
cells (data not shown). 
In related experiments using the same procedures, the yield of E from MVE-
infected C6/36 cell lysates was approximately one third of that in Sf9 cells. This is 
consistent with the results of immunofluorescence staining of infected C6/36 and Sf9 
cells; stronger staining was demonstrated in the Sf9 cells. 
5.3.10 Summary 
A recombinant baculovirus, the Autographa californica nuclear polyhedrosis virus, 
containing the MVE structural protein genes downstream from the polyhedrin promoter 
was generated by homologous recombination between the recombinant vector p VL941-
MVE and baculovirus DNA. A selection procedure based on detection of MVE cDNA 
allowed the isolation of three recombinant viruses. Analysis of restriction digest 
profiles, mRNA synthesis and MVE proteins for two of these demonstrated that they 
were identical. Infection of Sf9 cells with recombinant virus produced polyhedrin-MVE 
mRNA at a level which was approximately 125-fold less than that of polyhedrin mRNA 
in AcNPV-infected Sf9 cells. Several proteins were detected by anti-MVE HIAF in Sf9 
cells infected with recombinant baculovirus. A =55K protein corresponded in size to E 
and reacted with neutralizing mAbs against MVE E protein. We have tentatively 
identified this protein as E; however sequence at the N- and C-termini is needed to verify 
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that correct cleavage has occurred; the use of the term 'E' must therefore be considered 
provisional. A 24K protein observed in immunoblots may be prM but was not seen in 
labelling experiments. Other proteins of 40K and 90K were probably high mol. wt. 
precursors. MVE proteins were detected from 18-120 hours p.i. Proteolytic processing 
was studied in pulse-chase experiments; these demonstrated efficient cleavage of 
polyprotein precursors into a 54.5K protein. Use of tunicamycin demonstrated that the 
54.5K protein underwent Asn-linked glycosylation consistent with the properties of E. 
Cleavage of E-NS1-polyhedrin was incomplete in the presence of tunicamycin. The 
five neutralizing mAbs had reactivity patterns against the 54.5K protein similar to those 
against authentic E in MVE-infected cells. Localization by immunofluorescence staining 
with anti-E-5b mAb showed that E was distributed in Sf9 cells in the perinuclear region 
and at the cell surface. The yield of recombinant E was approximately 4-5 µg per 106 
cells; this was estimated by its reactivity with HIAF relative to a standardized amount of 
purified MVE. On the basis of reactivities with HIAF and immunofluorescence staining 
with anti-E-5b mAb, we conclude that the yield of E from Sf9 cells was significantly 
greater per cell than from MVE-infected C6/36 cells. 
5.4 DISCUSSION 
The aim of this study was to explore the expression of cDNA encoding the MVE 
structural proteins in the baculovirus expression system. Of major interest was the 
possibility of generating E protein in a 'native' conformation and in good yield. The 
method used involved the introduction into the transfer vectorpVL941, of MVE cDNA 
encoding the 5' untranslated region, C, prM, the complete E gene and a small portion of 
NS 1. Cotransfection of a lepidopteran cell line (Sf9) with recombinant plasmid and 
with baculovirus DNA generated the desired recombinant baculovirus, which was 
isolated using a strategy based on hybridization of infected cell DNA with labelled MVE 
cDNA. This method was superior to two other methods tested and led to the isolation of 
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two identical recombinants. We estimate that the yield of the AcNPV-MVE recombinant 
was of the order of 0.1 % of the total cotransfection progeny. 
Processing of recombinant MVE proteins in Spodoptera frugiperda cells 
Proteins corresponding in size to prM and E were detected in Sf9 cells infected 
with the recombinant AcNPV. The identity of recombinant E was confirmed using anti-
E mAbs (see below). The other MVE-specific proteins seen in Sf9 cells were probably 
high mol. wt. precursors and processing intermediates. These were tentatively 
identified by their mol. wts. as the following polyproteins: C-prM-E-NSl-poly, E-NSl-
poly and C-prM (the terms 'NS 1' and 'poly' denote 11 and 20 amino acids of the NS 1 
and polyhedrin proteins respectively; see below). 
The processing events in flavivirus-infected cells which produce the structural 
proteins include two types of cleavage; C, prM and E are produced from the pol yprotein 
by signalase cleavage in the lumen of the RER, where E and prM also undergo Asn-
linked glycosylation (Chapter 1). The expression of MVE E and prM in Sf9 cells 
infected with recombinant baculovirus is consistent with cleavage by signalase. We 
conclude that the polyprotein encoded in the recombinant baculovirus underwent 
translocation into the lumen of the RER, probably mediated by the signal sequences at 
the C-termini of C, prM and E, where cleavage by signalase produced the prM and E 
proteins. Although C was not detected in infected Sf9 cells, the appearance of prM and 
E proteins indicated that C was probably cleaved from the polyprotein precursor. The 
failure to detect C suggests that it was degraded after cleavage from the polyprotein. In 
a study of processing of Sindbis structural proteins in Sf9 cells using the AcNPV 
expression system (Oker-Blom and Summers, 1989), the capsid (C) protein is partly 
degraded. Since the C proteins of both Sindbis and MVE are thought to bind their 
respective viral genome RNAs soon after synthesis, C may be susceptible to degradation 
in Sf9 cells in the absence of genome RNA. 
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The second type of cleavage for the structural proteins converts prM to M 
(Chambers et al., 1990a). This occurs late in the virus maturation pathway or during 
virus release; the cleavage is frequently incomplete as released flavivirus particles 
commonly contain prM as well as M (Chater 1). We did not detect free Min Sf9 cells. 
This may relate to the fact that events in virus maturation which are important for this 
cleavage are not occurring in our system. However M is often not detected in cells 
infected with MVE and other flaviviruses (Lee et al., 1990; Shapiro et al., 1972; 
Westaway, 1987). Another explanation for our failure to detect M relates to the methods 
of labelling with 35S-methionine and of immunoblotting used for detection: MVE M may 
not be strongly labelled as it contains only one methionine residue (Dalgamo et al., 
1986); losses of M during transfer or blotting may occur due to its small mol. wt. (8K). 
We have assessed the kinetics of processing of MVE proteins in Sf9 cells by pulse-
chase experiments. Cleavage to generate the 54.SK protein occurred efficiently in Sf9 
cells and was complete well within 1.5 hours. Signalase cleavage at the N-terminus of 
prM was incomplete as the putative C-prM intermediate was detected after chase. The 
Asn-linked glycosylation of MVE proteins in Sf9 cells was examined using 
tunicamycin. The occurrence of Asn-linked glycosylation of E indicated that it was 
translocated into the lumen of the RER. We could not detect prM by labelling and thus 
its glycosylation could not be confirmed. C-prM was detected by pulse-labelling, but it 
appeared to be unglycosylated; an explanation for its lack of glycosylation and cleavage 
is that it was not translocated into the lumen of the RER. The inefficiency in the 
cleavage of E-NS 1-poly into E in tunicamycin-treated cells suggested that, in the 
absence of the attachment of glycans in the lumen, signalase cleavage at the C-terminus 
of E occurs inefficiently. Tunicamycin did not affect signalase cleavage at the N-termini 
of prM and E. Inhibition of glycosylation has been demonstrated to impair intracellular 
protein transport and cause aberrant protein folding (Leavitt et al., 1977; Machamer and 
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Rose, 1988). It is therefore possible that the conformation of unglycosylated E may 
have affected signalase activity. 
The observation of different mobilities of E generated in insect and primate cells 
may be related to a difference in composition of glycans in E. The MVE E protein 
(54.5K) in Sf9 cells has a similar mobility to E in MVE-infected C6/36 cells. E in 
MVE-infected Vero and SW13 cells appeared to be slightly larger. Insect cells such as 
C6/36 and Sf9 produce high mannose glycoproteins which are deficient in complex 
carbohydrates and may thus be smaller by comparison with glycoproteins in mammalian 
cells such as SW13 and Vero (Hsieh and Robbins, 1984; Kornfeld and Kornfeld, 
1985). 
Conformation of recombinant E protein 
The properties of the recombinant E from Sf9 cells were compared with those of 
authentic E to assess the usefulness of the baculovirus system in producing properly 
folded, functional MVE proteins. Antigenically, the recombinant protein could not be 
differentiated from authentic E in MVE-infected cells on the basis of its reactivity with 
five neutralizing mAbs which defined MVE epitopes E-lc, E- ld, E-5b, E-7 and E-8. 
E-lc, E-ld, E-5b and E-8 are probably all in domain A (Chapter 4). The anti-E-7 mAb 
defines a spatially distinct epitope, perhaps in domain B, but it has not been mapped. 
Epitopes in domain A are more sensitive to conformational changes induced by SDS, 
pH and disulfide reduction than are epitopes in domains B and C. Our data therefore 
suggest that this conformationally labile domain in Eis reproduced in the recombinant 
54.5K protein. 
In a study of JE structural protein synthesis in Sf9 cells using a baculovirus vector 
(Matsuura et al., 1989), two constructs, expressing prM (minus the N-terminus)-E-NS1 
(N-terminus only) or C (minus the N-terminus)-prM-E-NS 1 (N-terminus only) were 
compared for reactivities with nine E-specific mAbs (five were neutralizing). The 
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construct which expressed undeleted prM and E reacted with all nine mAbs by 
imrnunofluorescence; reactivities were similar to those seen with JE-infected cell lysates. 
The construct expressing deleted prM and intact E reacted with only eight mAbs, three 
of which showed decreased reactivities. As the E protein expressed for both constructs 
is glycosylated and was generated in similar quantity, the different mAb reactivities 
suggest a possible role for prM in the correct folding of JE E protein. 
Yield of recombinant E 
In our studies we have estimated that the yield of E protein in recombinant infected 
Sf9 cells was around 4-5 µg/106 cells, as judged using partially purified MVE as a 
standard. Comparisons were made between similar numbers of recombinant-infected 
Sf9 cells and MVE-infected C6/36 cells in terms of immunoreactivity with ID.AF against 
MVE. We found that the yield of E in C6/36 cells is approximately one third of that in 
Sf9 cells. Other expression studies on JE and DEN-4 proteins in Sf9 cells using 
baculovirus vectors (Matssura et al., 1989; Zhang et al., 1988) reported that yields of 
recombinant proteins were similar or lower than those in virus-infected cells. The 
available data on the expression of MVE, JE and DEN-4 envelope proteins in Sf9 cells 
therefore suggest that yields are approximately 500-fold lower than yields of polyhedrin 
protein in wild-type infected cells (1.2 mg/106 cells; Summers and Smith, 1987). 
Although it would be possible to propagate large quantities of cells in suspension 
cultures using new techniques of culturing Sf9 cells (see review by Cameron et al., 
1989), it is also possible that by altering the recombinant construct increased yields may 
be readily obtained. 
We have therefore explored some of the possible explanations for the low yield. It 
was probably not a result of protein degradation as the level of E was constant late in 
infection when little synthesis of MVE proteins occurred. The processing of precursors 
into E also appeared to be complete (see above). Given that the level of polyhedrin-
MVE mRNA in infected Sf9 cells was about 125-fold less than the level of polyhedrin 
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mRNA in AcNPV-infected Sf9 cells, the low level of polyhedrin-MVE mRNA was 
probably the dominant factor in determining the yield. p VL941 was not expected to be 
responsible for a low level of recombinant polyhedrin mRNA during infection. This 
vector has been used to express E.coli chloramphenicol acetyltransferase and B-
galactosidase, and the level of the corresponding mRN A is similar to the level of 
polyhedrin mRNA in wild type AcNPV-infected cells (Luckow and Summers, 1989). 
The low mRNA level for MVE may be related to the activity of the polyhedrin promoter, 
processing of transcript or the rate of degradation of mRNA. The introduction of MVE 
cDNA results in the insertion of an extra 90 nucleotides of untranslated sequence 
between the polyhedrin promoter and the region to be translated into MVE polyprotein. 
It also creates a much larger polyhedrin mRN A (2.5 kb) than the original construct 
(=0.7 kb). These two factors may have affected polyhedrin promoter activity, post-
transcriptional processing or the stability of hybrid mRN A. 
For the expression of the DEN-4 and JE proteins, the transfer vectors pAc373 and 
pAcYMl respectively were used (Matsuura et al., 1989; Zhang et al., 1988). The 
former is deleted in the sequence immediately upstream of the polyhedrin initiation 
codon and results in a reduced promoter activity compared to the wild-type polyhedrin 
promoter (Luckow and Summers, 1988b); pAcYMl has been used to generate high 
yields of foreign proteins in Sf9 cells (Matsuura et al., 1987). The recombinant 
baculovirus constructs used for MVE, DEN-4 and JE also differed in the lengths of viral 
noncoding and coding sequences downstream of the polyhedrin promoter. As the level 
of mRNA was not reported for the DEN-4 and JE studies, it is not clear if low mRNA 
level has caused poor expression. 
Results from our study suggest that in order to improve expression of MVE 
recombinant E, the level of polyhedrin-MVE mRNA has to be raised. To do this 
recombinant AcNPV which contains different sequences flanking the E gene could be 
constructed and examined for expression. 
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Localization of recombinant E in Sf9 cells 
From our study it is clear that the MVE E protein accumulates in the perinuclear 
region of infected cells as well as at the cell surface. This perinuclear accumulation was 
essentially the same as that seen in MVE-infected C6/36 cells. Perinuclear staining has 
also been observed in KUN- and DEN-2-infected Vero cells (Westaway and Goodman, 
1987), in YF-infected Vero cells (Gould et al., 1985) and in DEN-2 infected LLC-MK2 
cells (Cardiff et al., 1973). The appearance of Eat the surface of recombinant-infected 
Sf9 cells indicates that E can travel to the cell surface independently of the occurrence of 
virus maturation processes. In flavivirus-infected cells anti-E fluorescence is also 
observed at the cell surface (Westaway and Goodman, 1987) but this may be explained 
by adsorption of released virus as electron microscopic studies of cells infected with YF, 
MVE, JE and DEN-2 (Ishak, et al., 1988; Filshie and Rehacek, 1968; Hase et al., 
1987a; Hase et al., 1987b) have each demonstrated virus on the surface of infected cells. 
In most flavivirus-infected cells, virions appear to be assembled in the RER prior 
to release from the cell (Leary and Blair, 1980; Hase et al., 1987a; Filshie and Rehacek, 
1968; Ishak et al., 1988). In view of this, E may be expected to be retained in some 
subcellular compartment for virus assembly. Thus transport of recombinant E to the 
surface of Sf9 cells may be due to the disruption of the assembly process. A surface 
localization has also been reported for expression of recombinant E of JE using 
baculovirus vectors, but not during the expression of DEN-4 structural proteins by 
vaccinia virus or baculoviruses (Zhao et al., 1987; Bray et al., 1989; Zhang et al., 
1988). Similarly DEN-2 E protein expressed using a vaccinia virus vector is not 
detected on the cell surface (Deubel et al., 1988b). Possible explanations for these 
differences in distribution may include the level of expression of proteins, specific 
targeting signals present in the E proteins of different flaviviruses and the absence of 
other components of the assembly pathway. As the intracellular pathway of assembly of 
flaviviruses seems to favour retention of E in the membrane compartments where virion 
formation occurs, it will be of interest to investigate the factors mediating the transport 
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of E to cell surlace in Sf9 cells and determine whether abberant transport occurred in Sf9 
cells. 
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CHAPTER 6 
CONCLUSION 
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This thesis has dealt with several aspects of the molecular biology of Murray 
Valley encephalitis virus. One aim of the work was to study functionally significant 
regions in the MVE E protein. Building an understanding of the structure and function 
of the E protein is of significance for a number of reasons. First, the early events of the 
infection process for MVE and other flaviviruses are not well-defined although it is clear 
that E has a role in cell binding and in fusion with the host cell membrane either at the 
cell surf ace or in the endosome. Second, the E protein is the main target for neutralizing 
antibodies which contribute to protection against infection in vertebrate hosts. Third, the 
signals which direct the E protein and its precursors through a morphogenetic pathway 
to assemble infectious virus particles have not been identified. One approach adopted 
was to define neutralization determinants in the envelope E protein since neutralization of 
infectivity may be mediated by interference with cell binding or fusion. In another 
approach, an expression system in Spodoptera frugiperda (Sf9) cells was set up to 
generate MVE E protein with a 'native' conformation with the aim of using the 
expressed protein and expression system to investigate the possible roles of E described 
above. 
We attempted to map the epitopes defined by five neutralizing mAbs; the location 
of two of these was finally determined. A determinant of the E-8 epitope was mapped to 
residues 201-224 in Eby deletion analysis of bacterial fusion proteins containing E 
fragments. The neutralizing anti-E-8 mAb, which cross-reacts with other viruses in the 
JE serogroup and cross-protects against JE and KUN, probably recognizes a linear 
neutralization determinant. Peptides which represent overlapping segments within 201-
224 and site-directed mutagenesis targeted to the same region may be useful in defining 
the critical determinants of E-8. 
A complementary approach of sequencing neutralization escape variants mapped 
the E-lc determinants to Phe 274, Ser 276 and Ser 27iin E. Together with previous 
findings that Ala 126 is part of the E-lc epitope, these results indicate that the E-lc 
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epitope is a 'discontinuous' epitope assembled from residues far apart in the linear 
amino acid sequence of E. Both E- lc and E-8 are in domain A, which may contain two 
other neutralization epitopes. On the primary sequence of E, E-8 is close to the AS 
neutralization determinant of TBE. However both determinants of E- lc mapped here are 
distant from neutralization epitopes mapped for other flaviviruses; it is the only 
discontinuous epitope in flavivirus E proteins documented thus far. E-lc is defined by 
an mAb which neutralizes the infectivity of MVE in vitro and in vivo (Hawkes et al., 
1988). Investigation of the mechanism of n~utralization may be of value in deciding 
whether E-lc participates in receptor binding. Alternatively, it is possible that anti-E-lc 
mAb may neutralize infectivity of MVE by preventing the acid-induced conformational 
change thought to precede or accompany fusion. 
We have established that changes in the determinant of E- lc at Ser 277 and 
Ser 276 can modify the virulence of MVE for mice. The properties of these E-lc 
mutants point to a significant function for this epitope during infection and in the 
pathogenesis of MVE. Sequence analysis of additional escape variants and a more 
complete mapping of the residues involved in this epitope may therefore be of value in 
studies of the molecular pathogenesis of MVE. 
Our study of the virulence of E-lc variants complements earlier reports that 
passaged variants of MVE and a neutralization escape variant of TBE with changes at 
Asp 390 and Tyr 384 respectively are attenuated in mouse virulence (Lobigs et al., 
1990; Heinz et al., 1989). The role of Ser 277 and Asp 390 (which are in domains A 
and B respectively) in the function of E has yet to be defined. In more extensive studies 
of the significance of residue 277, it will be desirable to generate MVE mutants or MVE 
E proteins with specific changes at this residue or close by. The former can be achieved 
through the use of an infectious cDNA clone for MVE which can be subjected to site-
directed mutagenesis. Mutants generated would be useful in determining the effect on 
virulence of various changes at or near residue 277 and in pathogenesis studies where 
the tissue distribution and kinetics of spread of MVE mutants in mice can be compared. 
In the work described, we have expressed the MVE structural proteins in insect 
cells using a baculovirus vector. A 54.5K protein was generated by proteolytic 
processing and Asn-linked glycosylation of the polyprotein precursor. From its 
reactivity with MVE E-specific mAbs and its size it was clear that a protein closely 
resembling E had been generated, although the N- and C-termini of the protein were not 
characterized. With a yield of 5 µg E per 106 cells, this expression system could be 
scaled up to produce 'native' MVE E protein for functional, structural and protection 
studies. Isolation and purification of the E protein may require detergent solubilization 
and use of immuno-affinity columns coupled with E-specific mAbs. Structural analysis 
and crystallization of E may thus be feasible. The question of whether E undergoes 
oligomerization or intermolecular association with prM during morphogenesis could be 
investigated by cross-linking studies and protease treatment. 
The E protein from Sf9 cells, either purified or in crude lysates, could have other 
applications; these include the further definition of neutralization epitopes E-ld, E-5b, 
E-7 and E-8. Mutational analysis using the recombinant baculovirus construct could be 
employed to characterize these epitopes. We have generated a recombinant MVE 
transfer vector in this work which is amenable to mutation by restriction enzyme deletion 
or site-directed mutagenesis using Ml 3 phage. Cotransfection of Sf9 cells with such 
mutant transfer vectors and baculovirus DNA would generate recombinant baculoviruses 
expressing mutant E proteins. Effective procedures for cotransfection and isolation of 
recombinant baculovirus have been set up in this work so that the strategy described 
above can be performed. 
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The capacity to generate mutant E proteins will also be of value in studying cell 
binding and fusion. In view of the significance of residues around Ser 277 and 
Asp 390, the effect of mutation (by deletion or amino acid change) of these residues on 
the cell binding activity and fusion activity of E are of interest. The candidate fusion 
region (residues 98-111) could also be mutated to examine its effect on fusion. 
Experimental procedures for studying fusion activity have not been established for 
flaviviruses but an indirect approach for determining changes in the conformation of E 
as judged by mAb reactivities and proteolytic cleavage patterns has been used for TBE 
and JE (Guirakhoo et al., 1989). The expression of influenza virus haemagglutinin on 
the surface of monkey (COS) cells using the SV 40 expression system has allowed a 
study of the acid-activated fusion process (Gething et al., 1986; White et al., 1982) by 
cell to cell fusion. Thus various approaches may be investigated with the baculovirus 
expressed E protein. We have shown using the recombinant MVE baculovirus construct 
that the MVE E protein, as cleaved from a larger precursor, is retained in the RER-Golgi 
region as in normal virus infection. A point of interest in future studies will be to 
determine what features of E determine retention in these subcellular compartments. 
Such studies could involve a variety of modifications to the E gene or to the adjacent 
proteins in the polyprotein. . 
In summary, the work reported in this thesis has contributed to our understanding 
of the structure of the flavivirus E protein and the regions of functional significance in E. 
We have developed a good expression system for the MVE E protein in insect Sf9 cells 
which will allow further investigation of the functional determinants of E and of its roles 
in pathogenesis and during infection. 
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